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Abstract 
 
Hepcidin is the key regulator of iron homeostasis acting as a negative regulator of 
intestinal iron absorption. Several proteins have recently been identified to act as 
upstream regulators of hepcidin expression, such as HFE and hemojuvelin (HJV). 
Although hepcidin is regulated by iron, the molecules involved in this regulation and 
whether HFE is involved in this regulation remain to be clarified. The aims of this 
study were to investigate the molecules involved in hepcidin regulation by iron and 
the role played by HFE in this regulation, to understand the regulation of hepcidin 
and HJV expression during inflammation, and finally to investigate the possible role 
of upstream stimulatory factors (USFs) in the regulation of HJV expression.  
Wild type and HFE KO animal models were used to investigate the regulation of 
hepcidin  by  iron  in  vivo;  the  same  animal  models  and  in  vitro  studies  were 
conducted  to  study  the  regulation  of  hepcidin  and  HJV  expression  during 
inflammation. A possible regulation of HJV by USFs was also examined in vitro and 
in vivo using ChIP assay. 
In this study, it was found that iron regulates the expression of BMP-6, for which 
HJV acts as a co-receptor, and phosphorylation of SMADs 1/5/8 in the liver which in 
turn may regulate hepcidin gene expression in response to different iron status. 
Moreover, HFE seems to be involved in the regulation of downstream signalling of 
BMP-6 that regulates hepcidin expression in response to iron loading.  
It was also found that the pro-inflammatory cytokines regulate hepcidin and HJV 
expression differently during inflammation. TNF-alpha seems to act directly on HJV 
to suppress its transcription possibly via a TNFRE within the HJV promoter, while 
IL-6  induces  hepcidin  expression  via  STAT3  signalling.  In  addition,  acute 
inflammation  studies  in  mice  showed  that  although  hepcidin  expression  is 
upregulated as a result of inflammation,  HJV and BMP expression is selectively 
repressed in the liver suggesting a crucial requirement for the downregulation of  
 
 
 
4 
these genes in order to induce hepcidin during inflammation in vivo. However, this 
response seems to be HFE-independent. 
Finally, the study showed an interaction between USFs and the HJV promoter both 
in  vitro  and  in  vivo  suggesting  that  USFs  are  important  for  the  regulation  of 
hemojuvelin expression, and further strengthen the link between these transcription 
factors and iron metabolism. 
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bp  Base pair 
BPS-T  Phosphate buffered saline containing 0.05% Tween-20 
BSA  Bovine serum albumin 
Caco-2  Human intestinal epithelial cells 
cDNA  Complementary DNA 
ChIP  Chromatin-immunoprecipitation 
Cp  Ceruloplasmin* 
Ct  Cycle threshold 
C-terminal  Carboxyl terminal 
Dcytb  Duodenal cytochrome b* 
DEPC  Diethylpyrocarbonate 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DMT1  Divalent Metal Transporter 1* 
DMT1+IRE  Divalent Metal Transporter 1 with an iron response element 
DMT1-IRE  Divalent Metal Transporter 1 without an iron response element 
DNA  Deoxyribonucleic acid 
dNTP  Deoxyribonucleotide 5’-triphosphate 
dsDNA  Double stranded deoxyribonucleic acid 
DTT  Dithiothreitol 
ECL  Enhanced chemiluminescence system 
EDTA  Ethylenediaminetetraacetic acid 
EMSA  Electrophoretic mobility shift assay 
EPO  Erythropoietin 
ER  Endoplasmic reticulum 
ERK1/ERK2  Signal-regulated kinases 1/2 
FBS  Foetal bovine serum   19 
FBXL5  F-box and leucine-rich repeat protein 5 
Fe  Iron 
Fe
2+  Ferrous iron 
Fe
3+  Ferric iron 
GDF15  Growth differentiation factor 15 
GPI  Glycosylphosphatidylinositol 
HAMP  The hepcidin gene 
Hamp1
-/-  Hamp1 knockout 
H-chain (ferritin)  Heavy chain 
HCP1  Haem carrier protein 1 
HEK 293  Human embryonic kidney cells 
HFE  Haemochromatosis protein* 
HFE
-/-  HFE knockout 
HH  Hereditary haemochromatosis 
HIF  Hypoxia inducible factor 
HJV  Hemojuvelin* 
HJV
-/-  HJV knockout 
HL  Hepatic lipase 
HO1  Haem oxygenase 1 
Hp  Hephaestin* 
HRP  Horseradish peroxidase 
IgG  Immuno globulin 
IL-1  Interleukin 1 
IL-6  Interleukin 6* 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
IRE   Iron response element 
IREG1  Iron-regulated transporter-1* 
IRP  Iron- regulatory protein 
JAK  Janus kinase 
JH  Juvenile haemochromatosis 
kb  Kilo base 
kDa  Kilo Dalton 
Kg  Kilogram 
L  Litre 
LB  Luria broth 
L-chain (ferritin)  Light chain 
LEAP-1  Liver Expressed Antimicrobial Peptide-1 
LPS  Lipopolysaccharide   20 
M  Molar 
mA   Milli amps 
MAPK  Mitogen-activated protein kinase 
mg  Milligrams 
MHC  Major histo compatability 
m-HJV  Membrane-bound hemojuvelin 
min  Minute 
mL  Millilitre 
mRNA  Messenger ribonucleic acid 
MTP1  Metal Transporter Protein-1 
n  Sample size 
ng  Nanogram 
nm  Nanometre 
nM  Nanomolar 
Nramp2  Natural resistance-associated macrophage protein 2 
NTBI  Non transferrin bound iron 
N-terminal  Amino terminal 
ORF  Open reading frame 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PHD    Prolyl hydroxylase 
PHZ  Phenyl hydrazine 
pmol  Pico mole 
ppm  Part per million 
PVDF  Polyvinylidene Fluoride 
RE  Reticulo endocyte 
RGM  Repulsive guidance molecules 
RIPA buffer  Radioimmunoprecipitation assay buffer 
RNA  Ribonucelic acid 
rpm  Revolutions per minute 
R-Smads  Receptor-activated Smads 
SDS  Sodium deoxycholate 
SDS-PAGE  Sodium dedocyl sulphate Polyacrylamide Gel Electrophoresis 
SEM  Standard error of the mean 
s-HJV  Soluble hemojuvelin 
sla  Sex-linked anaemia 
SMAD  Mothers against decapentaplegic 
SMAD4  Common mediator SMAD*   21 
SP  Signal peptide 
ssDNA  Single stranded deoxyribonucleic acid 
STAT  Signal transducer and activator of transcription 
STEAP  Six-transmembrane epithelial antigen of prostate protein 
STEAP3  The epithelial antigen of prostate 3 
sTFR  Soluble TFR 
TAE  Tris-acetate-EDTA 
TBI  Transferrin bound iron 
TE  Tris-EDTA 
TEMED  3,3’,5,5’-tetramethyl-ethylenediamine 
TF  Transferrin* 
TFR1  Transferrin receptor 1* 
TFR2  Transferrin receptor 2* 
TFR2
-/-  TFR2 knockout 
TGF-  Transforming growth factor-* 
TIBC  Total iron binding capacity 
TM  Transmembrane domain 
TNF- Tumour necrosis factor-* 
UIBC  Unsaturated Iron-Binding Capacity 
USF  Upstream stimulatory factor* 
UTR  Untranslated region of an mRNA transcript 
UV  Ultra violet 
VHL  von Hippel-Lindau tumour suppressor 
VWF  von Willebrand factor 
ZIP14  Zrt-Irt-like protein 14* 
2m  2-microglobulin* 
g  Microgram 
M  Micromolar 
3’  3 prime terminal 
3D  Three dimensional 
5’  5 prime terminal 
   
   
   
   
 
*if written in italics name refers to the gene. 
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1.1 Importance of iron 
 
Following  oxygen,  silicon,  and  aluminium,  iron  is  the  fourth  most  bountiful 
constituent in the Earth’s crust. Iron is renowned to be an indispensable element for 
all  living  organisms  apart  from  a  few  bacterial  species  (Neilands  1974;  Stubbe 
1990).  Iron is fundamental for different biological processes such as the synthesis 
of DNA, RNA, and proteins, electron transport, cellular respiration, cell proliferation 
and differentiation, and regulation of gene expression (Andrews1999; Boldt 1999; 
Conrad et al. 1999; Gerlach et al. 1994; Wessling-Resnick 1999). It also forms the 
active centre of important enzymes, including aconitase (Jordanov et al. 1992) and 
ribonucleotide reductase (Uppsten et al. 2004). Moreover, it acts as a co-factor for 
haem-containing  enzymes  (Lieu  et  al.  2001),  and  cytochromes  of  the  electron 
transport  chain  as  well  as  oxygen  transport  to  tissues  through  haemoglobin 
(Winfield, 1965).  
Iron exists in two forms, ferrous (Fe
2+) and ferric (Fe
3+) states. The redox potential 
of iron makes it able to generate highly toxic free radicals in the presence of oxygen 
derivatives from Fe
2+ and Fe
3+ via Fenton’s reaction (Imlay and Linn 1988; Halliwell 
1994; Stadtman and Wittenberger 1985).  To abrogate the toxic effects of free iron, 
iron is usually bound to Fe-binding proteins, such as transferrin (TF) and ferritin 
(Richardson and Ponka 1997; Sahlstedt et al. 2002). 
 
1.2 Iron Distribution        
 
The body iron content depends on nutrition, gender, and general health condition. 
Iron represents approximately 35 and 45 mg/kg of body weight in adult women and 
men, respectively (Andrews 1999; Bothwell et al. 1995). About 60-70% of total body 
iron (~ 1800 mg) is integrated into haemoglobin of circulating red blood cells and 
about  300  mg  in  erythroid  precursor  cells  in  the  bone  marrow  (Figure  1.1).  In   24 
addition, about 30% of body iron is stored as ferritins and haemosidrins in liver cells 
(~  1000  mg)  and  reticuloendothelial  macrophages  (~  600  mg).  Another  10%  of 
essential body iron (~ 300 mg) is incorporated into myoglobins, cytochromes, and 
iron-containing enzymes, amounting to no more than 4–8 mg of iron (Conrad et al. 
1999).  
In the balanced physiological state, 1-2 mg of dietary iron is absorbed each day, 
which is adequate to reimburse the daily losses (Cook et al. 1973) (Figure1.1). The 
amount of dietary iron absorption is tightly regulated, as there is no iron excretory 
mechanism in humans and only a very small amount of iron is excreted in faeces 
and  urine  (Green et al. 1968;  Miret  et  al.  2003).  In  addition, approximately  1-2 
mg/day of iron is lost from the body by skin sloughing, and menstruation (Demaeyer 
1980).  Iron homeostasis is maintained by a firm control at the sites of iron uptake 
(duodenum), storage (liver), recycling (reticuloendothelial macrophages), and use 
(erythroid precursor).  
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Figure 1.1 Distribution of iron in adults.  
Dietary  iron  is  absorbed  by  duodenum  into  the  plasma.  Most  of  the  iron  is 
incorporated into haemoglobin of the red blood cells in the bone marrow, which are 
then  released  into  the  circulation.  Senescent  red  blood  cells  are  engulfed  by 
macrophages, which recycle iron into the circulation. Iron is stored in parenchymal 
cells  of  the  liver  and  reticuloendothelial  macrophages.  Adapted  from  (Andrews, 
1999). 
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1.3 Duodenal Iron absorption  
 
The  duodenum  is  the  primary  site  of  iron  uptake  in  mammals  (Duthie  1964; 
Johnson et al. 1983; Wheby et al. 1964). The duodenal lumen is covered by finger-
like projections (villi) that increase the absorptive surface area of the duodenum 
(brush border).  
Unlike in other nucleated cells, there are no transferrin receptors (TFRs) in the 
lumenal surface of absorptive enterocytes (Parmley et al. 1985; Pietrangelo et al. 
1992). Thus, iron must enter these cells via a mechanism that is dissimilar to the 
conventional transferrin (TF)-TFR pathway. 
Dietary iron exists in two forms, haem (from meat) and non-haem (from plant and 
dairy products). In humans, haem iron is more efficiently absorbed than non-haem 
iron and accounting for 20-30% of the absorbed iron (Bothwell and Charlton 1979); 
though haem iron represents a lesser fraction of dietary iron (~10-15%) (Carpenter 
and Mahoney 1992). The duodenal iron uptake of haem and non-haem iron occurs 
by different mechanisms (Siah et al. 2005), being different in the initial uptake step. 
Once inside the enterocyte, iron from each source then enters low molecular weight 
iron pools and is transferred across the basolateral border of the enterocyte to the 
blood via a common pathway (Forth and Rummel 1973; Peters et al. 1988). 
Haem iron enters the cell as an intact iron-protoporphyrin complex (Conrad et al. 
1966; Wyllie and Kaufman 1982; Parmley et al. 1981), possibly by endocytosis or 
by a recently identified haem receptor on the brush border of enterocytes, haem 
carrier protein 1 (HCP1) (Shayeghi et al. 2005). Then it is likely to be cleaved by 
intracellular microsomal enzyme, haem-oxygenase 1 (HO1) to release ferrous iron 
and form biliverdin (Raffin et al. 1974).  
Non-haem iron exists in the forms of Fe
2+ and Fe
3+ salts. Most Fe
2+ iron remains 
soluble even at pH7 and Fe
3+ iron becomes insoluble at physiological pH (values 
above 3) (Moore et al. 1944; Brise and Hallberg 1962); consequently, absorption of   27 
Fe
2+ iron salts is more efficient than absorption of Fe
3+ iron salts. However, most 
dietary non-haem iron is in the form of Fe
3+ iron, thus the reduction of Fe
3+ iron 
becomes compulsory for competent dietary iron absorption (Conrad et al. 1999). 
 
1.3.1  Molecular mechanisms of duodenal iron uptake (Figure 1.2) 
 
Different molecules involved in duodenal non-haem iron uptake are described in 
detail below. 
 
1.3.1.1 Dcytb 
 
In  the  intestinal  lumen,  the  reduction  of  Fe
3+  is  mediated  by  a  mucosal 
ferrireductase Duodenal cytochrome b (Dcytb) that is present on the apical surface 
of  the  duodenum  (Raja  et  al.  1992;  Riedel  et  al.  1995).  This  role  of  Dcytb  is 
supported by its high expression levels at the apical surface of enterocytes and its 
reductase property (McKie et al. 2001). Both Dcytb mRNA and protein levels are 
reduced in iron overload, and are increased in iron deficiency and hypoxia when 
iron absorption increases (Collins et al. 2005, McKie et al. 2001). 
The inhibition of ferrireductase activity in intestinal cells has been shown to diminish 
iron absorption (Han et al. 1995; Nunez et al. 1994). On the other hand, it was 
recently  shown  that  disruption  of  mouse  Dcytb  had  no  effect  on  intestinal  iron 
absorption  (Gunshin  et  al.  2005),  suggesting  the  existence  of  an  alternative 
ferrireductase. Ohgami et al. (2006) showed that members of six-transmembrane 
epithelial antigen of prostate protein (STEAP) have ferrireductase activity and could 
be a surrogate for Dcytb. 
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Figure 1.2 Iron absorption by the enterocyte. 
Non-haem iron is transported across the brush border via divalent metal transporter 
1 (DMT1) after being reduced into Fe
+2 by duodenal cytochrome b (Dcytb). Haem 
carrier  protein 1  (HCP1)  mediates  haem  iron  uptake  into the  cells,  iron  is then 
released by haem oxygenase-1 (HO1). Inside the cell, iron can either be stored as 
ferritin or be exported through the basolateral membrane to the blood by IREG1. In 
the blood,  iron  is  oxidised  by hephaestin  then circulates  in  the  blood bound  to 
transferrin (TF). Modified from (Chua et al. 2007). 
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1.3.1.2 DMT1 
 
Following  reduction  by  Dcytb,  Fe
2+  iron  transport  across  the  brush  border  is 
mediated  by  a  divalent  cation  transporter,  termed  natural  resistance-associated 
macrophage protein 2 (Nramp2) or divalent metal transporter 1 (DMT1) (Fleming et 
al. 1997; Gunshin et al. 1997, Tandy et al. 2000). DMT1 mRNA is ubiquitously 
expressed in most tissues and cell types, being higher in brain, proximal intestine 
and  thymus,  kidney,  and  bone  marrow  (Gunshin  et  al.  1997).  Furthermore,  its 
hepatic expression has been also reported (Trinder et al. 2000). There are two 
splice isoforms of DMT1 which differ at their C-terminal end. One contains an iron 
responsive element (IRE) within its 3’-UTR (DMT1+IRE), while the other isoform 
lacks this element (DMT1-IRE) (Fleming et al. 1997; Gunshin et al. 1997; Tabuchi 
et al. 2000). Only DMT1+IRE is regulated by iron levels in human cell culture and in 
the intestine (Zoller et al. 1999; Canonne-Hergaux et al. 1999; Byrnes et al. 2002). 
Two additional splice variants of exon 1 have recently been reported that differ at 
their N-terminal end (Hubert and Hentze 2002); however, these isoforms are not 
well characterised.  
The role of DMT1 in iron uptake was underscored by the effects observed with 
DMT1  mutations  in  two  rodent  models  of  iron  deficiency  anaemia,  namely  the  
microcytic anaemia mouse and the Belgrade rat (Fleming et al. 1997; 1998). Both 
rodent models are characterised by iron deficiency due to impaired iron uptake by 
the intestine and other tissues (Edwards and Hoke 1972; Fleming et al. 1998). The 
DMT1 mutation in microcytic anaemia mice leads to incorrect localisation of the 
protein to the plasma membrane (Canonne-Hergaux et al. 2000).  
Gunshin  and  coworkers  (2001)  showed  that  in  hepatic  (Hep3B)  and  intestinal 
(CaCo2)  cell  culture,  increased  cellular  iron  was  associated  with  a  decrease  in 
DMT1  mRNA  levels  while  expression  levels  increased  when  cells  were  iron 
deficient. This regulation occurs through binding of iron response proteins (IRPs) to   30 
the IRE which protects the mRNA from endocytic cleavage, increasing mRNA half-
life and consequently translated protein (Casey et al. 1988).  
On  the  contrary,  the  expression  of  DMT1-IRE  is  not  regulated  by  cellular  iron 
(Canonne-Hergaux et al. 1999, Gunshin et al. 2001).  
 
1.3.1.3 Ferritin 
 
In the enterocyte, surplus Intracellular iron can either be stored as ferritin (Torti and 
Torti 2002), or transferred across the basolateral membrane of the enterocyte to the 
plasma.  Ferritin  is  ubiquitously  expressed and  its  main function  is  to  store  and 
sequester excess iron in a soluble, non-toxic form (Theil 1983; Theil 1990).  
Ferritin is composed of a spherical protein shell of 24 subunits of two types, light (L) 
and heavy (H) chains with a central cavity able to store up to 4500 iron atoms in the 
form of hydrous ferric oxide phosphate (Mann et al. 1986; Theil, 1983; Thiel, 1990). 
Both  chains  have  the  same  3D  structure  and  share  50%  sequence  identity; 
however, they have different surface charges which give them different properties 
(Arosio et al. 1978; Harrison and Arosio 1996). L-chain is important for core iron 
binding, while H-chains confer ferroxidase activity required for iron incorporation 
(Levi et al. 1988; Levi et al. 1992).   
The 5’ UTR of ferritin mRNA contains an IRE  (Huang et al. 1999). During iron 
deficiency, IRPs bind to IRE and block translation; therefore increasing cellular iron 
availability. Ferritin is also regulated by cytokines, such as interleukin (IL)-6 and -1 
as well as interferon-Wei et al. 1990; Fahmy and Young 1993 Due to its iron 
sequestering capacity, ferritin seems to have an anti-oxidant function (Theil 2003).  
Ferritin  has  been  also  detected  in  the  plasma;  however,  Linder  et  al.  (1996) 
recognized a number of differences between tissue and plasma ferritin, suggesting 
that they might be encoded by different genes. Serum ferritin is commonly used to   31 
diagnose iron deficiency anaemia and hereditary haemochromatosis (iron overload) 
(Beutler et al. 2003). 
 
1.3.1.4 IREG1 
 
IREG1  (Iron-regulated  transporter-1),  also  known  as  ferroportin1,  Slc40a1,  and 
MTP1  (Metal  Transporter  Protein-1)  was  shown  by  three  laboratories to be  the 
putative basolateral iron exporter (Donovan et al. 2000; McKie et al. 2000; Abboud 
and Haile 2000).  
IREG1  was  found  to  be  expressed  in  basolateral  membrane  of  the  duodenal 
enterocyte where it mediates iron efflux to the circulation (Abboud and Haile 2000). 
It was also found to be expressed in placental syncytiotrophoblast, liver, spleen, 
and  reticuloendothelial  macrophages  (Donovan et  al.  2000;  McKie  et  al.  2000). 
IREG1  is  highly  conserved  among  species  with  90-95%  sequence  homology 
between human, rat, and mouse (Abboud and Haile 2000). 
IREG1 mRNA contains a functional IRE in its 5’ UTR (McKie et al. 2000; Abboud 
and Haile 2000), thus it is regulated by iron. Duodenal IREG1 mRNA and protein 
expression is decreased in iron loading and increased in iron deficiency (Anderson 
et al. 2002; Chen et al. 2003; Zoller et al. 2001). On the other hand, IREG1 protein 
expression is repressed in the liver of iron-deficient mice (Abboud and Haile 2000) 
and  is  increased  in  haemochromatosis  liver  due  to  iron overload  (Adams et  al. 
2003). These findings suggest the existence of regulatory mechanisms other than 
iron. Recently, a novel isoform of IREG1 was  identified in intestinal cells (Zhang et 
al.  2009).  This  isoform  lacks  IRE  and  is  believed  to allow  intestinal  iron  export 
during iron deficiency. 
Inflammation also affects IREG1 expression levels by repressing its expression in  
the lipopolysaccharide (LPS) model of the acute inflammation in the mouse (Yang 
et al. 2002). IREG1 is also post-transcriptionally regulated by hepcidin (as will be   32 
discussed later), which binds to IREG1 inducing its internalisation and lysosomal 
degradation (Nemeth et al. 2004b). 
IREG1  gene  mutations  are  associated  with  Ferroportin  disease,  an  autosomal 
dominant form of hereditary haemochromatosis (HH), which is characterised by iron 
accumulation  in  reticuloendothelial  macrophages  (Pietrangelo  2004).  This  effect 
highlights the role of IREG1 in iron release from reticuloendothelial macrophages.  
Recently,  selective  inactivation  of  the  murine  IREG1  gene  in  intestinal  cells 
documented that IREG1 is the key, if not only, intestinal iron exporter (Donovan et 
al. 2005). 
 
1.3.1.5 Hephaestin 
 
Hephaestin (Hp) is a membrane-bound multi-copper oxidase. It has high sequence 
homology  to  ceruloplasmin  (Cp),  a  serum  multi-copper  oxidase,  which  has 
ferroxidase  activity  (Syed  et  al.  2002).  The  role  of  Hp  in  iron  homeostasis  was 
identified in the studies of sex-linked anaemia (sla) in mice. These mice have a 
mutation in the Hp gene (Bannerman et al. 1973; Vulpe et al. 1999) and showed 
normal  iron  absorption,  yet  suffered from  impaired  iron  export  to  the  circulation 
resulting in microcytic anaemia (Manis 1971; Vulpe et al. 1999).  
Unlike Cp, Hp is highly expressed in intestinal villi and to a lesser extent in the lung, 
kidney, and brain (Vulpe et al. 1999; Klomp et al. 1996). 
Functional studies of IREG1 revealed that IREG1-mediated iron efflux requires an 
auxiliary ferroxidase activity (Donovan et al. 2000; McKie et al. 2000). However, the 
mechanisms  by  which  IREG1  mediates  iron  efflux  across  the  basolateral 
membrane  and  by  which  it  interacts  with  Hp  and  Cp,  remain  to  be  clarified. 
Oxidation of Fe
+2 to Fe
+3 by Hp is important for iron to bind to circulating plasma 
transferrin (Vulpe et al.1999). 
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1.3.2  Regulation of duodenal iron uptake 
 
 
As mentioned earlier, humans do not have the machinery to excrete excess iron; 
therefore, the process of iron absorption must be under a tight control to avoid 
pathological conditions associated with iron overload and deficiency. The control of 
duodenal  iron absorption  depends  on body  iron  needs.  In  studies  conducted  in 
recent years, it was shown that the control of intestinal iron absorption is achieved 
by controlling the expression of key iron transport proteins including DMT1, Dcytb, 
and IREG1.  
 
1.3.2.1 Regulation by hypoxia-inducible factor (HIF) 
 
Hypoxia-inducible factor (HIF) is a transcription factor that exists as a heterodimer 
composed of alpha subunits (HIF-1 and HIF-2) and beta subunit (HIF-1), which 
is  also  known  as  aryl  hydrocarbon  nuclear  translocator  (ARNT)  (Semenza  and 
Wang, 1992; Wang and Semenza 1993; Wang et al. 1995). Under normal oxygen 
conditions, the prolyl hydroxylase domain (PHD) family of proteins (PHD1, 2, and 3) 
hydroxylates HIF-1 and HIF-2followed by their ubiquitination by the E3 ubiquitin 
ligase,  von  Hippel-Lindau  (VHL)  tumour  suppressor  protein,  and  subsequent 
proteasomal degradation (Jaakkola et al. 2001; Ivan et al. 2001).  
Two  recent  studies  showed  that  iron  deficiency  stimulates  duodenal  HIF-2 
signalling that induces DMT1 and Dcytb expression, and accordingly increases iron 
absorption (Shah et al. 2009; Mastrogiannaki et al. 2009). Moreover, this response 
was not observed in mice lacking HIF-2.  
 
 
   34 
1.3.2.2 Regulation by iron regulatory proteins (IRPs) (Figure 1.3)  
 
Many proteins of iron metabolism are post-transcriptionally regulated by cellular iron 
levels.  This  regulation  involves  the  cytoplasmic  iron  regulatory  proteins  (IRPs) 
binding  to  the  iron-response  element  (IRE).  IRE  is  a  palindromic  sequence  of 
mRNA that forms a stem-loop structure (Hentze et al. 1987; Casey et al. 1988). 
DMT1 and TFR1 mRNA have IREs in their 3’-UTR that are stabilised upon IRP 
binding (Gunshin et al. 1997; Casey et al. 1988). In contrast, ferritin and IREG1 
mRNA  have  IREs  in  their  5’UTR  and  IRP  binding  decreases  protein  synthesis 
(Huang et al. 1999; McKie et al. 2000; Abboud and Haile 2000).  
Two IRPs exist in the mammalian cytoplasm (IRP1 and IRP2). IRP1 contains a 
4Fe-4S  cluster  and  possesses  aconitase  activity  (Rouault  et  al.  1991).  When 
cellular iron levels are low, IRP1 loses its Fe-S cluster and, hence, becomes able to 
bind IREs (Schalinske et al. 1997). Although IRP1 and IRP2 share 60% amino acid 
identity, IRP2 does not possess aconitase activity and is regulated by cellular iron 
as it is degraded when cellular iron levels are high and preserved in iron deficiency 
due to de novo synthesis  (Guo et al. 1995). However, it is likely that iron-sensing 
by  IRP2  is  mediated  by  F-box  and  leucine-rich  repeat  protein  5  (FBXL5) 
(Salahudeen et al. 2009; Vashisht et al. 2009). FBXL5 possesses ubiquitin ligase 
E3 activity, which targets IRP2 for proteasomal degradation. The role of IRP2  in 
regulation of IREG1 translation/DMT1 stability remains to be determined. However, 
it appears to be important for intestinal expression of ferritin, as selective disruption 
of IRP2 increased duodenal ferritin and non-haem iron levels (Ferring-Appel et al. 
2009).  
During iron overload states, IRPs fail to bind IREs of ferritin, DMT1, TFR1, and 
IREG1. Therefore, the protein expression of ferritin and IREG1 increase, while that 
of TFR1 and DMT1 decrease to limit further iron uptake (Casey et al. 1988; Hentze 
et al. 1988; Guo et al. 1995; Gunshin et al. 2001). Intestinal disruption of IRP1 and   35 
IRP2 in the mouse increases IREG1 and decreases DMT1 expression (Galy et al. 
2008). In addition, these mice presented malabsorption and dehydration and died at 
the age of 4 weeks. 
Recently, HIF-2mRNA was shown to possess an IRE within its 5’-UTR (Sanchez 
et al. 2007). During iron deficiency and hypoxia, HIF-2expression is repressed via 
IRP1-mediated  transcriptional  suppression  (Sanchez  et  al.  2009;  Zimmer  et  al. 
2008). Moreover, HIF-2deficient mice showed hypoferremia, decreased hepatic 
iron and hepcidin expression levels (Mastrogiannaki et al. 2009). 
IREG1 mRNA contains an IRE in its 5’-UTR. However, duodenal IREG1 expression 
increased in iron deficiency and decreased in iron overload in vivo (Abboud and 
Haile 2000; McKie et al. 2000).These findings are inconsistent with the regulation of 
genes with 5’-UTR IRE by IRPs. Recently, a novel IREG1 isoform lacking IRE was 
identified in intestinal cells (Zhang et al. 2009). This isoform is proposed to allow 
intestinal iron export during iron deficiency.    
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Figure 1.3 Regulation of iron transport genes by IRP-IRE pathway.  
Post-transcriptional  control  of  IRE-containing  mRNAs  is  mediated  by  IRP1  and 
IRP2. In high iron states, iron is sensed by FBXL5 that targets IRP2 for proteasomal 
degradation. On the other hand, IRP1 forms a cluster (Fe-S) that interferes with its 
binding to IRE. Unbinding of IRPs to IREs permits translation of IREG1, ferritin, and 
HIF-2 while it unstabilises DMT1 mRNA. In low iron conditions, binding of IRPs to 
IREs  results  in  translational  repression  of  ferritin,  IREG1,  and  HIF-2while  it 
stabilises DMT1 mRNA. Modified from (Knuston, 2010). 
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1.3.2.3 Regulation by hepcidin 
 
IREG1 protein expression is negatively regulated by hepcidin, which is sensitive to 
systemic iron changes. Binding of hepcidin to IREG1 results in its internalisation 
and degradation in the lysosomes. The decreased intestinal iron export causes iron 
deficiency  (Nemeth et al.  2004b).  The  role  of hepcidin  in  the  regulation  of  iron 
homeostasis will be discussed later in more detail. 
 
 
1.4 Iron circulation in the body 
 
 
1.4.1  Transferrin (TF) 
 
 
The main function of transferrin is iron transportation between sites of absorption, 
storage, and usage. It is an 80 kDa monomeric glycoprotein mainly produced by the 
liver (Morgan, 1981), and to a lesser extent by the mammary gland, testis, and the 
brain (Anderson et al. 1987; Bailey et al. 1988). Transferrin contains two globular 
domains;  each  domain  contains  a  high-affinity  binding  site  for  one  Fe
3+  iron 
molecule (Yang et al. 1984). . Both domains bind iron with high affinity (Yang et al. 
1984);  they  also  bind  copper,  cobalt,  manganese,  and  cadmium  but  with  lower 
affinity  (Aisen  et  al.  1969;  Davidson  et  al.  1989).  A  simultaneous  binding  of 
bicarbonate or carbonate to arginine and threonine residues is a requisite for iron 
binding to TF (Baker and Lindley, 1992). 
The affinity of TF for iron is pH-dependent. At pH lower than 6.5, iron is released 
from  TF;  while  at physiological  pH7.4,  iron  is  strongly  bound  to  TF.  This  is  an 
important property as it plays a vital role in the mechanism of iron release from TF.  
In the plasma, TF exists as a mixture of iron-free apotransferrin, monoferric, and 
diferric transferrin which depends on TF and iron concentrations in the blood. In the 
normal physiological state, about 20-50% of TF is saturated by iron (Morgan 1996).   38 
This incomplete saturation provides a shield against a sudden increase in plasma 
iron levels in certain diseases.   
 
1.4.2. Transferrin receptor 1 (TFR1) 
 
TFR1 is ubiquitously expressed in most cells apart from mature red blood cells 
(Davies  et  al.  1981;  Enns  et  al.  1982),  with  the  highest  expression  being  in 
placenta, erythroid marrow, and liver (Ponka and Lok 1999). It is a disulfide-linked 
homodimeric  glycoprotein  of  two  90  kDa  subunits  (Jing  and  Trowbridge  1987). 
Each TFR1 homodimer is able to bind two TF molecules (Enns and Sussman 1981; 
Sheth and Brittenham 2000). 
The affinity of TFR1 to diferric-TF is pH-dependent, at the physiological pH of 7.4, 
the  affinity  of  TFR1  to  diferric  TF  is  about  2000  times  higher  than  that  of 
apotransferrin.  On  the  other  hand,  at  the  endosomal  pH  of  5.5,  the  affinity  for 
apotransferrin is higher than diferric transferrin (Tsunoo and Sussman 1983).   
TFR1 expression is regulated by iron, where it is up-regulated by iron deficiency 
and down-regulated by iron overload (Casey et al. 1988; Hentze et al. 1988). Its 
expression  is  also  altered  by  hydrogen  peroxide  and  nitric  oxide  generated  by 
oxidative stress through Iron-regulatory protein (IRP) (Cairo and Pietrangelo 1995). 
 
1.4.3  TFR1 mediated iron uptake (Figure 1.4) 
 
 
The  TRF1-mediated  iron  uptake  occurs  by  receptor-mediated  endocytosis. 
Following the binding of TF to TFR1, the complex is internalised into endosomes 
through clathrin-coated pits. The vesicles are acidified by ATP-dependent proton 
pumps (Paterson et al. 1984), which decreases the affinity of TF for Fe
3+, while 
apoTF remains bound to TFR1 (Morgan 1983). Iron is then transported into the   39 
cytoplasm by DMT1 (Su et al. 1998). It is believed that Fe
3+ is reduced to Fe
2+ 
before being transported by DMT1. The epithelial antigen of prostate 3 (STEAP3), 
an  erythroid  reductase,  has  recently  been  identified  to  act  as  a  ferrireductase 
(Ohgami et al. 2005). Inside the cytoplasm, iron is either utilised or stored inside the 
cell. ApoTF-TRF1 complex is then returned to the cell surface (Morgan 1981). At 
physiological pH, apoTF dissociates from TFR1 and circulates in the blood where it 
can bind to iron and the cycle is repeated (Dautry-Varsat et al. 1983; Morgan 1983).  
Haemochromatosis protein (HFE) (which will be discussed later) is another factor 
that affects TF-bound iron uptake. It has been shown to bind to TFR1 to compete 
with TF for binding in placenta, enterocytes and transfected cells (Pakkila et al. 
1997; Feder et al. 1998; Lebron and Bjorkman 1999). However, the precise role of 
HFE in TFR1-mediated iron uptake is not clearly understood. 
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Figure 1.4 Transferrin mediated iron uptake. 
Diferric TF binds to TFR1 on the cell membrane, followed by internalisation of the 
complex  via  clathrin-coated  pits  into  endosomes.  The  endosome  is  acidified  by 
ATP-dependent  proton  pump  which  decreases  pH  within  the  lumen.  Acidic  pH 
causes dissociation of iron from the TF-TFR1 complex. Iron is then reduced by 
STEAP3 followed by its transport across the endosomal membrane by DMT1 to the 
cytosol. In the cytoplasm iron is either utilised or stored within the cell in ferritin. The 
TF-TFR1  complex  is  then  recycled  to  the  cell  membrane,  and  the  higher  pH 
dissociate TF from TFR1 and both can be used for additional cycles of iron uptake. 
Modified from (Andrews, 1999). 
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1.4.4 Transferrin receptor 2 (TFR2)    
 
 
In 1999, Kawabata et al. identified a second human TFR gene, named TFR2. It has 
two splice variants: the alpha () form which is 2.9 kb and beta () form which is 2.5 
kb (Kawabata et al. 1999). TFR2-is highly expressed in the liver; it is type 2 
transmembrane  glycoprotein  with  high  structural  similarity  to  TFR1  (about  66% 
sequence homology) (Kawabata et al. 1999). On the other hand, TFR2-lacks the 
transmembrane domain and part of the extracellular domain, suggesting that it is an 
intracellular protein (Kawabata et al. 1999).  
TFR2 is highly expressed in the liver (Merle et al. 2007); low expression levels have 
also been reported in spleen, heart, small intestine, kidney, and testicles (Kabawata 
et al. 1999; Fleming et al. 2000). 
Unlike TFR1, TFR2 mRNA does not have any IREs in its UTR (Kabawata et al. 
1999); therefore TFR2 is not transcriptionally regulated by iron (Fleming et al. 2000; 
Kawabata et al. 2000). TFR2 protein expression is decreased with iron deficiency 
and increased with iron overload, suggesting post-transcriptional regulation of TFR2 
(Robb and Wessling-Resnick 2004). TFR2 protein expression has been shown to 
increase  in  response  to  diferric  TF  in  a  time  and  dose-dependent  manner  in 
cultured hepatocytes, with no effect of non-transferrin-bound iron (NTBI) or apo TF 
(Johnson and Enns 2004). 
Like  TFR1,  TFR2  can  bind  TF-bound  iron  (TBI)  in  a  pH-dependent  manner 
(Kawabata et al. 2000). Yet, the affinity of TFR2 for TBI is 25-30 times lower than 
that of TFR1 (Kawabata et al. 2000; West et al. 2000). Moreover, the embryonic 
mortality of mice with genetic disruption of TFR1 (Levy et al. 1999) suggests that 
TFR2 can not compensate for the loss of TFR1.  
Regarding  HFE-TFR2  interaction,  an  early  study  using  soluble  forms  of  both 
proteins  did  not  show  any  interaction  (West  et  al.  2000).  Subsequently,  co-  42 
localisation between the two proteins has been reported in  enterocytes (Griffiths 
and Cox 2003). In addition, co-immunoprecipitation of HFE and TFR2 has recently 
been reported in liver cells over-expressing TFR2 and HFE (Goswami and Andrews 
2006). 
Both  of  TFR2  and  HFE  gene  mutations  lead  to  adult-onset forms of  hereditary 
hamochromatosis (Feder et al. 1996; Camaschella et al. 2000). 
 
1.5 Liver and iron metabolism 
 
The liver plays an imperative role in iron homeostasis: it takes up TBI and NTBI 
from the blood, stores surplus iron, and produces hepcidin (to be discussed later) 
which modulates intestinal iron absorption. In addition, it has RE macrophages that 
deliver iron to the blood TF through phagocytosis of effete erythrocytes. Liver also 
expresses proteins important for iron metabolism such as TF (Ponka et al. 1998), 
ceruloplasmin  (Hellman  and  Gitlin  2002),  haptoglobin  (Wassel  2000),  and 
haemopexin  (Tolosano  and  Altruda  2002).  Excess  iron  in  conditions  of  iron 
overload is stored in the liver as ferritin (Loreal et al. 2000; Philpott 2002). On the 
other hand, under conditions of iron deficiency, iron mobilisation from the liver takes 
place to provide iron to different cells. 
In a normal human adult, about 40% of the stored iron (which represents about 
10% of total body iron) is stored in the liver (Bacon and Tavill 1984; Searle et al. 
1994) with most of it found in hepatic parenchymal cells (Van Wyk et al. 1971). 
 
1.5.1  Iron uptake by hepatocytes (Figure 1.5) 
 
The liver can take up both TBI (Trinder et al. 1996) and NTBI (Craven et al. 1987; 
Parkes  et  al.  1995;  Randell  et  al.  1994;  Thorstensen  and  Romslo  1988).  As 
mentioned in section (1.4.3), TBI uptake occurs by receptor-mediated endocytosis   43 
of diferric TF. During iron overload, TF saturation may reach up to 100% which is 
accompanied by increased plasma NTBI levels, in which case the liver is able to 
take up NTBI to protect cells from its harmful effects. The liver can also take up 
other forms of iron including: ferritin (Adams et al. 1988; Osterloh and Aisen 1989), 
haem-haemopexin complex (Smith and Morgan 1981; Smith and Hunt 1990), and 
haemoglobin-haptoglobin (Kristiansen et al. 2001).  
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Figure 1.5 Iron uptake by hepatocytes. 
(1) TFR1 pathway: Diferric TF binds to TFR1 and is endocytosed into endosomes. 
Acidified  endosome  releases  iron  via  DMT1  after  being  reduced  to  Fe
2+  by 
STEAP3. Apo TF is recycled. (2) TFR2 pathway:  similar to the TFR1 pathway. (3) 
NTBI uptake: Iron is reduced by ferrireductase and transported inside the cytosol by 
the  iron  carrier.  (4)  Ferritin  uptake:  Ferritin  is  endocytosed  after  binding  to  its 
membrane  receptor.  The  endosome  is  then  transferred  to  the  lysosomal 
compartment  and  iron  is  then  either  directed  to  intracellular  ferritin  or  to  the 
transient iron pool.  (5) Uptake of haem-haemopexin and haemoglobin-haptoglobin 
complexes:  Complexes  bind  their  receptors  (CD91  for  haem-haemopexin  and 
CD163  for  haemoglobin-haptoglobin)  and  are  endocytosed  and  moved  to 
lysosomes. Haem is then removed and oxidised by HO1 and moved to transient 
iron pool. (6) Hepatic iron efflux: Iron is released from the hepatocytes by IREG1 
and oxidised by Cp before binding to TF. Modified from (Chua et al. 2007). 
 
HFE
 
TF
 
Transit iron pool 
Fe
2+ 
DMT1
 
Fe
3+ 
Fe
2+ 
TFR1
 
TFR2
 
Diferric-TF
 
Fe
3+ 
Fe
2+ 
IREG1
 
Ceruloplasmin
 
TF
 
Diferric-TF
 
Endosome
 
Ferritin
 
Ferritin
 
Ferritin receptor
 
Lysosome
 
HO
  Haem
 
Haemoglobin-  
haptoglobin
 
Haem- haemopexin 
Fe
3+ 
Fe
2+ 
NTBI
 
Ferrireductase
 
DMT1
 
ZIP14
 ?
 
STEAP3
 
1 
2 
3 
4 
5 
6   45 
1.5.1.1 Uptake of TBI 
 
TFR1  expression  has  been  well  known  since  1977  (Grohlich  et  al.  1977).  As 
described in section 1.4.3, TBI uptake occurs by receptor-mediated endocytosis of 
the TFR1-TBI complex, release of iron from acidic endosomes, and return of the 
TFR1-TF complex to the cell membrane (Figure 1.5). In hepatocytes, each cycle 
takes around 4-15 min (Morgan and Baker 1986; Bacon and Tavill 1984). Iron is 
reduced possibly by STEAP3, and transferred to the cytoplasm by DMT1 (Fleming 
et al. 1998; Trinder et al. 2000). Inside the cytosol, iron is either stored as ferritin or 
incorporated into haem synthesis in the mitochondria. 
Hepatic  iron  levels  affect  TBI  uptake,  as  it  is  decreased  in  dietary  iron-loading 
subsequent to decreased TFR1 expression (Chua et al. 2006a). On the other hand, 
TBI  uptake  is  increased  in  iron-deficient  liver  cells  owing  to  increased  TFR1 
expression (Morton and Tavill 1978; Trinder et al. 1990). 
However, at least two mechanisms have been documented for TFR1-independent 
TBI uptake. The first mechanism involves binding of iron-TF to low affinity sites on 
the  cell  membrane  with  subsequent  endocytosis  and  iron  release  from  the 
endosomes  via  DMT1  (Trinder  et  al.  1986,  Morgan  et  al.  1986).  The  second 
mechanism  involves  iron  release  from  TF  at  the  cell  membrane  which  is  then 
transferred inside the cell via a transporter. However, this pathway seems to require 
reduction  of  Fe
3+  to  Fe
2+,  as  iron uptake  by  hepatocytes  is  inhibited  by ferrous 
chelators (Thorstensen and Ramslo 1988; Thorstensen 1988).  The transporter-
mediated step in the second iron uptake mechanism seems to transport both TBI 
and NTBI, since TBI uptake by hepatoma cells is inhibited by NTBI (Trinder and 
Morga 1997) and vice versa (Chua et al. 2004; Graham et al. 1998b). Trinder and 
Morgan  (1997)  showed  that  NTBI  specifically  interferes  with  the  uptake  of  iron 
released from TF on the cell membrane.   46 
TFR2  can  also  transport  TBI;  however,  it  has  lower  affinity  for  TF  than  TFR1 
(Kawabata et al. 2000; West et al. 2000). It has been shown to mediate TBI uptake 
in TRF2 over-expressing CHO cells (Kawabata et al. 1999). 
 
1.5.1.2 Uptake of NTBI 
 
In the normal state, NTBI levels are less than 1M, while in cases of iron overload, 
levels can reach up to 10M (Breuer et al. 2000, al-Refaie et al. 1992). Elevated 
plasma levels of NTBI have been reported in HH patients (Grootveld et al. 1989) 
and  in  a  murine  model  of  HFE  HH  (Chua  et  al.  2004)      Liver  NTBI  uptake  is 
inhibited by divalent metals as zinc, manganese, and cobalt (Wright et al. 1986; 
Wright et al. 1988). The mechanism of NTBI uptake by the liver has been studied in 
both hepatoma cells (Randell et al. 1994; Trinder and Morgan 1998) and isolated 
rat hepatocytes (Parkes et al. 1995; Richardson et al. 1999). Iron dissociates from 
its ligand at the cell membrane which probably involves reduction of Fe
3+ to Fe
2+ by 
ferrireductase, and subsequently transported inside the cell by a carrier (Trinder 
and Morgan 1998; Graham et al. 1998a). Several NTBI transporters have been 
hypothesised,  among  them  DMT1,  calcium  channels,  and  Zrt-Irt-like  protein  14 
(ZIP14). The role of DMT1 in NTBI uptake was supported by the reduction of Fe
3+ 
to Fe
2+  before  being transported (Chua et al. 2004; Trinder and Morgan 1998); 
however, it is not known whether STEAP3 has a membrane ferrireductase activity 
similar to that reported in the endosomal membrane (Ohgami et al. 2005). The 
repression of hepatocyte NTBI uptake by divalent metals, suggests that both iron 
and divalent metals are taken up by the same transporter (Chua et al. 2004; Baker 
et al. 1998). Moreover, HFE knockout mouse hepatocytes showed an increase in 
NTBI uptake as well as an increase in DMT1 expression (Chua et al. 2004). The 
role of HFE in NTBI uptake is supported by a recent finding of Gao et al. (2008)   47 
who  showed  that  HFE  expression  in  HepG2  cells  inhibited  NTBI  uptake  and 
decreased ZIP14 protein levels. Nevertheless, the lack of DMT1 does not eliminate 
NTBI uptake by the liver, suggesting the existence of different carriers in liver cells 
(Gunshin et al. 2005).  
L-type  calcium  channels  have  been  shown  to  mediate  NTBI  uptake  by  cardiac 
muscle cells; however, it is not known if these are required for NTBI uptake by the 
liver (Oudit at al. 2003). ZIP14, a zinc transporter, has also been shown to mediate 
NTBI uptake by mouse liver cells (Liuzzi et al. 2006).  
 
1.5.1.3 Uptake of other forms of iron (Figure 1.5) 
 
Other iron complexes can be taken up by the liver;  however, it is likely to be a 
scavenging  mechanism  rather  than  iron  uptake.  These  forms  include:  ferritin, 
haemoglobin-haptoglobin complex, and haem-haemopexin complex. As it contains 
small amount of iron (Arosio et al. 1977; Pootrakul et al. 1988; Worwood et al. 
1976), ferritin is not regarded as a main source of iron in humans. Liver scavenges 
ferritin via receptor-mediated endocytosis after binding to a specific ferritin receptor 
(Adams  et  al.  1988;  Mack  et  al.  1983;  Osterloh  and  Aisen  1989).  Once 
endocytosed, ferritin can either be catabolised within lysosomes or directed to the 
cellular ferritin pool (Sibille et al. 1989; Unger and Hershko 1974). 
Uptake  of  haem-haemopexin  complexes  is  mediated  by  receptor-mediated 
endocytosis  after  binding  to  its  specific  receptor,  CD91  (Hvidberg  et  al.  2005). 
Inside the endosome, haem is degraded by haem oxygenase. Originally, like TF, it 
was believed that haemopexin was recycled back (Smith and Hunt 1990; Smith and 
Morgan  1978;  1979).  However,  recent  findings  have  suggested  that  lysosomal 
degradation might antagonise this hypothesis (Hvidberg et al. 2005).   
Haemoglobin-haptoglobin complexes bind to their receptor, CD163, and are taken 
up  by  receptor-mediated  endocytosis.  The  complex  is  then  degraded  in  the   48 
lysosomes to release haem, which is further degraded by HO1 to release iron (Higa 
et al. 1981).   
 
1.5.2  Iron efflux from hepatocytes 
 
Unlike iron uptake, little is known about hepatic iron release. Even in the presence 
of  external  chelators,  hepatocytes  have  limited  capacity  to  release  iron.  The 
released iron is approximately 20% of iron taken up (Baker et al. 1985; Chua et al. 
2003; 2006).  The  molecular  mechanism  of  hepatic  iron  efflux  is  believed  to be 
mediated via IREG1 (Abboud et al. 2000; McKie et al. 2000; Donovan et al. 2000). 
Expression of IREG1 in mouse hepatocytes is correlated with iron efflux (Chua et 
al. 2006b). Moreover, selective disruption of the IREG1 gene resulted in increased 
cellular iron accumulation (Donovan et al. 2005). IREG1 is expressed at quite high 
levels in hepatocytes and hepatic stellate cells, and to a lesser extent in sinusoidal 
endothelial cells (Zhang et al. 2004). Before binding to TF, released Fe
2+ has to be 
oxidised  to  Fe
3+.  Ceruloplasmin  (Cp)  is  believed  to  be  the  ferroxidase,  which 
promotes  iron  efflux  by  hepatocytes  (Young  et  al.  1997).  It  is  a  liver-derived 
glycoprotein that contains more than 95% of circulating copper (Hellman and Giltin, 
2002). Cp expression has also been reported in brain, spleen, testicles, and lungs 
(Yang et al. 1986; Koschinsky et al. 1986; Aldred et al. 1987; Klomp and Giltin 
1996; Yang et al. 1996). In addition, in mice lacking Cp and patients with Cp gene 
mutations, hepatocellular iron efflux is impaired (Harris et al. 1999; Miyajima et al. 
1987; Yoshida et al. 1995). However, the exact role of Cp and IREG1 in hepatic 
iron release remains to be fully clarified. 
Hepcidin is the other hepatocyte-derived protein (to be discussed later) believed to 
play  a  vital  role  in  iron  release.  It  has  been  shown to  inhibit  iron  release from 
different cell types, such as macrophages, enterocytes, and liver cells (Ganz 2005;   49 
Rivera et al. 2005) possibly via binding to IREG1, facilitating its internalisation so 
that it is unable to participate in iron efflux (Nemeth et al. 2004b). 
 
 
1.5.3  Hepcidin 
 
Two groups investigating small antimicrobial peptides in body fluids independently 
identified hepcidin in the urine (Park et al. 2001) and plasma (Krause et al. 2000).  It 
was named Liver Expressed Antimicrobial Peptide-1 (LEAP-1) (Kraus et al. 2000) 
and Hepcidin “hep” for hepatocyte and “idin” for its antimicrobial activity (Park et al. 
2001).  Despite  being  initially  isolated  from  blood  and  urine,  hepcidin  is  highly 
expressed in human and mouse liver and to a lesser extent in intestine, lung, heart, 
brain, and kidney (Pigeon et al. 2001; Kulaksiz et al. 2005). 
The human hepcidin gene (HAMP) was mapped to the chromosome 19 (Park et al. 
2001) and encodes an 84 aminoacid prepropeptide that possesses a cleavage site. 
This  is  then  modified to  give  20  and 25-aminoacid peptides  with eight  cysteine 
residues forming four intra-chain disulfide bonds (Figure 1.6) that are conserved 
across  hepcidin-producing  species  (Hunter  et  al.  2002).  The  hepcidin  disulfide 
bonds  were  recently  revised  (Jordan et  al.  2009).  Two of  them are  required to 
stabilise the anti-parallel sheets while the other bonds are required to maintain the 
bending of the peptide (Nemeth and Ganz 2009). Hepcidin has been shown to be a 
member of the cysteine-rich antimicrobial peptide family that includes defensin, so 
called because of its antibacterial and antifungal properties (Park et al. 2001; Klaus 
et al. 2000). Consistent with its role in immunity, hepcidin has been shown to be a 
type II acute-phase protein (Nemeth et al. 2003). 
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Figure 1.6 A schematic model of the major form of human hepcidin and its 
amino acid sequence.  
This schematic model shows the main 25 amino acid form of human hepcidin with 
its amino (N) and carboxy (C) termini. Acidic amino acids are shown in red, basic 
amino acids in blue. Recently revised disulfide bonds are in yellow and are also 
shown in the amino acid sequence. Adapted from (Nemeth and Ganz 2009). 
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1.5.3.1 Role of hepcidin in iron metabolism 
 
The  role of  hepcidin  in  iron  homeostasis  was  independently  recognized by  two 
groups  working  on  mice  (Pigeon  et  al.  2001; Nicolas  et  al.  2001).  During  their 
search for genes that were up-regulated in iron-loaded mice, Pigeon et al. (2001) 
identified  hepcidin  among  the  induced  genes.  Furthermore,  they  reported  a 
decrease in hepcidin mRNA expression when animals were fed a low iron diet, 
suggesting that iron regulates hepcidin gene expression. 
The  group  of  Nicolas  (Nicolas  et  al.  2001)  generated  a  mouse  strain  lacking 
functional  Upstream  stimulatory  factor  -2  (USF2)  and  accidentally  removed  the 
neighbouring hepcidin gene. These mice showed a severe iron-overload phenotype 
similar to that observed in HH. Subsequently, it was shown that disruption of the 
hepcidin  gene  per  se  resulted  in  iron  overload  in  mice  (Lesbordes-Brion  et  al. 
2006). In humans, hepcidin gene mutations were shown to be associated with a 
severe form of haemochromatosis, called Juvenile haemochromatosis (JH) (Roetto 
et al. 2003). In addition, mice lacking the hepcidin gene develop iron loading in the 
liver, heart, and pancreas due to increased duodenal iron uptake (Nicolas et al. 
2001). On the other hand, mice over-expressing hepcidin showed profound iron 
deficiency anaemia due to decreased duodenal iron uptake (Nicolas et al. 2002a).   
Unlike humans, two hepcidin genes were found in mice (HAMP-1 and HAMP-2) 
(Nicolas et al. 2001; Pigeon et al. 2001). While the role of HAMP-1 (hepcidin 1) in 
iron  homeostasis  is  established,  the  precise  functions  of  HAMP2  (hepcidin  2) 
remain to be fully clarified. In addition, no iron deficiency was observed in mice 
over-expressing  HAMP-2  (Lou  et  al.  2004).  Therefore,  in  the  thesis  only  the 
expression of hepcidin1 is studied. 
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1.5.3.2 Mechanism of hepcidin action 
 
Circulating  hepcidin  acts  by  adjusting  iron  efflux  to  the  blood  via  binding  to  its 
receptor,  IREG1.  This  binding  triggers  internalisation  and  degradation  of  the 
complex  in  lysosomes  (De  Domenico  et  al.  2007;  Nemeth  et  al.  2004b),  and 
consequently  cellular  iron  export  stops.  It  is  believed  that  binding  involves  an 
exchange of a disulfide bond between hepcidin and the ferroportin thiol residue 
Cys326,  as  patients  with  C326S  mutations  show  early-onset  iron  overload 
phenotype, and mutant IREG1 lost its hepcidin-binding ability in vitro (Fernandes et 
al.  2009).  The  shorter  20  aminoacid  form  of  hepcidin  can  not  repress  IREG1, 
suggesting that the five N-terminal amino acids of the mature protein are the most 
critical regions for IREG1 binding (Nemeth et al. 2006). Moreover, neither mutations 
to remove any of the disulfide bridges nor removal of the two C-terminal amino 
acids of hepcidin affected its biological activity (Nemeth et al. 2006). 
Loss of IREG1 function in macrophages leads to iron retention and hypoferraemia; 
likewise, loss of IREG1 from enterocytes results in reduced iron absorption. In vivo, 
hepcidin injection inhibited intestinal iron absorption in mice (Laftah et al. 2004).  On 
the  other  hand,  reduced  hepcidin  expression  in  iron-deficient  rodent  models 
increased IREG1 expression in duodenal enterocytes (Frazer et al. 2002; Weinstein 
et al. 2002), and subsequently increased iron absorption. In addition, hepcidin has 
been shown to repress iron uptake in human intestinal epithelial cells (Caco-2) by 
down-regulating DMT1 expression (Yamaji et al. 2004). 
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1.5.3.3 Regulation of hepcidin expression by hereditary iron storage diseases  
 
HH  includes  a  diverse  group  of  disorders  that  are  accompanied  by  hepcidin 
deficiency and subsequent iron overload and organ damage. Most HH cases are 
associated with mutations in the HFE gene (type I). In others, the mutations occur 
in  genes  encoding  proteins  that  are  important  for  iron  homeostasis  (non-HFE 
haemochromatosis;  Pietrangelo,  2004).  In  type  II  (juvenile)  haemochromatosis, 
mutations occur in the hemojuvelin (HJV) or hepcidin genes is the most severe form 
of  haemochromatosis  with  maximum  hepcidin  deficiency.  In  type  III 
haemochromatosis, mutations affect TFR2 gene, and in type IV mutations occur in 
SLC40A1  gene  encoding  IREG1.  These  genes  and  their  mutations  will  be 
discussed in detail below. 
 
1.5.3.3.1 HFE haemochromatosis (Type I HH) 
 
The  HFE  gene,  identified  by  Feder  et  al.  (1996)  belongs  to  the  major 
histocompatability complex I family (MHC 1). The gene is located on chromosome 6 
and  encodes  a  343  amino  acid  protein  with  a  22  amino  acid  signal  peptide, 
extracellular (1, 2, and 3), transmembrane, and cytoplasmic domains (Figure 
1.7).  Beta-2-microglobulin (2m) interacts with 3 domain which is important for 
surface expression of HFE (Cardoso and  de Sousa 2003; Waheed et al. 1997; 
Feder et al. 1997).  In addition, a lack of the 2m gene in mice alters the expression 
of HFE and causes iron overload similar to that of HH (Santos et al. 1996).  
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Figure 1.7 The HFE structure.  
Ribbon diagram (a) and a cartoon (b) showing HFE with its three-loop extracellular 
domain (1, 2, and 3), transmembrane domain, and a cytosolic tail. Like other 
MHC1 molecules, HFE associates with 2 microglobulin (2m) via its 3 domain. 
Adapted from (Lebron et al. 1999; Fleming and Sly 2002).  
 
 
 
Several  gene  mutations  in  HFE  have  been  linked  to  HH.  The  most  common 
mutation  is  a  tyrosine  for  cysteine  substitution  at  position  282  (C282Y),  which 
interferes with 3 domain folding, interaction with 2m, and surface expression of 
the protein (Feder et al. 1997; Waheed et al. 1997). This mutation is most common 
in people of Northern European origin; however, it can also occur in Asian and 
African people albeit less frequently (Rochette et al. 1999; Acton et al. 2006). A 
second mutation in HFE was characterised in HH patients, resulting in substitution 
of an aspartate for a histidine at position 63 (H63D). This mutation, unlike C282Y, 
has no effect on the interaction between 2m and HFEand surface expression of 
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the protein (Feder et al. 1997). However, the contribution of the H63D mutation to 
HH has been controversial. 
The role of HFE mutations C282Y and H63D were studied in mouse models with 
analogous mutations C294Y and H67D, respectively (Tomatsu et al. 2003). They 
showed that mice homozygous for C294Y had higher levels of liver iron followed by 
compound  heterozygous  for  C282Y  and  H63D  and  then  mice  homozygous  for 
H63D.  
C282Y homozygotes show inconsistent penetrance of iron overload (Beutler et al. 
2002). In addition, the estimated frequency of the C282Y mutation in patients of 
Northern European origin is 1 in 150 (Feder et al. 1996). This lead to a belief that 
this  mutation  has  low  penetrance  and  there  are  many  asymptomatic  cases  of 
haemochromatosis (Bomford 2002). Although many modulator genes have been 
tested (Lee et al. 2002) and it has been suggested that hepcidin gene mutation may 
affect the expression of HFE mutation (Merryweather-Clarke et al. 2003; Jacolot et 
al. 2004), the reasons of inconsistent HFE penetrance in humans have yet to be 
determined.  On  the  other  hand,  different  gene  modifiers  for  the  HFE  mutation 
phenotype have been characterised in mice of different backgrounds with genetic 
disruption of  HFE.  Rag1  is  believed  to be  one  of  the  modifiers,  as  HFERag1
-/- 
double mutant mice showed more iron overload than  HFE
-/- mice (Miranda et al. 
2004).  Smad4  has  also  been  shown  to  be  differently  expressed  in  high  iron 
absorbing DBA and low iron absorbing C57Bl/6 mouse strains (Coppin et al. 2007). 
When crossed with hepcidin transgenic mice, HFE
-/- mice showed no hepatic iron 
accumulation, suggesting a role of hepcidin in the prevention iron overload in HFE
-/- 
mice (Nicolas et al. 2003). 
Patients homozygous for C282Y have been shown to have less urinary hepcidin 
and  less  hepcidin  mRNA  expression  than  control  subjects  (Bozzini  et  al. 2007; 
Bridle et al. 2003). Moreover, these patients showed less hepcidin in response to   56 
iron depletion and failed to upregulate hepcidin in response to oral iron (Piperno et 
al. 2007).  
 
1.5.3.3.2 Juvenile haemochromatosis (Type II  HH) 
 
Juvenile  haemochromatosis  (JH)  is  an  early-onset  hereditary  recessive disorder 
characterised by severe iron deposition in parenchymal cells and organ damage, 
which usually develops before the age of 30 years (De Gobbi et al. 2002). JH is 
caused by mutations in genes encoding HJV (Type IIA JH) (Lanzara et al. 2004; 
Papanikolaou et al. 2004) or hepcidin (type IIB) (Roetto et al. 2003)  
 
1.5.3.3.2.1 Hemojuvelin haemochromatosis (Type IIA JH) 
 
Hemojuvelin (HJV; RGMc) is a member of the repulsive guidance molecules (RGM) 
family. The HJV gene was first identified by Papanikolaou et al. (2004). Similar to 
hepcidin, in mouse the expression of HJV is detected in the liver, skeletal muscle, 
and heart (Papanikolaou et al. 2004). On the other hand, the expression of RGMa 
and RGMb is confined to the developing and adult central nervous system. HJV has 
five splice isoforms encoding proteins of 200, 313, and 426 amino acids with three 
isoforms generating the same protein (Papanikolaou et al. 2004) (Figure 1.8) 
The  full-length  (426  amino  acid)  protein  is  characterized  by  multiple  domains, 
including
 an N-terminal signal peptide, a RGD integrin-binding motif, a
 partial von 
Willebrand  factor  (VWF)  type  D  domain,  and  a  C-terminal
 
glycosilphosphatidylinositol (GPI) anchor domain. All RGM proteins
 possess a Gly-
Asp-Pro-His  (GDPH)  sequence  (Monnier  et  al.  2002).  The  full-length  protein 
undergoes a partial autocatalytic cleavage (Lin et al. 2005) to reach the plasma 
membrane (m-HJV) as a cleaved heterodimer (Kuninger et al. 2006; Silvestri et al. 
2007).    57 
It has been recently shown that HJV can bind bone morphogenic proteins (BMP) 
(Babitt et al. 2006), members of the transforming growth factor (TGF)-superfamily 
of cytokines that play a crucial role in the development of tissues, in regulating cell 
proliferation, cell differentiation, and in apoptosis (Chen et al. 2004; Gambaro et al. 
2006; Varga and Wrana 2005). The mechanism of BMP-SMAD signalling will be 
discussed later. 
HJV
 is retained in the outer layer of the plasma membrane through the GPI anchor 
motif (m-HJV); however, it can also be found as a soluble
 form (s-HJV) both in vitro 
and  in vivo  (Lin et al. 2005; Kuninger et al. 2006). S-HJV was detected in cell 
culture  supernatants  of  transfected human  hepatoma  cells  (Hep3B)  and  human 
embryonic kidney cells (HEK 293) as well as in human and rat blood  (Lin et al. 
2005; Zhang et al. 2007).  
Treatment  of  HJV-transfected  Hep3B  or  HEK  293  with  organic  iron  or 
holotransferrin  reduced  the  amount  of  s-HJV  in  the  culture  medium.  Moreover, 
recombinant s-HJV suppressed hepcidin expression in human primary hepatocytes 
in a dose-dependent manner (Lin et al. 2005). The inverse correlation between iron 
loading and s-HJV concentration in vitro lead to the hypothesis that s-HJV could be 
a negative regulator of hepcidin. The authors proposed a model in which s-HJV and 
m-HJV reciprocally regulate hepcidin expression in response to iron-load (Lin et al. 
2005). However, it is not clearly known whether s-HJV only originates from m-HJV 
or whether it has different origin, possibly heart or skeletal muscle.  
Silvestri  et  al.  (2007)  showed that  HJV  mutants  defective  in plasma  membrane 
presentation  could  still  release  s-HJV.  They  suggested  that  s-HJV  does  not 
originate from m-HJV, but is independently secreted by the cell. However, robust 
evidence  supporting  the  secretion  model  is  lacking.  In  contrast,  a  recent  study 
provided evidence that s-HJV can originate from cell surface m-HJV (Kuninger et al. 
2006). Lin et al. (2007) reported that s-HJV is generated by a proprotein convertase 
through the cleavage at a conserved polybasic RNRR site. Furthermore, Silvestri et   58 
al. (2008a) showed that s-HJV originates from furin cleavage at the C terminus at 
position 332-335 of the protein in the ER. They also showed that this cleavage was 
induced by iron deficiency and hypoxia and that release of s-HJV might be a tissue-
specific  mechanism  signalling  the  local  iron  requirement  of  skeletal  muscles 
independently of the oxygen status of the liver (Silvestri et al. 2008a).  
s-HJV has been shown to hinder BMP-2 and BMP-4 signalling both in vitro (Lin et 
al. 2005) and in vivo (Babitt et al. 2007). BMP-2 administration increases hepcidin 
expression  and  decreases  serum  iron  levels  in  vivo;  moreover,  s-HJV 
administration  decreases  hepcidin  expression,  increases  IREG1  expression, 
mobilizes splenic iron stores, and increases serum iron levels in vivo (Babitt et al. 
2007). 
HJV  and  other  members  of  the  RGM  family  have  been  shown  to  bind  to  the 
receptor neogenin (Matsunaga et al. 2004; Rajagopalan et al. 2004).  Moreover, 
Zhang et al. (2005) showed that HJV-mediated iron accumulation is enhanced by 
neogenin in vitro suggesting a link between HJV, neogenin, and iron homeostasis. 
In addition, Zhang et al. (2007) demonstrated that HJV shedding in vitro could be 
mediated by neogenin.  However, whether HJV-neogenin interaction plays a role in 
hepcidin regulation by HJV remains unclear. Recently, Xia et al. (2008) showed that 
HJV-induced  BMP  signalling  in  vitro  was  not  altered  either  by  inhibition  of 
endogenous  neogenin  or  by  neogenin  over-expression.  Therefore,  the  hepcidin 
regulation via HJV-BMP signalling occurs independently of neogenin. 
HJV haemochromatosis is characterised by severe iron overload at a young age. 
The age of onset has been reported to be as young as five years; however, it 
mostly  occurs  when  patients  are  in  their  twenties.  Patients  with  HJV  mutations 
show high serum ferritin and transferrin saturation, cardiomyopathy, hypogonadism, 
and diabetes (Papanikolaou et al. 2005).  
HJV
-/- mice showed low hepcidin expression and hepcidin was not responsive to 
high  iron,  but  responsive  to  inflammation  by  lipopolysaccharide  (LPS).  Unlike   59 
human patients, HJV
-/- mice do not show diabetes or cardiomyopathy (Niederkofler 
et al. 2005); on the other hand, they show high iron loading in the liver, heart, and 
pancreas and decreased splenic iron as seen in the human disease (Huang et al. 
2005; Niederkofler et al. 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Structure of the HJV gene.  
A diagram showing five different HJV transcripts. Each of these transcripts may be 
translated into a polypeptide. Transcripts 3, 4 and 5 generate the same protein; 
therefore,  there  are  three  HJV  isoforms  of  426,  313  or  200  amino  acids. 
Untranslated sequence is coloured white, translated sequence black. The longest 
open reading frame (ORF) is shown below transcripts. (SP, signal peptide; RGD, 
tri-amino  acid  motif;  vWf,  partial  von  Willebrand  domain;  TM,  transmembrane 
domain). Adapted from (Papanikolaou et al. 2004). 
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1.5.3.3.2.2 Hepcidin haemochromatosis (Type IIB JH) 
 
This type of haemochromatosis is caused by mutations in the HAMP gene encoding 
hepcidin;  however,  this  type  of  haemochromatosis  is  less  frequent  than  HJV 
haemochromatosis (Lanzara et al. 2004; Papanikolaou et al. 2005). Patients with 
Type IIB JH have the same characteristics of Type IIA JH such as progressive iron 
overload,  hypogonadism,  diabetes,  and  cardiomyopathy  (Rideau  et  al.  2007; 
Matthes et al. 2004; Delatycki et al. 2004).  
Hamp1
-/-  mice  show  excessive  iron  loading  in  the  liver  but  they  show  less  iron 
loading in macrophages and spleen (Nicolas et al. 2001; Lesbordes-Brion et al. 
2006). Unlike human disease, Hamp1
-/- mice did not manifest diabetes or reduced 
insulin production despite excessive iron loading in pancreatic  cells (Ramey et al. 
2007).   
 
 
1.5.3.3.3 Haemochromatosis type III (TFR2 haemochromatosis) 
 
This was the second type of HH to be identified after the cloning of  HFE gene 
(Camaschella  et  al.  2000).  Mutations  in  TFR2,  as  with  HFE  mutations,  are 
associated with high serum ferritin and transferrin saturation, as well as hepatic iron 
loading (Camaschella et al. 2000; Roetto et al. 2001; Le Gac et al. 2004). Many 
patients with TFR2 haemochromatosis show low hepcidin expression levels that is 
not proportional to the degree of iron loading (Nemeth et al. 2005). 
TFR2
-/- mice manifest hepatic iron overload and low splenic iron content (Fleming et 
al. 2002; Kawabata et al. 2005). In these mice, hepcidin expression is not induced 
in response to iron (Kawabata et al. 2005; Wallace et al. 2005), while it is induced 
by inflammatory stimuli (Lee et al. 2004). 
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1.5.3.3.4 Haemochromatosis type IV (ferroportin disease) 
 
Haemochromatosis associated with IREG1 mutation is inherited as an autosomal 
dominant disorder. It is clinically different from other iron-storage diseases and it is 
also known as ferroportin disease (Pietrangelo, 2004). Most IREG1 mutations fall in 
two categories: (a) Loss of iron export activity due to loss of IREG1 function or loss 
of IREG1 surface localisation, which is characterised by high blood ferritin levels but 
without  a  rise  in  transferrin  saturation,  and  iron  accumulation  mainly  in 
macrophages (Montosi et al. 2001; Njajou et al. 2001; De Domenico et al. 2006; 
Drakesmith et al. 2005); (b) IREG1 mutations that cause loss of hepcidin binding 
activity without affecting iron export activity. It is characterised by elevated blood 
ferritin and transferrin saturation levels and hepatic iron loading (Drakesmith et al. 
2005; Sham et al. 2005).  
 
1.5.3.4 Regulation of hepcidin expression 
 
1.5.3.4.1 Regulation by inflammation, infection, and obesity 
 
Hepcidin expression is induced by inflammation and infection. In animal models and 
human subjects, injection of LPS or Freund’s adjuvant increased hepatic hepcidin 
mRNA  expression  (Pigeon  et  al.  2001;  Frazer et  al.  2004;  Kemna  et  al.  2005; 
Nemeth et al. 2004b). Despite the fact that the increase in hepcidin expression is 
favourable for the organism during the course of an infection as it limits the iron 
availability for the pathogen, prolonged increase has a harmful effect as it leads to 
the  development  of  anaemia  of  inflammation  (AI).  Increased  hepcidin  causes 
internalisation  and  degradation  of  IREG1  that  inhibits  iron  release  from 
macrophages causing hypoferremia characteristic of AI (Ganz 2006).  The same 
response of hepcidin and anaemia has been shown in turpentine oil-injected mice   62 
(Nicolas et al. 2002b; Weinstein et al. 2002). However, the anaemia was absent in 
mice lacking USF2/hepcidin, indicating that hepcidin mediates anaemia observed in 
treated  mice.  The  inflammatory  cytokines,  mostly  interleukin  (IL)-6,  induce 
activation  of  STAT-3  that  binds  to  the  hepcidin  promoter  region  to  activate 
transcription (Wrighting and Andrews 2006; Truksa et al. 2007; Verga Falzacappa 
et al. 2007). 
IL-6 binds to its receptor on the surface of hepatocytes. The receptor complex is 
composed  of  a    (80  kDa)  subunit  and  two  13kDa)  subunits    (Figure  1.9). 
Binding of IL-6 to subunit induces dimerisation of the -subunits, which in turn 
are phosphorylated by the cytosolic JAK (janus kinase) proteins (Heinrich et al. 
2003).  The  phosphorylation  of  the  -subunits  stimulates  the  STAT  (signal 
transducer and activator of transcription) pathway. STAT3 proteins bind to the -
subunits and after phosphorylation, detach from  subunit, and then translocate to 
the nucleus as dimers where they bind to a response element within the hepcidin 
gene promoter inducing its transcription (Wrighting and Andrews 2006; Truksa et al. 
2007; Verga Falzacappa et al. 2007).  
IL-6 induces hepcidin mRNA expression in vivo and in vitro (Nemeth et al. 2003; 
2004). Hepcidin expression in hepatocytes is induced by conditioned medium from 
LPS-treated  macrophages,  and  this  response  is  blocked  by  anti-IL-6  antibodies 
(Nemeth et al. 2003; Lee et al. 2005). However, mice with genetic disruption of the 
IL-6 gene are able to regulate hepcidin in response to endotoxin, suggesting the 
existence  of  other  factors  that  regulate  hepcidin  expression  (Lee  et  al.  2004). 
Interestingly,  the  treatment  of  primary  mouse  hepatocytes  with  IL-1  and  IL-1 
strongly  increases  hepcidin  mRNA  expression  (Lee  et  al.  2005),  suggesting 
possible regulation of hepcidin by different cytokines such as IL-1. 
Obesity is characterised by low-grade inflammation (Wellen et al. 2003; Greenberg 
and Obin 2006). Adipose tissue secretes different cytokines and adipokines (lago et   63 
al. 2007) that can affect iron metabolism through induction of hepcidin expression 
causing hypoferremia. Recently, leptin, the first discovered adipokine (Zhang et al. 
1994), has been shown to  induce  hepcidin  expression  in vitro  via  JAK2-STAT3 
signalling pathway in a time-  and dose-dependent manner (Chung et al. 2007). 
Therefore, leptin in conjunction with other pro-inflammatory cytokines can contribute 
to  hypoferremia  observed  in  obese  subjects.  Recently,  Aeberli  and  coworkers 
(2009)  showed  that  overweight  children  have  higher  hepcidin  levels  and 
hypoferremia despite normal dietary iron intake and bioavailability. They concluded 
that the reduced iron availability for erythropoiesis in overweight children is likely 
due  to  hepcidin-mediated  reduced  iron  absorption  and/or  increased  iron 
sequestration. 
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Figure 1.9 Mechanism of IL-6 induction of hepcidin expression. 
Binding  of  IL-6  to  the    subunit  of  the  receptor  induces  dimerisation  of  the 
subunits, which in turn are phosphorylated by the cytosolic JAK (janus kinase) 
proteins. The phosphorylation of  subunit stimulates the STAT pathway. STAT3 
proteins are then phosphorylated, detach from the  subunit, and then translocate 
to the nucleus as dimers where it binds to response element within the hepcidin 
gene promoter inducing its transcription. Modified from (Fleming, 2007) 
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1.5.3.4.2 Regulation of hepcidin by hemojuvelin, BMPs, and Smads 
 
Membrane expression  of  HJV  leads  to  increased  hepcidin expression;  similarly, 
lack of HJV expression as in JH, is accompanied by reduced hepcidin expression 
(Babitt et al. 2006; Niederkofler et al. 2005). Babitt et al. (2006) showed that m-HJV 
binds to the type I BMP receptor and enhance the signal produced by the binding of 
BMP-2 and BMP-4. However, this signalling pathway is inhibited by s-HJV (Babitt et 
al.  2007).  BMP-7 and  BMP-9  have  been  also shown  to  be  potent  activators  of 
hepcidin expression (Babitt et al. 2007; Truksa et al. 2006); however, their activity 
does not require HJV as they are not inhibited by s-HJV (Babitt et al. 2007). 
BMPs bind to combinations of type I and type II serine/threonine kinase receptors 
(Babitt  et  al.  2006).  The  binding  of  BMPs  to  their  receptors  results  in 
phosphorylation of type I by type II receptors that in turn phosphorylate a subset of 
receptor-activated  Smads  (R-Smads;  Smad1,  5  and  8),  which  then  bind  to  a 
common mediator Smad4. This complex then translocates to the nucleus where it 
binds to specific DNA motifs and regulates hepcidin gene transcription as shown in 
Figure 1.10.  The importance of Smads in hepcidin regulation was shown in mice 
with  liver-specific  Smad4  deficiency,  these  mice  showed  very  low  hepcidin 
expression levels with iron deposition in the liver, pancreas, and kidney (Wang et al. 
2005). Moreover, these mice lost their ability to regulate hepcidin in response to IL-
6 suggesting a possible interaction between IL-6 and the Smad signalling pathway.  
A  recent  study  by  Verga  Falzacappa  et  al.  (2008)  demonstrated  that  a  BMP-
responsive element (BMP-RE) within the hepcidin promoter is important for HJV-
dependent  hepcidin  gene  expression.  Moreover,  the  mutation  of  that  BMP-RE 
abolishes hepcidin induction by IL-6 suggesting a possible crosstalk between the 
IL-6 and BMP-Smad pathways at the level of the hepcidin promoter.      66 
Smad7 is a naturally occurring inhibitor of TGF- signaling. It interacts and forms a 
complex with activated TGF- type I receptors, thus blocking the phosphorylation 
and activation of receptor-Smads and subsequent downstream signals (Nakao et 
al. 1997, Hayashi et al. 1997, Imamura et al. 1997). Smad7 expression is induced 
by TGF-1 in hepatic stellate cells (HSCs) (Stopa et al. 2000), which leads to a 
negative feed-back loop of signal transduction. 
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Figure 1.10 Schematic diagram representing the role of hemojuvelin in the 
BMP signaling pathway and hepcidin regulation.  
Membrane  HJV  (m-HJV)  interacts  with  BMPs  and  type  I  (BMPR-I)  and  type  II 
(BMPR-II)  receptors  to  form  an  active  signalling  complex.  BMPR-II  then 
phosphorylates  BMPR-I  which  in  turn  phosphorylates  Smad1,  5,  and  8. 
Phosphorylated Smads then binds to Smad4, which translocates to the nucleus, 
where  it  binds  to  BMP  responsive  elements  within  the  hepcidin  promoter  and 
induces its transcription. Soluble HJV (s-HJV) is able to interfere with BMP-SMAD 
signalling. Smad7 inhibits signalling pathway at the level of Smad phosphorylation 
by the activated receptor complex. 
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1.5.3.4.3 Regulation hepcidin by HFE and TFR2    
 
Both  HFE  and  hepcidin  are  expressed  in  hepatocytes  (Holmstorm  et  al.  2003; 
Zhang et al. 2004). The role of hepatocyte-specific expression of HFE in regulation 
of iron homeostasis was confirmed by a recent study by Vujic spasic et al. (2008) 
conducted on HFE
-/- mice. They found that hepatocyte-specific expression of HFE 
in these mice restores normal iron homeostasis. Therefore, HFE seems to function 
upstream  of  hepcidin  to  control  iron  homeostasis.  In  addition,  mice  with  HFE 
disruption have low hepcidin expression (Ahmad et al. 2002; Bridle et al. 2003); 
moreover, when these mice were crossed with mice over-expressing hepcidin their 
iron overload was normalised (Nicolas et al. 2003). These findings suggest that 
HFE  participates  in  the  regulation  of  iron  absorption  via  regulation  of  hepcidin 
expression; yet through an unknown mechanism.  
HFE has been shown to interact with TFR1 (Feder et al. 1998; Waheed et al. 1999) 
via its 1 and 2 domains (Bennett et al. 2000). This binding lowers the affinity of 
TFR1 for Fe-TF by competing for iron-binding sites (Feder et al. 1998; Waheed et 
al.  1999).    After  the  identification  of  TFR2  and  its  implication  in  type  III 
haemochromatosis  (Camaschella  et  al.  2000),  an  interaction  between  HFE  and 
TFR2 was hypothesised similar to TFR1. However, this interaction could not be 
shown using soluble forms of both proteins in vitro (West, Jr et al. 2000). Recently, 
co-immunoprecipitation  studies  have  demonstrated  an  interaction  between  HFE 
and TFR2 (Chen et al. 2007; Goswami and Andrews 2006). In addition, it was 
found that TFR2 competes with TFR1 for HFE binding.  
TFR2 mutations are associated with low hepcidin expression levels (Nemeth et al. 
2005), suggesting that this molecule is involved in hepcidin regulation and both 
TFR2 and HFE may be a part of the same pathway (Ganz and Nemeth 2006; 
Nemeth et al. 2005). It is hypothesised that the TFR2-HFE complex acts as an iron 
sensor, which regulates hepcidin expression in response to Fe-TF; however, this   69 
remains  to  be  confirmed.  Recently,  hepcidin  induction  by  holotransferrin  was 
associated with an interaction between TFR2 and HFE (Gao et al. 2009) suggesting 
the formation of a signalling complex composed of holotransferrin, TFR2, and HFE 
that  stimulates  hepcidin expression.  On  the  other  hand,  holotransferrin failed  to 
induce hepcidin expression in primary mouse hepatocytes lacking either HFE or 
TFR2  (Gao  et  al.  2009).    However,  a  recent  report  showed  that  holotransferrin 
induced hepcidin expression in HFE-deficient primary mouse hepatocytes (Ramey 
et al. 2009). In vitro, the binding of TFR2 to holotransferrin resulted in stimulation of 
the mitogen-activated protein kinase (MAPK) pathway that was accompanied by 
increased  phosphorylation  of  p38  and  extracellular  signal-regulated  kinases  1/2 
(ERK1/ERK2)  (Calzolari  et  al.  2006).  A  similar  response  to  holotransferrin  was 
recently reported in isolated primary mouse hepatocytes which was blocked by an 
ERK  inhibitor,  implicating  ERK1/2  in  hepcidin  expression  in  response  to 
holotransferrin (Ramey et al. 2009).    
 
1.5.3.4.4 Regulation of hepcidin by iron 
 
The investigation of the mechanism of hepcidin expression by iron has been very 
difficult. In mouse models, both short-term and chronic iron administration result in 
increased hepatic hepcidin mRNA expression (Nemeth et al. 2004a; Pigeon et al. 
2001).  In  human  studies,  oral  iron  administration  increased  urinary  hepcidin 
excretion (Nemeth et al. 2004a); likewise, phlebotomy-induced iron deficiency in 
mice reduced hepcidin expression (Nicolas et al. 2002b).  
In spite of the huge hepcidin response to iron in vivo, only a moderate response to 
holotransferrin has been reported in isolated primary hepatocytes and HepG2 cells 
(Lin et al. 2007; Gehrke et al. 2003). In addition, NTBI treatment of hepatocytes and 
HepG2 cells suppresses hepcidin expression (Nemeth et al. 2003; Gehrke et al. 
2003). In primary hepatocytes, hepcidin induction by holotransferrin is blocked by s-  70 
HJV and noggin, an inhibitor of BMP signalling (Lin et al. 2007). These findings are 
in  agreement  with  the  hypothesis  that  release  of  s-HJV  is  regulated  by 
holotransferrin, where its release is inhibited by holotransferrin, resulting in m-HJV-
mediated enhanced responsiveness to BMPs.  
However, the mechanism of iron sensing in hepatocytes is not clearly understood. 
HFE and TFR2 are thought to be iron sensors by hepatocytes (Johnson and Enns 
2004;  Robb  and  Wessling-Resnick  2004;  Goswami  and  Andrews  2006).  TFR2 
protein expression is modulated by Fe-TF in a time- and dose-dependent manner 
(Johnson and Enns 2004; Robb and Wessling-Resnick 2004); moreover, HFE can 
increase  TFR2  levels  independently  of  Fe-TF  (Chen  et  al.  2007).  These  data 
suggest that HFE indirectly regulates hepcidin expression via modulation of TFR2 
expression (Chen et al. 2007). 
 
1.5.3.4.5 Regulation of hepcidin by anaemia, erythropoietic drive, and hypoxia 
 
In humans, iron absorption is mainly synchronised by the rate of erythropoiesis and 
iron  stores.  Erythropoiesis  regulates  iron  absorption  regardless of  iron  stores  to 
provide  adequate  iron  for  the  production  of  red  blood  cells.  In  mice  models, 
phenylhydrazine- or phlebotomy- induced anaemia are associated with low hepcidin 
expression  (Nicolas  et  al.  2002b;  c).  They  also  showed  that  hypoxia  and 
erythropoietin  (EPO)  suppress  hepcidin  expression.  Therefore,  anaemia  may 
suppress  hepcidin  expression  through  tissue  hypoxia,  EPO,  or  increased 
erythropoiesis.  Pak  et  al.  (2006)  showed  that erythropoiesis  is  the  main  driving 
force  to  suppress  hepcidin  expression.    They  showed  that  blockage  of 
erythropoiesis  by  chemicals,  by  EPO  neutralising  antibodies,  or  by  irradiation 
eliminates the hepcidin-suppressive effect of anaemia (Pak et al. 2006; Vokurka et 
al. 2006).     71 
Cases of anaemia with ineffective erythropoiesis, such as -thalassemia major are 
characterised by increased iron absorption and subsequent iron overload (Nemeth 
and Ganz 2006; Origa et al. 2007) suggesting that erythropoietic drive dominates 
over iron overload in hepcidin regulation.  
Increased  erythropoiesis  is  also  associated  with  increased  levels  of  EPO  and 
soluble TFR (sTFR), both of which are associated with low hepcidin expression 
(Kattamis  et  al.  2006).  sTFR  is  produced  by  proteolytic  cleavage  of  TFR,  and 
circulates in the blood in the form of a monomer bound to TF. sTFR levels increase 
when less iron is available or when erythropoitic drive is stimulated (Beguin 2003; 
Nemeth et al. 2005). However, no alteration in hepcidin expression was found in 
mice overexpressing sTFR (Flanagan et al. 2006), a finding that remains to be 
justified.  These findings support the hypothesis that the erythron creates a novel 
mediator that is transported to hepatocytes to regulate hepcidin expression. One 
possible candidate is growth differentiation factor 15 (GDF15), a member of the 
TGF- superfamily isolated from thalassemia patients’ sera that has been shown to 
suppress hepcidin expression in vitro (Tanno et al. 2007). However, it remains to be 
clarified whether GDF15 is the modulator of hepcidin expression in thalassemia 
and/or  whether  there  are  additional  candidates.  Recently,  twisted  gastrulation 
protein  (TWSG1)  has  been  suggested  to  mediate  hepcidin  suppression  in 
anaemias with ineffective erythropoiesis. In addition, high TWSG1 expression levels 
were reported in a mouse model of thalassemia (Tanno et al. 2009).  TWSG1, a 
BMP-binding protein, is produced by developing erythroblasts and was shown to 
suppress  hepcidin  mRNA  in  vitro  by  interfering  with  BMP-mediated  hepcidin 
regulation (Tanno et al. 2009).  
 
Hypoxia is associated with a reduction in hepcidin gene expression in vivo and in 
vitro  (Nicolas  et  al.  2002b;  Choi  et  al.  2007).  Hypoxia  may  exert  its  effect  on 
hepcidin expression via different pathways. As mentioned earlier, hypoxia induces   72 
furin  expression  that  in  turns  cleaves  HJV  (Silvestri  et al.  2008a). Alternatively, 
hypoxia can induce the hepatic expression of the hypoxia-inducible factor-1 alpha 
(HIF1  subunit  (Semenza  2007)  that  associates  with  the  human  and  murine 
hepcidin promoter (Peyssonnaux et al. 2007). Mice with hepatic disruption of the 
Hippel-Lindau  gene  causing  increased  HIF1expressionpresent  a  marked 
suppression  in  hepcidin  expression.  Moreover,  IL-6  induction  of  hepcidin  was 
abrogated by stabilisation of HIF1suggesting that the hypoxia signal overrides 
the inflammatory one (Peyssonnaux et al. 2007).  
 
1.5.3.4.6 Regulation of hepcidin by TMPRSS6 
 
TMPRSS6, also known as matriptase-2, encodes a type II plasma serine protease 
(Velasco et al. 2002). The protein is mainly expressed in the liver of mice and 
humans  and  is  highly  conserved  in  mammals  (Ramsay  et  al.  2008).  Mice  with 
genetic  disruption  in  the  serine  protease  domain  of  matriptase2  (Mask)  and 
TMPRSS6
-/-  mice  have  truncal  alopecia  and  microcytic  anaemia  because  of 
decreased intestinal iron absorption owing to increased hepcidin expression (Du et 
al. 2008; Folgueras et al. 2008). In addition, TMPRSS6 was shown to abrogate 
hepcidin induction by IL-6, BMPs, and HJV in vitro (Du et al. 2008).     
Patients with mutations in TMPRSS6 have iron-refractory iron deficiency anaemia 
(IRIDA).  These  patients  show  high  hepcidin  expression  despite  iron  deficiency 
(Finberg et al. 2008; Guillem et al. 2008; Melis et al. 2008; Silvestri et al. 2009). 
These findings from mice and humans imply that matriptase2 is important to sense 
iron  deficiency  in  mammals  and  acts  as  a  potent  inhibitor  of  hepcidin  mRNA 
expression (Du et al. 2008).  
Recently, Silvestri et al. (2008b) identified HJV as a substrate for matriptase-2, a 
finding that might provide an explanation for the anaemia observed with TMPRSS6   73 
mutations.  They  demonstrated  a  physical  interaction  between  matriptase-2  and 
HJV by immunoprecipitation. Moreover, they showed that over-expression of wild-
type matriptase-2 and HJV in vitro induced a cleavage of HJV, which was absent in 
cells over-expressing mutant matriptase-2 lacking the proteolytic domain.  
Truska et al. (2009) examined the relationship between HJV and matriptase-2 in 
vivo  by  crossing  mice  lacking  HJV  with  mice  lacking  the  protease  domain  of 
matriptase-2. This mouse model presented iron overload, high plasma iron and TF 
saturation, and low hepcidin levels. Moreover, these mice retain the ability to induce 
hepcidin in response to BMP-2, BMP-4, BMP-9, and IL-6, but not to dietary iron. 
The similarity between the phenotype of these mice and HJV
-/- mice supports the 
hypothesis  that  matriptase-2  acts  on  HJV  rather  than  another  substrate 
downstream  (Truska  et  al.  2009).  In  vitro,  matriptase-2  cleaves  m-HJV  and 
generates multiple cleavage products and loss of m-HJV (Silvestri et al. 2008b). 
However, whether these cleavage products generated by matriptase2 are able to 
antagonise the binding of BMPs to cognate receptors, similar to s-HJV, remains to 
be determined.  
In contrast, the s-HJV generated in response to iron deficiency or hypoxia in vitro 
has no effect on the surface expression of m-HJV (Silvestri et al. 2008a) suggesting 
that these stimuli act mainly by generating s-HJV, which acts as an antagonist for 
BMP-induced hepcidin expression. Lee (2009) suggested that the main function of 
matriptase-2  is  to  degrade  m-HJV  removing  its  positive  effect  on  hepcidin 
expression rather than generate soluble antagonists.  However, it remains to be 
determined how matriptase-2 is regulated and whether it is regulated by iron. 
 
1.5.3.4.7 Regulation of hepcidin by upstream stimulatory factors (USFs) 
 
The upstream stimulatory factors (USFs) are members of the basic helix-loop-helix 
leucine zipper (b-HLH-LZ) family of transcription factors. Their highly conserved C-  74 
terminal domain is important for their DNA binding and dimerisation (Littlewood and 
Evan  1995).  Sawadogo  (1988)  was  first  to  explain  USFs,  he  showed  that 
adenovirus major late promoter (AdML) was transactivated by HeLa cell nuclear 
components  through  binding  to  the  E-box  motif  with  the  canonical  sequence 
CANNTG. In human, rat, and mouse, USFs has been shown to exist in two different 
forms, USF1 and USF2, encoded by two distinct genes (Henrion et al. 1995; 1996; 
Aperlo  et  al.  1996;  Lin  et  al.  1994).  Although  they  are  ubiquitously  expressed 
expressed in mammalian cells, the 43 kDa USF1 and 44 kDa USF2 proteins are 
expressed in different mammalian cells to different extents (Sirito et al. 1994; Viollet 
et al. 1996). USF1 and USF2 have been shown to bind DNA as homodimers and 
heterodimers and have comparable DNA binding abilities (Viollet et al. 1996; Sirito 
et al. 1992). However, Viollet et al. (1996) showed that the USF1-USF2 heterodimer 
is the main DNA binding species in vivo. These transcription factors control a broad 
range  of  genes  including  glucose-responsive  genes,  genes  for  glycoprotein  B, 
vasopressin,  and  cyclin  B1, as  well  as  genes  that  control  the  circadian  rhythm 
(period, timeless, and clock) (Yamashita et al. 2001; Wang and Sul 1995; Casado 
et al. 1999; Vallone et al. 2004; Farina et al. 1996; McDonald et al. 2001; Camara-
Clayette  et  al.  1999).  Gene  ablation  studies  in  mice  have  linked  USF2  to  iron 
metabolism. These mice showed lack of hepcidin expression and severe tissue iron 
overload (Nicolas et al. 2001). Moreover, USF1 and USF2 have been shown to 
regulate hepcidin gene expression through binding to E-boxes in hepcidin gene 
promoter  (Bayele  et al.  2006);  these  investigators  also  suggested  that hepcidin 
expression  might  also  be  under  pulsatile  or  rhythmic  transcriptional  control. 
Interestingly, TGF-and2m, which play a role in iron metabolism, are similarly 
regulated  (Scholtz  et  al.  1996;  Gobin  et  al.  2003).  Therefore,  USFs  might  be 
involved in iron homeostasis through regulation of these genes.  
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1.6 Aims 
 
Hepcidin is the key regulator of systemic iron homeostasis acting as a negative 
regulator of intestinal iron absorption. In recent years, several proteins have been 
identified to act as upstream regulators of hepcidin expression, such as HFE and 
HJV. Despite the fact that HFE was discovered more than a decade ago, the exact 
role of HFE in hepcidin regulation is not clearly understood. Although hepcidin is 
regulated by iron, the molecules involved in this regulation, and whether HFE is 
involved in this regulation, remain to be clarified. Moreover, little is known about the 
regulation of HJV expression. Therefore, the aims of this study were: 
  To further elucidate the mechanism of hepcidin regulation by iron in vivo and 
the role of HFE in hepcidin regulation by iron (Chapter 3). 
  To study the regulation of hepcidin and HJV expression during inflammation 
by LPS in vivo and pro-inflammatory cytokines in vitro and the role of HFE in 
their regulation (Chapter 4). 
  To investigate the possible regulation of HJV expression by USFs (Chapter 
5). 
Wild-type and HFE KO animal models were used to investigate the regulation of 
hepcidin  by  iron  in  vivo;  the  same  animal  models  and  in  vitro  studies  were 
conducted  to  study  the  regulation  of  hepcidin  and  HJV  expression  during 
inflammation. A possible regulation of HJV by USFs was also examined in vitro and 
in vivo using the ChIP assay.   76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: General Materials and Methods 
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2.1 Gene expression levels by Real-Time Polymerase Chain Reaction  
 
 
2.1.1 RNA extraction by TRIzol
® reagent 
 
Precautions were taken against contamination of samples with RNAses. The bench 
working area was cleaned with RNAse ZAP (Ambion Ltd., UK), disposable gloves 
were worn at all times, and sterile disposable plasticware and pipettes for RNA 
work only were used.  
RNA  extraction  was  carried  out  using  the  TRIzol
®/chloroform  extraction  and 
isopropyl  alcohol  precipitation  according  to  the  manufacturer’s  instructions 
(Chomczynski and Sacchi 1987). TRIzol
® reagent (Invitrogen Ltd., UK) was added 
to the cells or frozen tissue (1mL was used per well of six well plate or 100mg 
tissue) and then transferred to sterile 1.5mL microcentrifuge tubes. Samples were 
then  incubated  at  room  temperature  for  5  minutes  for  complete  dissociation  of 
nucleotide/protein complexes. Chloroform (Sigma, UK) was added to the samples 
(200L/ sample) and samples were shaken vigorously by hand for 15 seconds. 
Tubes were incubated at room temperature for 3 minutes, and then centrifuged at 
12,000 x g for 15 minutes at 4
oC. The mixture separated into a lower red, phenol-
choloroform  phase,  which  contained  DNA  and  protein  and  a  colourless  upper 
aqueous phase containing the RNA. The aqueous phase was carefully removed 
with a pipette and transferred to a clean microcentrifuge tube and the lower organic 
phase was discarded.  
The RNA was precipitated from the aqueous phase with isopropyl alcohol (Sigma, 
UK)  (500L/  sample),  by  vortexing,  incubating samples for  10  minutes  at  room 
temperature and centrifuging at 12,000 x g for 10 minutes at 4
oC. The supernatant 
was  removed  and  the  RNA  pellet  washed  in  70%  ethanol  (1mL/sample)  and 
centrifuged at 8000 x g for 5 minutes at 4
oC. The supernatant was removed and the   78 
pellet  air-dried  for  10  minutes  at  room  temperature.  The  RNA  pellet  was 
resuspended in DEPC- treated water (Ambion Ltd., UK). 
  
2.1.2  RNA concentration and purity 
 
The RNA concentration was quantified by measuring the absorbance of RNA in 
water at 260nm using a spectrophotometer (Beckman DU 650 Spectrophotometer, 
High Wycombe, UK). The concentration was calculated using the formula: 
RNA concentration (g/mL) = A260 x dilution x 40. The RNA had an A260/280 ratio 
between  1.8  and  2.00  indicating  RNA  free  of  contamination.  RNA  quality  was 
further assessed by running the RNA solution on a 2% agarose/Tris-Acetate EDTA 
(TAE) gel stained with ethidium bromide and visualised under UV light to show RNA 
integrity and to detect the presence of contaminating DNA. The RNA samples were 
kept at -80
oC until required. 
 
2.1.3 cDNA synthesis 
 
Complementary  DNA  was  synthesised  using  the  Abgene  Reverse-iT  1
st  Strand 
Synthesis Kit (Abgene, UK) using the PTC-100 thermocycler (MJ Research, NV, 
USA). Following DNase I (Ambion Ltd., UK) treatment for 30 minutes at 37
oC, 1g 
of total RNA was used as a template and incubated with 500nM oligo dT primer and 
water  for  5  minutes  at  70
oC  to  denature  any  secondary  structure.  First  strand 
synthesis  buffer,  dNTPs,  and  reverse  transcriptase  were  added.  Reaction 
components were incubated at 47
oC for 60 minutes then at 70
oC for 10 minutes to 
inactivate the enzyme. cDNA was stored at -20
oC until required. 
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2.1.4 Real-Time PCR amplification 
 
Real-time quantitative gene analysis was performed using a Lightcycler system II 
(Roche  Diagnostics  GmbH,  Germany),  Lightcycler  version  3.5  software  (Roche 
Molecular Biochemicals, Germany) and QuantiTect SYBR
® Green PCR Kit (Qiagen, 
UK). QuantiTect SYBR
® Green master mix contains SYBR
® Green, HotStart Taq 
DNA Polymerase and a dNTP mix (including dUTP). SYBR
® green present in the 
PCR mixture binds to dsDNA, but not ssDNA, which is excited at 494nm and emits 
light at 521nm. Monitoring of emissions at 521nm allows indirect quantification of 
the dsDNA concentration within the reaction capillary. Fluorescence at 521nm is 
quantified  within  each  reaction  capillary  following  the  completion  of  every  PCR 
extension step. The PCR cycle at which the fluorescence reaches a threshold value 
is used as a measure of relative template concentration. The second derivative 
maximal method was used to determine threshold values of fluorescence. Cycle 
threshold (Ct) values were obtained for each gene of interest and the housekeeping 
gene.  Gene  expression  was  normalized  to  that  of  the  housekeeping  gene  and 
represented as  ΔCt  values.  For  each  sample the  mean of  the ΔCt  values  was 
calculated. SYBR green does not interfere with PCR cycling as it dissociates from 
the  DNA  product  during  the  denaturation  step of  the  following  PCR  cycle.  The 
experiment was performed in duplicate. For each sample, the gene of interest and 
the housekeeping gene were run in parallel. Each PCR reaction mix contained 1L 
of cDNA template, 5pmol forward and 5pmol reverse primers, 10L 2x QuantiTect 
SYBR
® Green PCR master mix and water to a final volume of 20L. The primers 
used  for  real-time  PCR  were  synthesised  by  Sigma-Genosys  Ltd.  (Poole,  UK). 
BLAST  (http://www.ncbi.nlm.nih.gov/BLAST/)  searches  were  conducted  on  all 
primers to ensure unique specificity to the gene of interest. Primers’ suitability was 
determined by producing a single product of the correct length after PCR cycling   80 
and agarose gel electrophoresis. A single peak on the meltcurve analysis was also 
used to determine the suitability of the primers used. For the primers’ sequences 
see Table1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   81 
Table 2.1 Mouse and human primer sequences used for real-time PCR analysis 
 
Primer  Accession No*  Forward 5´---------------3´  Tm
o  Reverse 5´---------------3´  Tm
o 
Product 
length (bp) 
Mouse β-Actin  NM_007393.2  GACGGCCAAGTCATCACTATT  65.0  CCACAGGATTCCATACCCAAGA  66.8  88 
Mouse hepcidin 1  AF503444.1  CCTATCTCCATCAACAGATG  57.0  AACAGATACCACACTGGGAA  59.4  170 
Mouse TNF-  NM_013693.2  CCAGACCCTCACACTCAGATCA  66.6  CACTTGGTGGTTTGCTACGAC  64.4  58 
Mouse IL-6  NM_031168.1  AGTTGCCTTCTTGGGACTGA  63.8  TCCACGATTTCCCAGAGAAC  64  156 
Mouse TGF-  NM_011577.1  CACCGGAGAGCCCTGGATA  67.4  TGTACAGCTGCCGCACACA  68.1  72 
Mouse hemojuvelin  NM_027126.3  TGCCAGAAGGCTGTGTAAGG  65.3  TCTAAATCCGTCAAGAAGACTCG  63.4  149 
Mouse Bmp-6  NM_007556  ATGGCAGGACTGGATCATTGC  68.4  CCATCACAGTAGTTGGCAGCG  67.8  53 
Mouse Bmp-2  NM_007553.2  TGGAAGTGGCCCATTTAGAG  63.8  TGACGCTTTTCTCGTTTGTG  63.9  165 
Mouse Bmp-4  NM_007554.2  ACGTAGTCCCAAGCATCACC  63.9  TCAGTTCAGTGGGGACACAA  64.3  262 
Human GAPDH  NM_002046.3  TGGTATCGTGGAAGGACTC  60.1  AGTAGAGGCAGGGATGATG  59.2  129 
Human hepcidin  NM_021175.2  CTGCAACCCCAGGACAGAG  66  GGAATAAATAAGGAAGGGAGG  59.3  191 
Human hemojuvelin  NM_145277.4  GGAGCTTGGCCTCTACTGGA  65.7  ATGGTGAGCTTCCGGGTG  66.3  100 
 
            *GenBank accession numbers (http://www.ncbi.nlm.nih.gov)  82 
2.1.5 Real time PCR cycling parameters 
 
The real time PCR conditions were as suggested in the manufacturer’s protocol 
(Qiagen, UK), this included an initial denaturation at 95
 oC for 15 minutes, followed 
by PCR cycles of denaturation at 94
 oC for 15 seconds, annealing at 65
 oC for 20 
seconds,  extension  at  72
  oC  for  30  seconds.  The  temperature  of  fluorescence 
acquisition was set at 2
oC below the product melting temperature and held for 5 
seconds. Meltcurve analysis followed each RT-PCR run. 
The ratio of relative abundance of the gene of interest to constitutively expressed 
housekeeping  gene  was  calculated  by  the  Lightcycler  Relative  Quantification 
software version 1.0 (RelQuant) (Roche Diagnostics GmbH, Germany). 
 
2.1.6 Analysis of melting curve 
 
Meltcurve analysis was performed after PCR amplification cycles. Each dsDNA has 
its own melting temperature based on its length and G-C content; therefore, melting 
curve analysis can be used to identify unwanted PCR by-products such as primer- 
dimers and non-specific products. This analysis involved heating the PCR products 
at 65
 oC for 10 seconds; the temperature was then slowly increased to 95
oC with a 
ramp rate of 0.5
oC/second, whilst the fluorescence was monitored continuously. At 
65
oC  all  DNA  in  the  PCR  product  is  double  stranded;  therefore,  SYBR  green 
binding  and  fluorescence  emission  is  maximal.  As  the  temperature  is  elevated, 
DNA  is  denatured,  SYBR  green  dissociates  and  fluorescence  is  decreased. 
Meltcurve was produced by plotting fluorescence against temperature (Figure 2.1).  
Primer-dimers and other non-specific products can be identified using this method 
as they usually melt at lower temperatures than the desired product. Increasing the 
fluorescence  acquisition  temperature  used  during  PCR  to  above  the  melting 
temperature  of  the  primer-dimer  and  non-specific  products,  eliminates  any   83 
fluorescence due to the presence of these products. The presence of a single peak 
in  melting  curve  indicates the  specificity of  the primers  used  (Figure 2.2).  PCR 
products were also analysed by gel electrophoresis, as described in Section 2.  
 
 
 
Figure 2.1 Representative graph of the meltcurve of a gene product.  
At 65
oC all DNA in the PCR product is double stranded; therefore, SYBR green 
binding  and  fluorescence  emission  is  maximal.  As  the  temperature  is  elevated, 
DNA is denatured, SYBR green dissociates and fluorescence is decreased. 
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Figure  2.2  Representative  graph  of  meltcurve  peak  analysis  of  a  gene 
product. 
A graph of meltcurve peak analysis of a gene PCR product showing a single peak 
that indicates specificity of the primers used for PCR amplification. 
  
 
2.2  Agarose gel electrophoresis 
 
To  visually  analyse  DNA  and  RNA,  samples  were  resolved  on  1%  (w/v) 
agarose/TAE gels containing 0.5 g/mL ethidium bromide (Sigma, UK). Samples 
were run alongside the molecular weight markers (Bioline, UK) using a horizontal 
gel  apparatus  (Bio-Rad,  UK).  Gels  were  prepared  by  dissolving  2g  agarose  in 
200mL of 1X TAE by microwaving. Ethidium bromide (0.5g/mL) was then added to 
the cooled molten agarose and then poured into a gel cast, a comb added and the 
gel allowed to set for 30 minutes at room temperature before use. 
Before  loading,  DNA  or  RNA  was  mixed  with  0.6  volume  of  6x  loading  buffer 
(0.25% bromophenol blue (w/v), 40% Sucrose (w/v) in water). Electrophoresis was 
carried out at 120 volts for 20 minutes. DNA/RNA  bands were visualised under   85 
ultraviolet illumination and images were captured using a Fluor-S MultiImager (Bio-
Rad). 
2.3 Generation of HJV promoter-reporter construct 
 
2.3.1 Amplification of HJV promoter 
 
A portion of the human HJV promoter extending 1.2Kb upstream of the beginning of 
the  first  HJV  exon  was  amplified  by  PCR  from  placental  genomic  DNA  as  a 
template  using  the  PTC-100  thermocycler  (MJ  Research)  and  Phusion  High- 
Fidelity DNA Polymerase (New England Biolabs, UK). The following primers were 
used: sense 5’ CATGCTAGCAAGTGACCCTCCTGCCTCAG,  the  NheI restriction 
site  is  underlined; antisense 5’  CATCTCGAGCTGCTGTCTCACTGAGGTCA,  the 
XhoI restriction site is underlined, both synthesised by Sigma-Genosys Ltd.. The 
PCR reaction mix contained 250ng of  human genomic DNA, forward and reverse 
primers to a final concentration of 0.5M, 10L 5x Phusion HF Buffer, 500M each 
of dNTPs, 1 unit of Phusion DNA polymerase, and water to a final volume of 50L. 
The cycling parameters were 98
oC for 10 seconds (denaturation), 72
oC for 2 min 
(annealing and extension); 35 cycles of PCR were performed with a final extension 
for 7 min at 72
oC. This was followed by gel electrophoresis of the PCR product, as 
described in Section 2.2 The PCR product was purified from the gel as described in 
Section 2.3.2 below. 
 
2.3.2 Gel extraction of PCR products 
 
PCR  products  were  purified  from  TAE  gels  using  a  Geneclean  kit  (BIO101, 
Anachem Ltd, Luton, UK). About 300mg of the product was excised from the gel 
using a clean scalpel and placed into a 1.5mL microcentrifuge tube with 400L of 
glassmilk. Tubes were then incubated at 55
oC for 10 minutes to dissolve the gel. 
Glassmilk-DNA/gel  mixture  was  placed  into  Geneclean  spin  filter  column  and   86 
centrifuged at  12,000  x  g for  1  minute  to bind  the  DNA  to  the  membrane  and 
glassmilk/gel in the flowthrough was discarded. The membrane was washed with 
wash buffer and dried by centrifugation at 12,000x g for 2 minutes. DNA was then 
resuspended in 15L elution buffer and collected by centrifuging at 12,000 x g for 1 
minute.  The  DNA  concentration  was  quantified  using  a  spectrophotometer 
(Beckman DU 650 Spectrophotometer) and calculated using the formula: 
DNA concentration (g/mL) = A260 x dilution x 50 
 
2.3.3 Restriction digestion of the PCR product 
 
Restriction digestion of clean PCR product was performed in 1X NEB buffer 2 (10 
mM Tris-HCl, 10 mM MgCl2, 50 mM NaCl, 1 mM Dithiothreitol (DTT) pH 7.9, 10 
units of NheI, 10 units of XhoI (New England Biolabs) and water to a final volume of 
50 L. The reaction was incubated at 37
oC for 24 hours followed by incubation at 
65
  oC for 10 minutes to inactivate the enzymes. The digested PCR product was 
then purified as described in Section 2.3.2 
 
2.3.4 Ligation of the PCR product into luciferase reporter vector 
 
The PCR product was cloned into NheI and XhoI sites of pre-digested pGL3 basic 
vector (Promega, UK) (Figure 2.3) to generate a HJV promoter-luciferase reporter 
construct (HJVP1.2-luc). Ligation reaction was carried out using 200ng of clean-
digested PCR product, 100ng of digested pGL3-basic vector, NEB’s 2X T4 DNA 
ligase buffer (100mM Tris-HCl, pH 7.5; 20mM MgCl2; 20 mM DTT; 2mM ATP), 4.5 
units of T4 DNA ligase. The 10L reaction was incubated at 12
oC overnight. 
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Figure 2.3 pGL3-Basic Vector circle map showing different cloning sites.  
The  vector  contains  cDNA  encoding  the  modified  firefly  luciferase  (luc+),  the 
ampicillin resistance gene in E. coli (Amp
r), and the origin of replication in E. coli 
(ori). From http://www.promega.com/tbs/tm033/tm033.pdf. 
 
 
 
2.3.5 Transformation 
 
DH5-  competent  cells  (Invitrogen)  were  retrieved  from  -80
oC  storage  and 
immediately placed on ice until thawed. To 100L of cells, 5L ligation product was 
added. A pipette tip was used to mix the reaction by stirring, taking care not to 
pipette  up  and  down.  The  tube  was  kept  on  ice  for  30  minutes  and  was 
subsequently heat-shocked for 35 seconds in a water bath set exactly at 42
oC. The 
tube  was  then  put  on  ice  for  2  minutes  after  which  500L  of  SOC  medium 
(Invitrogen) was added and the tube incubated at 37
oC, 230 rpm for 60 minutes. 
Cells were plated out onto selection plates: LB agar with 100g/mL ampicillin and 
left  to  grow  overnight  at  37
oC.  Individual  colonies  were  then  picked  up  and   88 
resuspended  in  5mL  LB  broth  at  37
oC,  230  rpm  overnight.  Plasmid  DNA  was 
isolated  using  Nucleospin
®  plasmid  miniprep  columns  (Macherey-Nagel,  Duren, 
Germany), as described in Section 2.3.6 below. 
 
2.3.6 Plasmid DNA isolation 
 
Cells were pelleted at 11,000 x g for 30 seconds and supernatant was discarded. 
The  pellet  was  resuspended  in  250L  of  buffer  A1,  after  which  250L  of 
SDS/alkaline lysis buffer (A2) was added and the sample was inverted 6-8 times 
and incubated at room temperature for 2 minutes.  Neutralisation buffer A3 (300L) 
was  added  and  the  tube  was  inverted  gently  6-8  times.  The  sample  was  then 
centrifuged  at  12,000  x  g  for  10  minutes  at  room  temperature.  A  Nucleospin
® 
plasmid column was placed into a collection tube and the resulting supernatant was 
added to the column. This was centrifuged for 1 minute at 11,000 x g and the 
flowthrough  was  discarded.  The  Nucleospin
®  column  was  washed  with  600L 
washing buffer (AW) and then centrifuged at 11,000 x g for 1 minute, discarding the 
flow through. The column was centrifuged again for 2 minutes to dry the membrane. 
The column was placed into a clean microcentrifuge tube and 50l of elution buffer 
AE was added to the centre of the column. This was left to stand for 2 minutes and 
then centrifuged at 11,000 x g for 1 minute.  
 
2.3.7 Restriction digestion of isolated plasmid 
 
The resulting eluent was then digested with NheI and XhoI performed in 1X NEB 
buffer 2 (10 mM Tris-HCl, 10 mM MgCl2, 50 mM NaCl, 1 mM DTT), 10 units of Nhe 
I , 10 units of Xho I (New England Biolabs) and water to a final volume of 20L. The 
reaction was incubated at 37
oC for 2 hours. The digested samples were then run on   89 
a 1% agarose/ethidium bromide gel in parallel with the undigested one to verify that 
they contained the correct size of promoter insert. The plasmid was then sent for 
sequencing (Wolfson Institute for Biomedical Research, UCL, UK).  
 
2.4 Growth and propagation of HuH7 and HepG2 cells 
 
The  HuH7 and  HepG2  human  hepatoma  cell  lines  were from  our  departmental 
liquid nitrogen frozen stocks (Department of Biochemistry and Molecular Biology, 
UCL, UK). The cells were removed from liquid nitrogen storage and left at room 
temperature for 1 minute to thaw. The cell-containing ampoule was then placed into 
a 37
oC water bath for 3 minutes to ensure that the cells were completely thawed. 
Cells were then gently added to a 75cm
2 flask containing complete growth medium, 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen), supplemented with 10% 
heat-inactivated foetal bovine serum (FBS) (Invitrogen),  1X  antibiotic-antimycotic 
mixture (Invitrogen) containing 100 units penicillin, 100g streptomycin, and 250ng 
amphotericin  B per  mL  medium.  The  cells  were  grown  at  37
oC  in  a humidified 
atmosphere of 5% CO2 in air.  
 
2.5 Transfection of HuH7 and HepG2 cells and luciferase studies 
 
Transfections  were  performed  using  Lipofectamine  2000  (Invitrogen).  The  day 
before transfection, cells were seeded onto Costar 24-well plates (Corning, USA) at 
densities of approximately 10
4 cells per well and the medium was changed after 24 
hours  until  the  cells  reached  85%  confluence.  For  each  well  to  be  transfected, 
200ng of HJVP1.2-luc, mtHJVP1.2-luc, or 200ng of the empty pGL3Basic vector 
(Promega) and 50ng pSVgal vector (Promega), which was used as an internal 
control  to  normalize  transfection  efficiencies,  were  diluted  in  50L  OptiMEM  1   90 
(Invitrogen). In addition, for each well to be transfected, 1L of Lipofectamine2000 
was diluted into 50L OptiMEM 1. Both diluted DNA and Lipofectamine were added 
together and mixed gently. The mixture was then incubated at room temperature for 
20 minutes to allow DNA-liposome complexes to form. Meanwhile, wells containing 
cells  to  be  transfected  were  washed  with  serum-free  DMEM  and  all  remaining 
residual liquid was removed by aspiration. Serum-free DMEM (800L) was then 
added to each well. To each well, 100L of complex was gently added and plates 
were  incubated  at  37
oC  overnight.  The  medium  was  then  replaced  with  fresh 
DMEM with 10% FBS and antibiotics. After a further 24 hours, the medium was 
replaced  with  fresh  serum-free  DMEM  or  serum-free  DMEM  containing  TNF- 
(20ng/ml; R&D Systems, Minneapolis, MN, USA) for 24 hours. This was done in 
triplicate.  At  the  end  of  the  incubation  period,  the  medium  was  removed  by 
aspiration and the cells were washed twice with PBS (Invitrogen). Cells were lysed 
with  100L  1X  Reporter  Lysis  Buffer  (Promega)  ensuring  that  all  cells  were 
covered. Plates were then placed into the -80
oC freezer for a freeze-thaw cycle to 
ensure complete lysis of all cells. Cells were transferred to a microcentrifuge tube, 
and placed on ice. The tube was vortexed and then centrifuged at 12,000 x g for 15 
seconds at room temperature. The supernatant was transferred to a new tube and 
then stored at -80
oC for future use. 
The luciferase assay was carried out using Luciferase Assay System (Promega), 96 
well plates (Nunc, Paisley, United Kingdom) and a Tropix microplate luminometer 
(Applied Biosystems, Foster city, CA, USA). Cell lysate (20L) was added to each 
well. The luminometer was programmed to inject 100L of the Luciferase Assay 
Reagent  per  well  then  to  measure  the  light  emitted  for  10  seconds.  The  -
galactosidase assay was done using  the  Beta-Glo reagent (Promega). Beta-Glo 
(20L) reagent was added per well and the plate was incubated for 30 minutes at   91 
room  temperature  before  measurement  of  light  emission  using  the  microplate 
luminometer. 
 
2.6  Western blot analysis 
 
2.6.1 Preparation of cell and tissue lysate  
 
Cells were washed twice with cold PBS taking care not to disturb the monolayer. To 
each well, 200L of ice-cold RIPA buffer (50mM Tris-HCl pH 8.0, 150mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing Complete Mini Protease 
Inhibitor Cocktail (Roche) and phosphatase inhibitors (Sigma) was added. Plates 
were  kept  at  -80
oC  to  aid  cell  lysis,  lysates  were  then  transferred  to  sterile 
microcentrifuge tubes. For total tissue lysate preparation, tissues were placed in a 
microcentrifuge  tube  and  homogenised  in  RIPA  buffer  with  protease  and 
phosphatase inhibitors using a Pellet Pestle 
® Motor (Anachem, UK). Tubes were 
then kept for 30 minutes on ice. Tubes from both cell and tissue lysates were then 
placed into a microcentrifuge at 4
oC and spun for 15 minutes at 13000 x g. The 
supernatant was then transferred to a fresh sterile microcentrifuge tube and stored 
at -80
oC for future use. The pellet was discarded. 
 
2.6.2 Protein quantification in cell and tissue lysates 
 
Proteins were quantified by using the BCA Protein Assay Kit (Pierce). Standards 
were prepared from bovine serum albumin (BSA) (ranging from 0-2000g/mL). The 
working reagent (WR) was freshly prepared by mixing 50 parts of BCA™ Reagent 
A with 1 part of BCA™ Reagent B.    92 
In a 96-well microplate, 25μl of each standard or unknown sample replicate were 
added per well. To each well, 200μl of the WR was added and the plate was mixed 
thoroughly on a plate shaker for 30 seconds. The plate was then incubated at 37°C 
for  30  minutes  followed  by  cooling  to  room  temperature. Absorbance  was  then 
measured at 570nm using a plate reader (Labsystem Multiscan MS, UK). 
The  average  absorbance  of  the  blank  replicates  was  subtracted  from  the 
absorbance measurements of all other individual standard and sample replicates.  
A standard curve was prepared by plotting the average blank-corrected absorbance 
for each standard vs. its concentration in μg/ml (Figure 2.4). The standard curve 
was used to determine the protein concentration of each unknown sample. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 BCA protein standard curve.  
The standard curve was made by plotting the average blank-corrected absorbance 
for  each  standard  vs.  its  concentration  in  μg/ml.  The  equation  used  for 
determination of protein concentration is shown on the figure. 
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2.6.3 SDS-PAGE 
 
Sodium  dodecyl  sulphate-polyacrylamide  gel  electrophoresis  (SDS-PAGE)  was 
performed using XCell SureLock™ and 1.5 mm gel cassettes (Invitrogen). A 12% 
(v/v) gel was prepared using 0.375M Tris-HCl (pH 8.8), 12% (v/v) bisacrylamide 
(Sigma),  0.1%  (w/v)  SDS,  0.0625%  (w/v)  ammonium  persulphate  and  0.0003% 
(v/v) TEMED. The gel solution was mixed and approximately 8ml was poured into 
gel cassettes. About 2mL of butanol was added to the top of the gel to exclude air 
and encourage a straight interface. After the gel had set (after approximately 60 
minutes), the butanol was washed off with distilled water. A 4% (v/v) stacking gel 
was then prepared using 0.125M Tris-HCl (pH 6.8), 4% (v/v) bisacrylamide, 0.1% 
(w/v) SDS, 0.0625% (w/v) ammonium persulphate and 0.0003% (v/v) TEMED. The 
gel (about 2mL) was poured into the remaining space and lane-forming 1.5 mm 
plastic  combs  (10  tooth)  (Invitrogen)  were  quickly  inserted.  The  gel  was  left  to 
polymerise for approximately 45  minutes. Once  the  gel  had  set,  the  comb  was 
carefully  removed  and  the  apparatus  was  assembled  according  to  the 
manufacturer’s instructions for running of the gel. Reservoir buffer was prepared 
from 10X Glycin-Tric-SDS buffer (Sigma) by mixing 1 part of 10X buffer with 9 parts 
of distilled water. This was added to the gel-containing apparatus taking care to 
cover the wells with buffer. About 50g of protein/sample was mixed with an equal 
volume of 2X loading buffer (0.5M Tris-HCl (pH 6.8), 4.4% (w/v) SDS, 20% (v/v) 
glycerol,  3%  (v/v)  DTT  and  0.02%  (w/v)  bromophenol  blue  in  distilled  water). 
Samples  were  loaded  into  each  well  along  with  a  Kaleidoscope  Prestained 
Standard (Bio-Rad). The gel was run at 120V until the bromophenol dye front had 
migrated to about 1cm from the bottom of the gel (approximately 1 hour). Cassettes 
were levered apart using a spatula.  
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2.6.4 Immunoblotting 
 
Protein was transferred onto a PVDF membrane (Amersham Pharmacia Biotech 
UK Ltd, Berkshire, UK) by semi-dry blotting for 2 hours at a constant current of 
1mA/cm
3 (Trans-blot semi-dry transfer cell, Bio-Rad). Protein transfer was verified 
by staining the membrane with Ponceau S reagent (Sigma) for 5 minutes at room 
temperature. The stained proteins are bright pink in colour. Ponceau S reagent was 
removed by rinsing with distilled water. Membrane was blocked with PBS-T (PBS 
with  0.1%  (v/v)  Tween  20)  containing  5%  non-fat  milk  for  1  hour  at  room 
temperature  to  block  non-specific  antibody  binding.  The  membrane  was  then 
incubated with 1:500 diluted primary antibody overnight at 4
oC on a rocking platform 
and then washed 3x for 10 minutes each in PBS-T. Primary antibody was probed 
with HRP-conjugated IgG 1:5000 diluted in PBS-T for 1 hour at room temperature, 
with continuous rocking. Following secondary antibody incubation, the membrane 
was washed 3 times with PBS-T for 10 minutes (each) at room temperature. The 
membrane was then subjected to enhanced chemiluminescence (ECL) detection 
(Amersham Life Science). Equal volumes of Reagent 1 and Reagent 2 were mixed 
together then added to the membrane and left for 1 minute. Membrane was then 
photographed by a CCD camera of a Fujifilm LAS-1000 system (Fuji photo film Co., 
Ltd, Japan) and images were captured. 
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2.6.5 Stripping and re-probing western blots 
 
 
Following ECL, PVDF membranes were either placed directly into PBS-T, or stored 
wrapped in SaranWrap at 4
oC. Where re-probing with anti-actin primary antibody 
(Abcam,  UK)  was  required  as  a  loading  control,  antibodies  were  stripped  from 
membranes by immersing them in freshly prepared stripping buffer (62.5 mM Tris-
HCl, pH 6.7; 2% SDS; 100 mM 2-mercaptoethanol) at 50
oC for 30 minutes with 
occasional agitation. The membrane was then washed repeatedly in PBS-T before 
blocking and re-blotting following standard procedures, as described before. 
 
2.7 Statistical analysis 
 
Data  is  presented  as  mean  ±  standard  error  of  the  mean  (SEM).  Statistical 
significant  differences  (p<0.05)  between  two  groups  were  determined  using 
Student’s two-tailed unpaired t-test. To test the statistically significant differences 
between groups in experiments with more than two groups, ANOVA followed by 
Bonferroni  post  hoc  test  was  used.  Statistical  analysis  was  conducted  with 
Graphpad Prism software (San Diego, CA). 
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Chapter 3: Regulation of Hepcidin Expression by Iron 
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3.1 Introduction 
 
Hepcidin is a key regulator of systemic iron homeostasis. It mainly coordinates iron 
usage and storage with iron uptake (Ganz 2006). It exerts its function by binding to 
IREG1 on the surface of hepatocytes, macrophages, and enterocytes, and inducing 
its internalisation and degradation (Nemeth et al. 2004b), and subsequently leads to 
iron accumulation in macrophages and liver as well as a reduction in intestinal iron 
absorption. 
Hepcidin production is stimulated by dietary or parenteral iron loading (Pigeon et al. 
2001);  therefore,  it  provides  a  feedback  mechanism  to  decrease  intestinal  iron 
absorption.  In  contrast,  hepcidin  expression  is  decreased  in  response  to  iron 
deficiency, anaemia, and hypoxia (Nicolas et al. 2002b); therefore, this provides 
more iron to be directed to the bone marrow to sustain erythropoiesis. However, no 
iron  responsive  elements  (IRE)  have  been  identified  within  the  hepcidin  gene 
suggesting  that  hepcidin  modulation  by  iron  is  not  mediated  by  iron  regulatory 
proteins, but by other signalling pathways. 
Mutations in hepcidin, hemojuvelin, HFE, and TFR2 genes are all associated with 
abnormally low hepcidin expression levels despite iron overload (Roetto et al. 2003; 
Papanikolaou et al. 2004; Nemeth et al. 2005; Piperno et al. 2007). Mutations in the 
HFE gene are associated with the first characterised form of HH. Despite the fact 
that HFE was discovered more than a decade ago (Feder et al. 1996), the role of 
HFE in hepcidin regulation is not clearly understood. HFE binds to TFR1 (Parkkila 
et  al.  1997;  Feder  et  al.  1998;  Waheed  et  al.  1999)  and  TFR2  (Goswami  and 
Andrews 2007; West et al. 2000; Waheed et al. 2008). In addition, mice with liver-
specific  disruption  of  HFE  present  the  same  phenotype  as  HFE  KO  mice 
suggesting that the liver is the main site of HFE action to regulate iron homeostasis 
(Vujic  Spasic  et  al.  2008).  However,  these  findings  did  not  elucidate  how  HFE 
regulates  hepcidin  expression  and  iron  homeostasis.  Recently  it  has  been   98 
hypothesised that HFE is sequestered by TFR1, and that Fe-TF displaces HFE 
from  TFR1.  HFE  in  turn  binds  to  TFR2  and  this  complex  signals  to  regulate 
hepcidin expression. However, the exact mechanism remains to be fully elucidated. 
Recently,  Babitt  et  al.  (2006)  showed  that  the  BMP-Smad  signalling  pathway 
regulates  hepcidin  expression.  This  pathway  involves  members  of  the  TGF- 
superfamily, as described in Chapter 1. 
HJV has been shown to act as a BMP co-receptor to induce hepcidin expression. 
Further support for the role of BMP-Smad signalling in hepcidin regulation comes 
from the finding that mice with liver-targeted disruption of the Smad-4 gene develop 
iron overload and express very little hepcidin; in addition, these mice fail to induce 
hepcidin in response to inflammatory stimulation or iron (Wang et al. 2005). Taken 
together,  these  findings  clearly  demonstrate  the  importance  of  the  BMP-Smad 
signalling pathway in the regulation of hepcidin expression.  
Although hepcidin is regulated by iron, the molecules involved in this regulation are 
not clearly identified. In particular, the involvement of HJV-BMP-Smad signalling in 
hepcidin regulation by iron remains to be clarified. Moreover, the role of HFE in this 
signalling pathway is not known. Therefore, this study is aimed to  elucidate the 
involvement of BMP-Smad signalling in hepcidin regulation by iron. To study the 
effect of iron deficiency, mice were either fed with a control iron diet or an iron-
deficient diet. To induce iron loading, C57Bl/6 wild-type mice were injected with an 
iron compound (sodium ferric gluconate). To investigate whether HFE is involved in 
hepcidin regulation by iron and BMP-Smad signalling pathway, HFE KO mice were 
also examined in the settings of iron deficiency and iron loading. 
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3.2 Methods 
 
3.2.1 Effect of dietary iron deficiency on C57Bl/6 wild-type and HFE KO mice 
 
Weanling (at the age of 3 weeks) wild-type C57Bl/6 (n=10) and HFE KO (of C57Bl/6 
background strain; n=10) female mice were supplied by the Comparative Biology 
Unit  at  the  Royal  Free  and  UCL  Medical  School,  London.  All  the  experimental 
procedures  were  conducted  in  agreement  with  the  UK  animals  (Scientific 
Procedures) Act, 1986. Animals were kept in a 12 hour light-dark cycle, provided 
with water ad libitum, and were fed either a control diet (RM1 diet; 180 mg Fe/kg 
diet; n= 5 of each genotype) or an iron-deficient diet (7.5 mg Fe/kg diet; n=5 from 
each genotype) for 4 weeks. At the end of the experimental period (at 7 weeks of 
age),  mice  were  terminally  anaesthetised  with  intraperitoneal  pentobarbitone 
sodium (Sagatal, Rhone-Merieux, UK, 90 mg/Kg). The livers were collected, snap 
frozen  in  liquid  N2,  and  stored  at  -80
oC  for  real-time  PCR  analysis,  liver  iron 
quantification, and immunoblotting. Blood was collected by cardiac puncture and 
serum  was  separated  from  the  blood  for  serum  iron  measurement  using  a 
commercial kit (Pointe Scientific Inc, USA) as described below.   
 
3.2.2 Effect of parenteral iron loading on C57Bl/6 wild-type and HFE KO mice 
 
Weanling C57Bl/6 and HFE
 KO female 3 week old mice were fed a normal iron 
RM1  diet  for  two  weeks,  after  which  2.5  mg  iron  as  sodium  ferric  gluconate 
(Ferrlecit
®,  Rhone-Poulenc  Rorer,  UK)  or  an  equal  volume  of  saline  was 
administered intraperitoneally three times per week for two weeks. Three days after 
the  last  iron  injection,  mice  were  terminally  anaesthetised  with  intraperitoneal 
pentobarbitone sodium. Livers were collected for hepatic iron, mRNA quantification, 
and immunoblotting. Blood samples were collected by cardiac puncture. Serum was   100 
separated from clotted blood samples after centrifugation for 10 minutes at 5000 x g 
and used for iron measurement. 
 
3.2.3 Liver iron quantification in wild-type and HFE KO mice by a modified 
Torrance and Bothwell method (Torrance and Bothwell 1980) 
 
Liver samples were oven dried at 55
oC for at least 72 hours to ensure that  the 
tissue was completely dry. Dried samples were then accurately weighed and placed 
in clean and dry 1.5mL microfuge tubes. Samples were then digested in 1 mL acid 
mixture (30% HCl, 10% trichloroacetic acid) at 65
oC for 20 hours. A blank was also 
prepared in the same way, but without tissue sample. After acid digestion, samples 
were  taken out of  the  oven  and  left  to  cool  at  room  temperature.  The  working 
chromogen reagent and iron standard solution were freshly prepared just before the 
assay. The composition of the reagents was as follows: 
 
Working chromogen solution 
20mL  distilled  water,  20  mL  saturated  sodium  acetate,  and  4  mL  Chromogen 
reagent (0.1% bathophenanthroline sulfonate and 1% thioglycollic acid). 
 
Iron Standard solution 
423l distilled water, 27l HCl, and 50l stock iron solution (20mM). 
Blanks, standards, and samples were prepared in triplicate in plastic cuvettes with 
the amounts as shown in the table below: 
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Working 
chromogen 
reagent (mL) 
Fe  Standard 
(l) 
Blank/Sample 
(l) 
Distilled  water 
(l) 
Blank  1  0  25 from blank  225 
Standard  1  125  25 from blank  100 
Samples  1  0 
25  from 
sample 
225 
 
Samples were incubated at 37
oC for 10 minutes, after which, the absorbance of 
blank,  standard, and  sample  triplicates  were  measured  at  535nm  against  water 
blank using a spectrophotometer (Beckman DU 650 spectrophotometer). Results 
are expressed per gram dry weight of tissue. 
 
3.2.4 Measurement of serum iron and transferrin saturation 
 
Serum  iron and  transferrin  saturation  was  measured  by  using  a  commercial  kit 
(Pointe Scientific Inc.) as instructed by the manufacturer and described below.  
 
3.2.4.1 Measurement of serum iron 
 
In a 96-well plate, 40L of each sample, standard, and water blank were added per 
well in duplicate. Iron buffer reagent (200L) was then added into each well and the 
absorbance (A1) was measured at 560nm using a plate reader. Iron colour reagent 
(4L) was added to each well and plate was incubated at 37
oC for 10 minutes, after 
which the absorbance was measured at 560nm (A2). 
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Total Serum iron in each sample was calculated using the following formula: 
   
 
 
3.2.4.2 Measurement of Unsaturated Iron-Binding Capacity (UIBC) 
 
In a 96-well plate, 160L of UIBC reagent were added to samples, standards, and 
blanks wells. Aliquots (40L) from each sample, standard, and 80L from water as 
a blank were added per well in duplicate. 40L from standard or water were added 
to  sample  or  standard  wells,  respectively.  Absorbance  was  then  measured  at 
560nm (A1). Iron colour reagent (4L) was added to each well, and the plate was 
incubated at 37
oC for 10 minutes, after which the absorbance was measured at 
560nm (A2). 
 
 
 Total UIBC in each sample was calculated using the following formula 
 
 
 
Total iron binding capacity was then calculated using the following formula 
TIBC (g/dL) = Serum iron + UIBC 
 
Transferrin saturation was then calculated by the following formula using serum iron 
and TIBC: 
TF saturation (%) = serum iron/TIBC x 100 
 
 
X 500      (g/dL)  A2 sample - A1 sample 
A2 standard - A1 standard    
 
A2 sample-A1 sample 
A2 standard-A1 standard    
 
X 500      (g/dL)  500 -  103 
3.3 Results 
 
3.3.1 Effect of dietary iron deficiency on wild-type and HFE KO mice 
3.3.1.1 Effect on liver iron content, serum iron, transferrin saturation 
 
Liver iron levels in both wild-type and HFE KO mice fed an iron deficient diet for 4 
weeks  were  significantly  decreased  (Figure  3.1).  In  addition,  serum  iron  and 
transferrin saturation were also decreased in wild-type and HFE KO mice fed an 
iron deficient diet but this did not reach statistical significance (Figure 3.2). Of note, 
when fed on a control iron diet, serum iron and transferrin saturation were higher in 
HFE  KO  mice  compared  to  wild-type  animals  fed  on  a  control  (RM1)  diet.  In 
addition, liver iron content was significantly higher in HFE KO mice fed on a RM1 
diet  compared  to  wild-type  animals.  When  fed  on  an  iron  deficient  diet,  no 
difference was observed in liver iron, serum iron, and transferrin saturation between 
wild-type and HFE KO mice.   
 
 
 
 
 
 
 
 
 
Figure 3.1 Effect of dietary iron deficiency on hepatic iron content in wild-type 
(WT) and HFE KO mice.  
Mice were fed either a control (RM1) or an iron deficient (ID) diet for 4 weeks after 
being weaned. The liver was removed and iron was quantified. Hepatic iron content 
was significantly decreased by the iron deficient diet in both genotypes. Hepatic iron 
content was significantly higher in HFE KO than wild-type mice fed on an RM1 diet. 
Data are mean±SEM, n=5 mice per group, *** denotes significant difference from 
the RM1 diet group (p<0.001). 
# denotes significant difference from the equivalent 
wild-type group (p<0.001).  
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Figure 3.2 Effect of dietary iron deficiency on serum iron (A) and transferrin 
saturation (B) in wild-type (WT) and HFE KO mice.  
Mice were fed either a control (RM1) or an iron deficient (ID) diet for 4 weeks after 
being weaned. The serum was separated from the blood and serum total iron and 
transferrin saturation were measured. Serum iron and transferrin saturation were 
decreased  in  WT  and  HFE  KO  mice  fed  an  iron  deficient  diet  though  not 
significantly.  Moreover,  when  fed  on  a  control  iron  diet,  HFE  KO  mice  showed 
higher serum iron and transferrin saturation than WT mice. Data are mean±SEM, 
n=5 mice per group.  
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3.3.1.2 Effect on hepatic gene expression 
3.3.1.2.1 Effect on hepcidin 1 and hemojuvelin gene expression 
 
Analysis of hepcidin 1 and HJV gene expression in wild-type and HFE KO mice fed 
an iron deficient diet showed a significant decrease in hepcidin 1 expression in both 
genotypes with no change in HJV expression (Figure 3.3). Hepcidin 1 expression in 
HFE  KO  mice  was  lower  than  that  of  wild-type  animals  fed  on  an  RM1  diet; 
however, it did not reach statistical significance. 
 
 
   
 
 
 
 
 
 
 
 
Figure  3.3  Effect  of  dietary  iron  deficiency  on  hepatic  gene  expression  of 
hepcidin 1 (A) and HJV (B) in wild-type (WT) and HFE KO mice.  
Hepcidin1 mRNA expression significantly decreased in mice fed on an iron deficient 
diet with no change in HJV expression in both genotypes. Data are mean±SEM, 
n=5  mice  per  group,  **  denotes  significant  difference  from  the  RM1  diet  group 
(p<0.01). 
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3.3.1.2.2 Effect on BMP-2, BMP-4, and BMP-6 gene expression 
 
To investigate the effect of iron deficiency on hepatic expression of BMPs and the 
role of HFE in the response, gene expression levels of BMP-2, -4, and -6 mRNAs 
were quantified in wild-type and HFE KO mice fed an iron deficient diet. As shown 
in Figure 3.4, dietary iron deficiency significantly decreased the hepatic expression 
of  BMP-6  in  both  mouse  genotypes  with  no  change  in  BMP-2  and  BMP-4 
expression levels. The expression of BMP 2, 4, and 6 were not significantly different 
between HFE KO and wild-type mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.4  Effect  of  dietary  iron  deficiency  on  hepatic  gene  expression  of 
BMP-2 (A), BMP-4 (B), and BMP-6 (C) in wild-type (WT) and HFE KO mice.  
Hepatic expression of BMP-6 was significantly decreased in WT and HFE KO mice 
fed on  an iron deficient diet;  whereas, no change was observed in  BMP-2  and 
BMP-4 expression levels  Data are  mean±SEM, n=5 mice per group,  **  denotes 
significant difference from the RM1 diet group (p<0.01). 
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3.3.1.3 Effect on Smad 1, Smad 5, and Smad 8 phosphorylation in the liver 
 
To  investigate  whether  dietary  iron  deficiency  affects  the  downstream  signal  of 
BMP, phosphorylated Smad1, 5, and 8 were quantified by Western blotting in the 
liver of wild-type and HFE KO mice fed an iron deficient diet. As shown in Figure 
3.5, dietary iron deficiency caused a significant decrease in the phosphorylation of 
Smad 1/5/8 in wild-type and HFE KO mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Effect of dietary iron deficiency on Smad1/5/8 phosphorylation in 
wild-type (WT) and HFE KO mice.  
(A) Western blot analysis of liver lysates from control or iron-deficient WT and HFE 
KO  mice  using  an  antibody  to  phosphorylated Smad1/5/8,  β-actin  was used as 
loading  control.  (B)  Chemiluminescence  was  quantified  using  Quantity  One 
software  and  the  ratio  of  phosphorylated  Smad1/5/8  to  β-actin  was  calculated. 
Mean ratios of four samples (± SEM) are represented on this figure, relative to the 
mean  ratio  of  the  control  wild  type  mice  or  HFE  KO  mice.  Phosphorylation  of 
Smad1/5/8 was significantly decreased by iron deficiency in wild-type and HFE KO 
mice. Statistically significant differences relative to control mice were determined by 
Student t tests. ** denotes significant difference from the RM1 diet group (p<0.01). 
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3.3.2 Effect of parenteral iron loading on wild-type and HFE KO mice 
3.3.2.1 Effect on liver iron content, serum iron, transferrin saturation 
 
Parenteral Iron loading significantly increased liver  iron content, serum iron, and 
transferrin  saturation  in  wild-type  and  HFE  KO  mice  (Figure  3.6  and  3.7).  The 
serum  iron  was  significantly  higher  in  saline-injected  (control)  HFE  KO  mice 
compared to control wild-type animals. Moreover, no differences were observed in 
the liver iron and transferrin saturation between wild-type and HFE KO mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Effect of parenteral iron loading on hepatic iron content in wild-
type (WT) and HFE KO mice.  
Five week old WT or HFE KO mice fed on an RM1 diet were either injected with 
saline (control) or sodium ferric gluconate (Fe loaded) for 2 weeks. The liver was 
removed and iron was quantified. Hepatic iron content was significantly increased 
by iron loading in both genotypes. Data are mean±SEM, n=5 mice per group. *** 
denotes significant difference from the control group (p<0.001).  
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Figure  3.7  Effect  of  parenteral  iron  loading  on  serum  iron  and  transferrin 
saturation in wild-type (WT) and HFE KO mice.  
Five week old WT or HFE KO mice were either injected with saline (control) or 
sodium ferric gluconate (Fe loaded) for 2 weeks. The serum was separated from 
the blood and serum total iron and transferrin saturation were measured. Serum 
iron and transferrin saturation were significantly increased in iron-loaded wild-type 
and  HFE  KO  mice.  Data  are  Mean±SEM,  n=5  mice  per  group.  ***,  **  denotes 
significant  difference  from  the  control  group  (p<0.001,  p<0.01  respectively). 
# 
denotes significant difference from the equivalent wild-type group (p<0.05).  
 
 
B 
WT KO
0
20
40
60
80
100
Control
Fe Loaded
S
e
r
u
m
 
T
F
 
s
a
t
u
r
a
t
i
o
n
 
(
%
)
***  ** 
A 
WT KO
0
100
200
300
Control
Fe loaded
S
e
r
u
m
 
i
r
o
n
 
(

g
/
d
L
)
***  *** 
# 
 110 
 
3.3.2.2 Effect on hepatic gene expression 
3.3.2.2.1 Effect on hepcidin 1 and HJV gene expression 
 
In iron loaded wild-type and HFE KO mice, the hepatic expression of hepcidin 1 
significantly increased with no change in HJV expression levels. Of note, in HFE 
KO  mice,  the  iron-induced  hepcidin  1  expression  was  less  prominent  and 
significantly lower than that of wild-type mice as shown in Figure 3.8.   
 
 
Figure 3.8 Effect of parenteral iron  loading  on hepatic gene expression of 
hepcidin 1 (A) and HJV (B) in wild-type (WT) and HFE KO mice.  
Hepcidin1 gene expression significantly increased in iron-loaded WT and HFE KO 
mice  with  no  change  in  HJV  expression  in  both  genotypes.  Of  note,  the  iron-
induced hepcidin expression was less prominent and significantly lower in HFE KO 
mice. Data are mean±SEM, n=5 mice per group, ***, * denotes significant difference 
from  the  control  group  (p<0.001,  p<0.05  respectively) 
#  denotes  significant 
difference from the equivalent wild-type group (p<0.01). 
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3.3.2.2.2 Effect on BMP-2, BMP-4, and BMP-6 gene expression 
 
To investigate the effect of iron loading on hepatic expression of BMPs and the role 
of HFE in the response, gene expression levels of BMP-2, 4, and 6 were quantified 
in wild-type and HFE KO mice subjected to parenteral iron loading. As shown in 
Figure 3.9, iron loading significantly increased the hepatic expression of BMP-6 in 
both mouse genotypes with no change in BMP-2 and BMP-4 expression levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Effect of iron loading on hepatic gene expression of BMP-2 (A), 
BMP-4 (B), and BMP-6 (C) in wild-type (WT) and HFE KO mice.  
Hepatic expression of BMP-6  was significantly increased in iron-loaded WT and 
HFE KO mice, whereas, no change was observed in BMP-2 and BMP-4 expression 
levels.  Data  are  mean±SEM,  n=5  mice  per  group,  ***,  **  denotes  significant 
difference from the control group (p<0.001, p<0.01 respectively). 
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3.3.2.3 Effect on Smad 1/5/8 phosphorylation in the liver 
 
To investigate whether BMP-6 induction in response to iron loading was reflected 
by an increase in phosphorylation of Smad 1/5/8 and whether HFE is involved, the 
phosphorylated Smad 1/5/8 was quantified in the liver of iron-loaded wild-type and 
HFE KO mice by western blotting. As shown in Figure 3.10, parenteral iron loading 
significantly  increased  the  phosphorylation  of  Smad  1/5/8  in  wild-type  mice.  In 
contrast, Smad1, 5, and 8 phosphorylation was not significantly induced by iron 
loading in HFE KO mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Effect of iron overload on phosphorylation of Smad 1/5/8 in the 
liver of wild-type (WT) and HFE KO mice.  
(A) Western blot analysis of liver lysates from control or iron-loaded WT and HFE 
KO mice using an antibody to phosphorylated Smad1/5/8 with β-actin as a loading 
control. (B) Chemiluminescence was quantified using Quantity One software and 
the ratio of phosphorylated Smad1/5/8 to β-actin was calculated and plotted. Mean 
ratios of four samples (± SEM) are represented on this figure, relative to the mean 
ratio  of  the  control  wild  type  mice  or  HFE  KO  mice.  Iron  loading  significantly 
increased the phosphorylation of  Smad 1/5/8 in WT mice; whereas, Smad 1/5/8 
phosphorylation  was  not  significantly  increased  in  iron-loaded  HFE  KO  mice. 
Statistical  significant  differences  relative  to  control  mice  were  determined  by 
Student t tests. **P < 0.01. 
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3.4 Discussion 
 
It is well known that hepcidin is regulated by iron; yet, the exact mechanism and 
molecules  involved  in  this  regulation are  still  unknown.  It  has been  shown  that 
BMP-Smad signalling is one of the most important pathways involved in hepcidin 
regulation (Babitt et al. 2006; Babitt et al. 2007). However, whether  BMP-Smad 
signalling pathway is involved in hepcidin regulation by iron is not clear. 
HFE mutations are accompanied by inappropriately low hepcidin expression levels 
(Piperno et al. 2007). However, the mechanism by which HFE regulates hepcidin 
gene expression is not clearly understood. 
In this chapter, the hypothesis that regulation of hepcidin by iron status entails the 
BMP-Smad  signalling  pathway  was  examined.  To  investigate  the  effect  of  iron 
deficiency, C57Bl/6 mice were either fed a control or an iron-deficient diet. To study 
the effect of iron loading, mice were either injected with saline or iron (sodium ferric 
gluconate). 
To explore whether HFE is involved in hepcidin regulation by iron, HFE KO mice 
were also investigated in the settings of dietary iron deficiency and parenteral iron 
loading. In addition, whether iron status modulates Smad signalling in these mice 
through  phosphorylation  of  receptor  activated  smad  1/5/8  was  examined.  The 
activation  of  Smad1,  Smad5,  and  Smad8  is  the  main  BMP  signalling  pathway 
(Miyazawa et al. 2002). 
My data shows that when fed on an iron-deficient diet, both wild-type and HFE KO 
mice showed a decrease in liver iron content, serum iron, and transferrin saturation. 
In contrast, in iron-loaded wild-type and HFE KO mice the liver iron, serum iron, and 
transferrin saturation were increased. 
It was also found that hepatic gene expression of hepcidin1 was reduced by dietary 
iron deficiency in wild-type and HFE KO mice. Moreover, hepcidin 1 expression in 
control HFE KO was lower compared to wild-type mice which is inappropriate for   114 
liver  iron  levels  in  these  mice.  These  results  of  hepcidin  1  expression  are  in 
agreement with previous published reports (Ahmad et al. 2002; Bridle et al. 2003; 
Bondi et al. 2005; Latunde-Duda et al. 2004; Nicolas et al. 2002b; Vokurka et al. 
2006). In  contrast, no change in  HJV  expression was  observed in iron-deficient 
wild-type and HFE KO mice. A similar finding was recently reported by Constante et 
al.  (2007).  These  results  suggest  that  hepcidin  1  down-regulation  during  iron 
deficiency is not dependent on HFE, and dietary iron deficiency does not regulate 
hepatic HJV expression. Interestingly, hepatic expression of BMP-6 mRNA, but not 
BMP-2  and  BMP-4,  and  phosphorylated  Smad  1/5/8  proteins  were  reduced  by 
dietary iron deficiency in wild-type and HFE KO mice. These findings suggest that 
iron deficiency suppresses hepatic BMP-6 expression and its downstream signal 
(pSmad  1/5/8),  which  in  turn  may  cause  suppression  of  hepcidin  1  gene 
expression; however, this effect is not dependent on HFE.  
 
In iron-loaded wild-type mice, the hepatic mRNA expression of hepcidin1, BMP-6, 
and phosphorylation of Smad 1/5/8 proteins were induced. In contrast, no change 
was observed in HJV, BMP-2, and BMP-4 expression levels. Similar findings were 
recently  reported  by  another  group  who  studied  dietary  iron  loading  in  different 
mouse strains from the one used in this study (Kautz et al. 2008).  
The data suggest that parenteral iron loading induces hepcidin 1 gene expression 
in accordance with previous reports (Pigeon et al. 2001; Nemeth et al. 2004a), 
while it has no effect on HJV gene expression which was shown by others (Gleeson 
et al. 2007; Krijt et al. 2004). In addition, the data suggests that the expression of 
BMP-6 mRNA and Smad 1/5/8 phosphorylation are induced by iron loading which 
may subsequently induce hepcidin 1 gene expression.  
In iron-loaded HFE KO mice, although they showed induction of BMP-6 similar to 
that observed in wild-type mice, hepcidin1 induction was significantly lower than 
that of iron-loaded wild-type mice. Additionally, the phosphorylation of Smad 1/5/8   115 
was not significantly increased in response to parenteral iron loading, which may 
explain why hepcidin1 was inappropriately induced by iron loading in these mice. 
Conversely, no change was observed in the expression of  HJV, BMP-2, BMP-4 
mRNAs  in  iron-loaded  HFE  KO  mice.  The  data  demonstrates  that  BMP-6 
expression was appropriately induced by iron loading in HFE KO mice, indicating 
that BMP-6 induction by iron is HFE-independent; however, the induction of Smad 
1/5/8 is altered by the lack of functional HFE. 
It was also found that although HFE KO mice showed higher BMP-6 expression 
levels compared to wild-type controls, they expressed similar levels of pSmad1/5/8 
and  there  was  less  hepcidin  1  expression  compared  to  wild-type  mice.  These 
findings further support the assumption that Smad signalling is impaired in HFE KO 
mice. This hypothesis is also supported by a recent study by Kautz et al. (2009), 
who showed that BMP-Smad signalling is not enhanced in HFE KO mice despite 
increased BMP-6 expression.     
Although iron injection has recently been shown to increase the phosphorylation of 
Smad 1/5/8 in zebra fish and mouse liver extracts (Yu et al. 2008), the precise TGF-
superfamily  ligand  involved  in  this  induction  is  unknown.  Moreover,  hepcidin 
expression has been shown to be induced by different TGF-familyligands both in 
vitro (Babitt et al. 2006; Wang et al. 2005; Truksa et al. 2006)  and in vivo (Babitt et 
al. 2007; Andriopoulos et al. 2009). However, the relatively high doses of BMP 
ligands  used  in  these  studies  may  not  mimic  the  physiological  response  to 
endogenous BMP ligands. This may also explain why some of the recent findings 
showed a similar hepcidin induction in response to BMPs in hepatocytes from both 
wild-type and HFE KO mice (Truska et al. 2006), as the relatively high doses of 
BMP ligands might overrule the requirement for functional HFE. 
Recently,  exogenous  BMP-6  was  shown  to  induce  hepcidin  expression  in  vivo 
(Andriopoulos  et  al.  2009)  and  in  vitro  (Babitt  et  al.  2007).  In  addition,  siRNA   116 
inhibition of endogenous BMP-6 in vitro reduces hepcidin expression levels (Babitt 
et al. 2007). These findings clearly demonstrate that hepcidin expression is not only 
induced by exogenous BMP-6, but it is also repressed when endogenous BMP-6 is 
reduced. S-HJV has been shown to interfere with BMP-Smad signalling in vitro and 
in vivo (Babitt et al. 2007). However, it has recently been shown that BMP-6 was 
selectively inhibited by S-HJV in vivo and in vitro (Andriopoulos et al. 2009). Taken 
together, these findings, in addition to the data shown here, converge to suggest 
that BMP-6 is the ligand of TGF-that plays an important role in hepcidin regulation 
by iron in vivo.  
My data also showed that iron-induced hepcidin1 expression was lower in HFE KO 
mice compared with wild-type mice despite their appropriate induction of BMP-6 
expression  in  response  to  iron.  Moreover,  the  hepatic  levels  of  phosphorylated 
Smad 1/5/8 (an intracellular mediator of BMP-6 signalling) were inappropriately low 
for their liver iron levels and BMP-6 expression levels.  Altogether, the data shown 
here  and  recently  published  reports  (Corradini  et  al.  2009;  Kautz  et  al.  2008) 
suggest that iron regulates hepatic expression of BMP-6 and pSmad1/5/8 in vivo 
(i.e reduced by iron deficiency and induced by iron loading). In addition, the iron-
induced  downstream  signal  of  BMP-6,  which  is  shown  here  as  pSmad1/5/8,  is 
impaired in HFE KO mice. These results suggest that HFE may be involved in the 
regulation  of  downstream  signals  of  BMP-6  that  induce  hepcidin  expression  in 
response to iron loading. 
The results shown here, in conjunction with the findings of the others (Schmidt et al. 
2008;  Kautz  et  al.  2008;  Corradini  et  al.  2009),  suggest  that  the  iron-sensing 
process may occur at two different levels. Iron overload increases BMP-6 mRNA 
expression. It is not known how iron regulates BMP-6 mRNA; however, the results 
shown here suggest that it is not mediated by HFE. Induced BMP-6 then signals via 
Smad 1/5/8 to stimulate hepcidin expression via a common mediator, Smad-4 as 
mentioned before. The second mechanism of iron sensing involves HFE. It was   117 
recently  proposed  that  during  iron  loading  HFE  is  displaced  from  TFR1  by 
holotransferrin, and then interacts with TFR2 forming a complex that acts to induce 
hepcidin expression (Schmidt et al. 2008; Gao et al. 2009). Based on  the  data 
shown  here,  it  is  suggested  that  HFE  may  interact  with  the  HJV/BMP-6/Smad 
signalling  pathway  to  induce  hepcidin  expression  in  response  to  iron  loading. 
However, the exact mechanism by which HFE hinders this signalling pathway and 
whether TFR2 is involved needs further investigation.   
 
3.5 Conclusion 
 
In conclusion, the study of the regulation of hepcidin in response to dietary iron 
deficiency and parenteral iron loading in wild-type and HFE KO mice suggest that 
hepcidin  regulation  by  iron  status  is  modulated  by  the  BMP-6/Smad  signalling 
pathway in vivo. The data suggest that iron regulates the expression of BMP-6 and 
phosphorylation of Smads 1/5/8 in the liver which in turn may regulate hepcidin 
gene expression in response to different iron status. Moreover, HFE seems to be 
involved  in  the  regulation  of  downstream  signalling  of  BMP-6  that  regulates 
hepcidin  expression  in  response  to  iron  loading  in  vivo.  The  data  propose  a 
mechanism by which HFE may be involved in iron-induced hepcidin expression via 
its  interaction  with  HJV/BMP-6/Smad  signalling.  However,  the  exact  molecular 
mechanism remains to be fully clarified.  
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Chapter 4: Regulation of Hepcidin and Hemojuvelin 
Expression during Inflammation 
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4.1 Introduction 
 
Inflammatory stimuli are associated with profound alterations in iron homeostasis. 
Among the most important of these changes are the redistribution of iron into RE 
marcrophages  and  reduced  intestinal  iron  absorption  causing  hypoferremia 
(Cartwright and Wintrobe  1952;  Cartwright  1966;  Lee 1983;  Cortell  and  Conrad 
1967). Similar findings  have also  been  reported  in  mice exposed  to endotoxins 
(Cartwright and Lee 1971).  
The impairment of iron efflux by enterocytes and RE macrophages is believed to 
play an important role in host defense against infection and cancer (Weinberg 1992; 
Jurado 1997). However, it also limits iron availability for erythropoiesis resulting in 
anaemia (Moldawer et al. 1989). 
Pro-inflammatory cytokines have been shown to modulate the expression of iron 
transport  and  storage  proteins  in  a  variety  of  cell  types  (Johnson  et  al.  2004; 
Ludwiczek  et  al.  2003;  Yang  et  al.  2002).  During  inflammation,  IL-6  induces 
hepcidin expression and hypoferremia in vivo (Nemeth et al. 2004a). The finding 
that  hepcidin  is  modulated  by  inflammatory  cytokines  has  linked  hepcidin  to 
anaemia of inflammation (Ganz 2003; Roy and Andrews 2005). Increased hepcidin, 
in turn, decreases intestinal iron absorption (Laftah et al. 2004; Roy et al. 2004; Roy 
and Andrews 2005; Yamaji et al. 2004; Chung et al. 2009). 
LPS injection in humans induces IL-6 within 3 hours and increases urinary hepcidin 
with subsequent hypoferremia (Kemna et al. 2005). In addition, IL-6 injection in 
humans increases hepcidin and decreases serum iron in just 2 hours (Nemeth et al. 
2004a).  As  mentioned  in  Chapter  1,  IL-6  regulates  hepcidin  expression through 
phosphorylation  of  STAT3  that  binds  to  the  IL-6  responsive  element  within  the 
hepcidin gene promoter. 
LPS injection is associated with increased hepatic IL-6 expression while turpentine 
oil  induces  local  irritation  that  results  in  recruitment  of  inflammatory  cells  and   120 
induction  of  IL-6  in  injured  muscles  in  mice  (Sheikh  et  al.  2006).  In  addition, 
turpentine oil injection induces hepatic expression of IL-6, IL-, and TNF-in rats 
(Sheikh et al. 2007). Turpentine oil injections in mice result in increased hepcidin 
expression and hypoferremia (Nicolas et al. 2002b; Sheikh et al. 2007). However, 
the lack of hypoferremia in turpentine-injected Hepcidin KO mice suggests that the 
hypoferremia is hepcidin-dependent (Nicolas et al. 2002b). 
Hemojuvelin, a BMP co-receptor, has been shown to be an important upstream 
regulator of hepcidin expression, as previously mentioned in Chapter 1. In mice 
lacking HJV, hepcidin induction in response to iron is abrogated. On the other hand, 
these mice retain the ability to regulate hepcidin in response to inflammation by 
LPS and IL-6, though to a lesser extent than wild-type animals (Niederkofler et al. 
2005). Moreover, HJV expression is down-regulated in the liver of mice injected 
with LPS (Niederkofler et al. 2005). These findings suggest that HJV is not fully 
involved in the hepcidin response to inflammatory stimuli while it is required for 
hepcidin response to iron. However, it is not clear how  HJV is regulated during 
inflammation.  
Recently it has been shown that mice lacking hepatic Smad-4 express very low 
hepcidin levels. In addition, the response of hepcidin to inflammation is abrogated in 
these mice (Wang et al. 2005). Moreover, Verga Falzacappa et al. (2008) identified 
a BMP-RE that lies near the IL-6 RE in the hepcidin gene promoter. They found that 
this RE is not only required for the BMP response but also for IL-6 responsiveness. 
Taken together, these findings suggest a possible cross-talk between the BMP-
Smad and IL-6 signalling pathways; however, this link remains to be clarified. 
Evidence for the requirement of HFE for hepcidin induction during inflammation is 
conflicting. Roy et al. (2004) reported that mice lacking HFE do not respond to LPS 
with increased hepcidin expression as wild-type animals. In another study, the LPS 
response is significantly different among animals (Lee et al. 2004).  A recent study 
by  Constante  et  al.  (2006)  showed  that  HFE
  knockout  (KO)  mice  are  able  to   121 
regulate hepcidin by LPS as do wild-type animals. These contradictory findings on 
the requirement of HFE for hepcidin induction during acute inflammation suggest 
that the study of HFE
 KO mice during the inflammatory response requires further 
investigation.   
This study is aimed to investigate the modulation of hepcidin, HJV, and BMP-Smad 
signalling and the role of HFE in their regulation during inflammation.  
To investigate the effect of acute inflammation on  hepcidin and HJV expression 
levels in vivo, C57Bl/6 mice were injected with LPS and sacrificed after 6 hours, the 
time at which maximal hepcidin induction and HJV repression have been reported 
(Yeh et al. 2004; Niederkofler et al. 2005; Krijt et al. 2004).  
To  understand  the  effect  of  inflammation  on  BMP-Smad  signalling  in  vivo,  the 
hepatic expression of BMP mRNAs and phosphorylated Smad-1/5/8 protein levels 
were measured in the liver of saline- and LPS-injected mice. 
To  investigate  the  role  of  HFE  in  hepcidin,  HJV,  and  BMPs  response  during 
inflammation in vivo, acute inflammation was induced by LPS in C57Bl/6 HFE
 KO 
mice. 
To investigate the direct effect of major cytokines produced during inflammation on 
hepcidin and HJV expression in vitro, HuH7 human hepatoma cells were treated 
with IL-6 and TNF-These cells were also used to study the mechanism of HJV 
suppression during inflammation.  
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4.2 Methods 
  
4.2.1 Acute inflammation induced by LPS in C57Bl/6 wild-type and HFE
 KO 
mice 
 
Mice were fed on an RM1 diet (190mg iron/Kg) for six weeks after being weaned (3 
weeks of age). Acute inflammation was induced by a single intra-peritoneal injection 
of 5g LPS/g body weight (Escherichia coli serotype 055:B5, Sigma, UK). Control 
mice  were  similarly  injected  with  an  equivalent volume of  sterile  saline  solution 
(0.09% NaCl). The animals were sacrificed 6 hours after injection; livers were snap 
frozen for mRNA, protein, and iron quantification. Blood was collected by cardiac 
puncture  and  serum  was  separated  for  iron  and  transferrin  saturation 
measurements using a commercial kit (Pointe Scientific, USA). Hepatic expression 
of  phosphorylated  Smad-1/5/8  was  quantified  by  Western  blotting  using  a 
commercial antibody (1:500 dilution, Cell signalling, UK). As a loading control, -
actin protein was quantified using anti-actin antibody (1:5000 dilution, Abcam). 
 
4.2.2 Pro-inflammatory cytokines treatment of HuH7 cells 
 
HuH7  cells  were  cultured  in  Dulbecco’s  modified  Eagle’s  medium  (DMEM) 
containing 10% FBS and antibiotics and maintained in a humidified atmosphere of 
5% CO2 at 37
oC. The cells were seeded in 6-well plates (Nunc, UK). Once 80-85% 
confluent, the medium was changed and replaced by fresh medium with vehicle 
(control) or medium containing recombinant human IL-6 (10ng/mL; R&D Systems, 
UK) or recombinant human TNF-(20ng/mL; R&D Systems). Both cytokines were 
reconstituted in sterile PBS containing 0.1% bovine serum albumin. After treatment, 
medium was removed and cells were washed with PBS. RNA extraction, cDNA   123 
synthesis, and RT-PCR amplification for hepcidin and HJV  were carried out as 
described in Section 2.1. 
 
4.2.3 Effect of TNF-treatment on HJV mRNA and protein expression in HuH7 
cells 
 
HuH7 cells were seeded in 6-well plates and treated with TNF-(20ng/mL) for 6, 
12, 24, and 48 hours followed by RNA extraction, cDNA synthesis, and RT-PCR 
amplification of HJV mRNA. 
To investigate the effect of TNF- on HJV protein expression, cells were treated 
with  TNF-  for  16  hours  followed  by  protein  extraction  and  immunoblotting 
detection of HJV protein as described in Section 2.6 using a commercial anti-HJV 
antibody (Santa Cruz Biotechnology, UK). -actin was used as a loading control.  
   
4.2.4 Effect of TNF-treatment on luciferase activity of HJV promoter-reporter 
construct (HJVp1.2-luc) 
 
A HJV promoter-reporter construct was generated as described in Section 2.3. This 
construct was used to investigate the mechanism of TNF- down-regulation of HJV 
expression. HuH7 cells were transfected with HJVp1.2-luc and treated with TNF- 
for 24 hours. Luciferase activity was measured as described in Section 2.5.  
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4.2.5 Site-directed mutagenesis of TNF- response element (TNFRE) within 
HJV promoter 
 
A  single  consensus  TNFRE,  GGC  (A/T)  GCC,  was  manually  identified  in  the 
HJVP1.2-luc. This sequence has been shown to be responsible for down-regulation 
of  several  human  genes  in  response  to  TNF-,  including  osteocalcin, 
thrombomodulin,  alkaline  phosphatase,  and  c-myc  (Li  and  Stashenko  1993; 
Ohdama et al. 1991; Weiss et al. 1988; Watt et al. 1983). As shown in Figure 4.1, 
this site lies 290 nucleotides upstream of the start of the HJV first exon.  
 
 
TTCGTCCTTC TGAAATACTC TGCAAAGATA GGAGAGGGGC TATGAACTAC 
CTCTGCTATG GATCTTATTC AAAGTCAGCT ACCTCCTAGA TACTATCTGT 
AGAACCTAAA TGTAATATTC AGCATAGCAG GGATGAACAT GGTAAATGAA 
AGGTATCCAA TTGCCCACTG TAATTTTTAA AGGCCAGGAG CTCAACATTA 
TTGAAAATGC TGGAGGGCTG CCTGGAGTAG GCAGTGACCA CAGAGTCACA 
CAAGCTGGAA TTGGATATCC AACTTGTCTG TCATATTTCT CTCCTCCCTC 
CCTGACTTGG CACTCAATAC TCCATATTCT TTCTAATCCT CTAACCCTCC 
CCACTCCCCC AACTCCCACA CCCTACCCCC ACCAACGTTC CTGGAATTTT 
GGACTTAGCT ATTTTTAAAA CCGTCAACTC AGTAGCCACC TCCCTCCCTG 
CTCAGCTGTC CAGTACTCTG GCCAGCCATA TACTCCCCCT TCCCCCCATA 
CCAAACCTTC TCTGGTTCCC TGACCTCAGT GAGACAGCAG 
 
 
Figure 4.1 Portion of the amplified sequence of the HJV promoter showing 
TNFRE.  
The consensus TNF- RE (green) lies 290 nucleotides upstream of the start of the 
first exon (yellow).   
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To test whether the identified TNFRE is functional, HJVP1.2-luc was subjected to 
site-directed  mutagenesis  using  the  QuickChange  Site-Directed  Mutagenesis  kit 
(Stratagene, UK) as instructed by the manufacturer. The mutant primers were 
as follows: sense TGAAAATGCTGGAGGAATTCTTGGAGTAGGCAGTG 
and  antisense  CACTGCCTACTCCAAGAATTCCTCCAGCATTTTCA,  and  the 
EcoRI restriction site is underlined. An EcoRI restriction site was thereby introduced 
instead of TNFRE within the HJVP1.2-luc. After initial denaturation for 1 minute at 
95
oC, PCR cycling parameters were 95
oC (1 minute), 55
 oC (1 minute), and 65
 oC (6 
minutes), for a total of 18 cycles. Following DpnI digestion of wild-type HJVP1.2-luc, 
transformation of INVF’ competent cells (Invitrogen) with the mutagenesis reaction 
and  selection  on  Luria  agar/ampicillin  plates,  plasmid  DNA  was  purified  from 
overnight  cultures  of  single  colonies  and  digested  with  EcoRI  (New  England 
Biolabs), which cuts at two sites within mutant plasmid (as there is a single EcoRI 
within  the  wild-type  HJVP1.2-luc  sequence  in  addition  to  the  replaced  TNFRE) 
producing  an  approximately  400  bp  product  which  was  used  to  distinguish  the 
mutant  construct  from  the  wild-type  one.  The  mutant  construct  was  designated 
mtHJVP1.2-luc.  
           
 
 4.2.6  Effect  of  TNF-treatment  on  luciferase  activity  of  HJVp  1.2-luc  and 
mtHJVP1.2-luc 
 
HuH7 cells were transfected with HJVp 1.2-luc or mtHJVP1.2-luc and treated with 
TNF- for 24 hours. Luciferase activity was then measured as described in Section 
2.5.  
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4.3 Results 
 
4.3.1  Effect  of  LPS-induced  inflammation  on  serum  iron  and  transferrin 
saturation in wild-type C57Bl/6 and HFE
 KO mice 
 
LPS  was  used  to  induce  acute  inflammation  in  wild-type  and  HFE  KO  mice. 
Animals were treated for 6 hours. LPS treatment caused a significant decrease in 
serum iron in WT and HFE KO mice (p<0.05). Transferrin saturation was lower in 
LPS injected WT (P<0.05) and HFE KO mice; however, in the latter it did not reach 
statistical  significance.  Moreover, serum  iron  and  transferrin  saturation  were not 
significantly higher in HFE KO than WT mice (Figure 4.2).  
 
 
 
 
 
 
 
 
 
Figure 4.2 Total serum iron (A) and transferrin saturation (B) following LPS 
injection of wild-type (WT) and HFE KO mice.  
C57Bl/6 WT and HFE KO mice 9 weeks old were injected with 5g LPS/g body 
weight or an equivalent volume of saline and sacrificed after 6 hours. LPS treatment 
significantly  decreased  serum  iron  in  both  genotypes.  Treatment  decreased 
transferrin saturation in wild-type and HFE KO mice; however, in HFE KO mice it 
did not reach statistical significance. Data are mean±SEM of 5 mice per group. 
*, ** 
denotes  significant  difference  from  the  saline–injected  group  (p<0.05,  p<0.001 
respectively). 
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4.3.2 Effect of LPS-induced acute inflammation on liver iron and hepatic gene 
expression in wild-type C57Bl/6 and HFE KO mice 
 
4.3.2.1 Effect of LPS-induced acute inflammation on hepatic iron content 
 
Liver iron content was measured in wild-type C57Bl/6 and HFE
 KO mice treated 
with LPS for 6 hours. Acute inflammation increased hepatic iron content in wild-type 
mice though not significantly and no change in liver iron was observed in LPS- 
injected HFE KO mice. In addition, liver iron was significantly higher in HFE KO 
mice compared to control and LPS-injected wild-type animals (Figure 4.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.3  Liver  iron  content  in  WT  C57Bl/6  and  HFE  KO  mice  in  acute 
inflammation.  
Mice were injected with LPS for 6 hours. After which, the liver was removed and 
iron was quantified and presented as  g/g dry weight. LPS treatment  increased 
hepatic iron content in WT mice though not significantly with no change in hepatic 
iron  content  in  LPS-injected  HFE  KO  mice.  Moreover,  hepatic  iron  content  was 
significantly higher in HFE KO mice. Data are mean±SEM of five mice per group.* 
denotes  significant  difference  from  LPS-injected  WT  mice  (p<0.05).  **  denotes 
significant difference from the saline–injected WT mice (p<0.01).  
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4.3.2.2 Effect of LPS-induced acute inflammation on hepatic IL-6 and TNF- 
gene expression  
 
To confirm the occurrence of acute hepatic response to inflammation, hepatic IL-6 
and TNF- mRNA levels were analysed by RT-PCR in saline- and LPS- injected 
mice.  As  expected,  treatment  with  LPS  significantly  increased  IL-6  and  TNF- 
expression levels in the liver of wild-type and HFE KO mice (Figure 4.4)  
 
 
 
 
 
Figure  4.4  Effect  of  acute  inflammation  on  hepatic  IL-6  (A)  and  TNF-  (B) 
expression levels in wild-type and HFE KO mice.  
IL-6 and TNF- mRNA expression levels were analysed by real time PCR. LPS 
treatment  significantly  increased  IL-6  and  TNF-  expression  in  both  genotypes. 
Data are mean±SEM of five mice per group.*p<0.05, **p<0.01, ***p<0.001 in LPS-
injected mice compared to saline-injected controls.  
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4.3.2.3 Effect of LPS-induced acute inflammation on hepatic hepcidin 1 gene 
expression  
 
To  investigate  the  effect  of  acute  inflammation  on  hepatic  hepcidin  1  mRNA 
expression and the possible role of HFE in this response, gene expression levels 
were  quantified  by  RT-PCR  in  saline-  and  LPS-injected  wild-type  and  HFE  KO 
mice. Treatment with LPS significantly increased  hepcidin 1 expression levels in 
wild-type and HFE KO mice, and hepcidin1 induction was similar in both genotypes 
(Figure  4.5).  HFE  KO  mice  showed  less  hepcidin  1  expression  than  wild-type 
animals though the decrease did not reach statistical significance. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Effect of acute inflammation on hepatic hepcidin 1 expression in 
wild-type and HFE KO mice.  
Hepcidin 1 mRNA levels were analysed by RT-PCR. LPS treatment significantly 
increased hepcidin 1 expression in both genotypes. Data are mean±SEM of five 
mice per group. *p<0.05, **p<0.01 in LPS-injected mice compared to saline-injected 
controls.  
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4.3.2.4  Effect  of  LPS-induced  acute  inflammation  on  hepatic  HJV  gene 
expression  
 
To explore the effect of acute inflammation on hepatic HJV mRNA expression and 
the possible role of HFE in this response, hepatic  HJV mRNA expression levels 
were  analysed  by  RT-PCR  in  saline-  and  LPS-  injected  wild-type  and  HFE  KO 
mice. Treatment with LPS significantly decreased  HJV expression levels in wild-
type and HFE KO mice (Figure 4.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Effect of acute inflammation on hepatic  hemojuvelin  expression 
levels in wild-type and HFE KO mice. 
HJV  mRNA  expression  levels  were  analysed  by  RT-PCR.  LPS  treatment 
significantly decreased HJV expression in both genotypes. Data are mean±SEM of 
five  mice  per  group.**p<0.01  in  LPS-injected  mice  compared  to  saline-injected 
controls.  
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4.3.2.5 Effect of LPS-induced acute inflammation on hepatic BMPs and TGF- 
gene expression 
To further understand the possible link between inflammation and the BMP-Smad 
signalling pathway and whether HFE is involved, liver-expressed BMPs (2, 4, and 
6) and TGF- gene expression levels were analysed by RT-PCR in wild-type and 
HFE  KO  mice  injected  with  LPS.  LPS  treatment  significantly  decreased  the 
expression levels of BMP2, BMP4, and BMP6 (Figure 4.7) in wild-type and HFE KO 
mice. On the other hand, LPS had no effect on the expression levels of TGF-in 
either genotypes (Figure 4.7D). 
 
Figure  4.7  Effect  of  acute  inflammation  on  hepatic  BMP-2  (A),  BMP-4  (B), 
BMP-6 (C), and TGF- (D) expression in wild-type and HFE KO mice. 
BMP-2, BMP-4, BMP-6, and TGF- mRNA expression were analysed by RT-PCR. 
LPS treatment significantly decreased BMP-2, BMP-4, BMP-6 with no change in 
TGF- expression expression in both genotypes. Data are mean±SEM of five mice 
per group. **p<0.01, ***p<0.001 in LPS-injected mice compared to saline-injected 
controls.  
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4.3.3 Effect of LPS-induced acute inflammation on liver phosphosmad 1, 5, 
and 8 protein expression in WT C57Bl/6 and HFE KO mice 
 
To examine the effect of acute inflammation on downstream signal of BMPs, protein 
expression levels of phosphorylated Smad 1/5/8 were analysed in wild-type and 
HFE KO mice injected with LPS. LPS treatment had no effect on pSmad 1, 5, and 8 
protein expression levels in both genotypes (Figure 4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.8  Smad1/5/8  phosphorylation  is  not  changed  by  LPS  injection  in 
wild-type C57blk/6 and HFE
 KO mice.  
(A) Western blotting of liver lysates from saline- or LPS-injected WT and HFE
 KO 
mice using an antibody to phosphorylated Smad1/5/8, β-actin was used as loading 
control.  (B)  Chemiluminescence  was  quantified  using  Quantity  One  software  to 
calculate  the  ratio  of  phosphorylated  Smad1/5/8  to  β-actin.  Mean  ratios  of  four 
samples (± SEM) are represented on this figure, relative to the mean ratio of the 
saline-injected WT or HFE
 KO
 mice.  
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4.3.4  Effect  of  pro-inflammatory  cytokines  on  hepcidin  and  HJV  mRNA 
expression in HuH7 cells 
 
HuH7 cells were used to study the effect of pro-inflammatory cytokines, IL-6 and 
TNF- on hepcidin and HJV mRNA expression in vitro. 
 
4.3.4.1 Effect of IL-6 treatment on hepcidin and HJV mRNA expression  
 
IL-6 treatment (10ng/mL for 24 hrs) of HuH7 cells significantly increased hepcidin 
mRNA expression three fold with no effect on HJV expression (Figure 4.9). 
 
 
Figure 4.9 Quantitative RT-PCR analysis of hepcidin (A) and HJV (B) mRNA 
expression in HuH7 cells following IL-6 treatment.  
HuH7 cells were incubated for 24 hours in the presence of vehicle (control) or IL-6 
(10ng/mL). RT-PCR analysis of hepcidin and HJV gene expression showed that 
hepcidin  mRNA  levels  were  significantly  induced  by  IL-6,  while  HJV  mRNA 
expression levels remained unchanged. Data are mean± SEM of 6 samples from 3 
separate experiments performed in duplicate. ***p<0.001.  
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4.3.4.2 Effect of TNF- treatment on hepcidin and HJV mRNA expression  
 
TNF- treatment (20ng/mL for 24 hrs) of HuH7 cells significantly decreased HJV 
mRNA expression levels with no effect on hepcidin mRNA expression (Figure 4.10). 
 
 
 
 
 
 
 
Figure 4.10 Quantitative PCR analysis of hepcidin (A) and HJV (B) expression 
in HuH7 cells following TNF- treatment.  
HuH7 cells were incubated for 24 hours in the presence of vehicle (control) or TNF-
  (20ng/mL).  Quantitative  PCR  analysis  of  hepcidin  and  HJV  gene  expression 
showed that hepcidin mRNA expression levels remained unchanged in response to 
TNF-, while HJV mRNA expression levels were significantly repressed. Data are 
mean± SEM of 6 samples from 3 separate experiments performed in duplicate. 
***p<0.001. 
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4.3.4.3 Effect of TNF- treatment on HJV mRNA expression at different time 
points 
 
HuH7 cells that were exposed to TNF- (20ng/mL) for 6, 12, 24, and 48 hours 
demonstrated  that  HJV  mRNA  expression  levels  significantly  decreased  in 
response  to  TNF-in  a  time-dependent  manner.  The  maximal  repression  was 
observed after  24  hours,  and  HJV  mRNA  expression  levels  returned  to  normal 
values after 48 hours (Figure 4.11). 
 
 
Figure 4.11 Quantitative PCR analysis of HJV mRNA expression in HuH7 cells 
following TNF- treatment at different time points.  
HuH7 cells were incubated in the presence of vehicle (control) or TNF- (20ng/mL) 
for 6, 12, 24, and 48 hours. Quantitative PCR analysis of HJV mRNA expression 
showed that HJV mRNA expression levels decreased in response to TNF-in a 
time-dependent manner reaching its maximal repression levels after 24 hours, and 
returning to normal expression levels after 48 hours. Data are Mean± SEM of 6 
samples from 2 separate experiments in triplicate. *p<0.05, ***p<0.001.  
 
Control 6  12  24  48 
0.0
0.5
1.0
1.5
Time (Hrs)
R
e
l
a
t
i
v
e
H
J
V
 
e
x
p
r
e
s
s
i
o
n
/
G
A
P
D
H
* 
*** 
***   136 
4.3.4.4  Effect  of  TNF-  treatment  (20ng/mL)  for  16  hours  on  HJV  protein 
expression in HuH7 cells 
 
To explore whether the repression of HJV mRNA expression in response to TNF- 
is mirrored by a suppression at protein levels, HuH7 cells were incubated in the 
presence of TNF- for 16 hours followed by protein extraction and immunodetection 
of HJV protein by western blotting. As shown in figure 4.12, HJV protein levels were 
significantly repressed in TNF- treated cells compared to control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
Figure  4.12  Effect  of  TNF-  treatment  on  HJV  protein  expression  in  HuH7 
cells.  
(A) Cell lysates from control and TNF- treated cells (n = 6 in each group) were 
analyzed by Western blotting with an antibody to HJV, β-actin was used as loading 
control.  A  representative  experiment  is  shown.  (B)  Chemiluminescence  was 
quantified using Quantity One software to calculate the ratio of HJV expression to 
β-actin. Mean ratios of four samples (± SEM) are represented on this figure, relative 
to the mean ratio of the control cells. Statistical significant differences relative to 
control cells were determined by Student t tests. **p < 0.01. 
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4.3.4.5 Effect of TNF- treatment on HJV promoter-reporter activity 
In order to determine the mechanism of HJV suppression in response to TNF-, 1.2 
Kb of the human HJV promoter was cloned as a transcriptional fusion with firefly 
luciferase  to  give  HJVP1.2-luc  (Figure  4.13).  The  luciferase  activity  reported  by 
HJVP1.2-luc-transfected  HuH7  cells  showed  that  the  basal  luciferase  activity  of 
HJVP1.2-luc was inhibited by 40% following TNF- treatment (P<0.0001) (Figure 
4.14), suggesting that the cloned promoter region is responsive to TNF-











Figure 4.13 1% Agarose/ ethidium bromide gel of HJV promoter construct and 
restriction enzymes digest.   
Lane 1 is a 10 Kb molecular weight marker, lane 2 is undigested HJVp1.2-luc, lane 
3 is plasmid digested with NheI and XhoI showing 1.2 Kb insert, lane 4 is plasmid 
digested with EcoRI and XhoI showing the correct pattern.  
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Figure  4.14  Effect  of  TNF-  on  luciferase  activity  reported  by  HJVP1.2-luc 
transfected HuH7 cells.   
Transfected  HuH7  cells  were  incubated for  24 hours  in  the  presence of  TNF- 
(20ng/ml).  Luciferase  activity  reported  by  HJVP1.2-luc-transfected  cells 
demonstrated  that  the  basal  luciferase  activity  of  HJVP1.2-luc  was  significantly 
decreased following TNF- treatment. Data are mean ± SEM, n=12 from 3 separate 
experiments. **p<0.0001. 
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4.3.4.6 Effect of TNF-  treatment on luciferase activity of  HJVP1.2-luc and 
mtHJVP1.2-luc 
 
A single consensus TNFRE was identified in the HJVP1.2-luc sequence. In order 
to ascertain whether this site is functional and responsible for TNF- suppression 
of  HJV  expression,  site-directed  mutagenesis  was  performed.  The  TNFRE  was 
replaced by an EcoRI restriction site to generate mtHJVP1.2-luc (Figure 4.15). As 
shown  in  Figure  4.16,  the  luciferase  activity  reported  by  HJVP1.2-luc  was 
suppressed by 33%  following  TNF-  treatment (p<0.0001).  On  the other hand, 
mtHJVP1.2-luc  activity  did  not  change  following  TNF-  treatment.  These  data 
strongly suggest that TNF- suppresses the transcription of HJV through this RE.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.15  1%  Agarose/ethidium  bromide  gel  of  HJV  promoter  construct 
with mutated TNFRE and restriction enzyme digest.  
Lane 1 is a 10 Kb molecular weight marker, lane 2 is undigested mtHJVp1.2-luc, 
lane 3 is plasmid digested with EcoRI showing the expected band size of 400 bp 
(arrow). 
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Figure 4.16 Luciferase reporter activity of  HJVP1.2-luc and mtHJVBp1.2-luc 
transfected Huh7 cells following TNF- treatment.  
HuH7 cells were transfected with HJVP1.2-luc or mtHJVP1.2-luc to verify that the 
identified TNFRE is functional. Transfected HuH7 cells were incubated for 24 hours 
in  the  presence  of  TNF-  (20ng/ml).  The  data  demonstrated  that  the  basal 
luciferase  activity  of  HJVP1.2-luc  was  significantly  decreased  following  TNF- 
treatment, whereas no significant difference was observed in luciferase activity of 
mtHJVP1.2-luc following TNF- treatment. These data suggest that this element is 
important for TNF- responsiveness. Data are mean ± SEM, n=12 of 3 independent 
experiments. ***p<0.0001. 
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4.4 Discussion 
  
 
The regulation of hepcidin and HJV expression in response to acute inflammation 
was investigated in C57Bl/6 mice. The possible interaction between inflammation 
and  BMP/Smad  signalling  was  also  investigated  in  LPS-induced  acute 
inflammation. To explore whether HFE is involved in the regulation of hepcidin and 
HJV expression during inflammation or the interaction between inflammation and 
BMP-Smad signalling, HFE KO mice were also examined in the setting of acute 
inflammation. 
The direct regulation of hepcidin and HJV expression by pro-inflammatory cytokines 
was also examined in vitro using a human hepatoma cell line (HuH7). These cells 
were  also  used  to  study  the  mechanism  of  HJV  regulation  during  inflammation 
using a HJV promoter-reporter construct. 
The results showed that C57Bl/6 mice respond to LPS by increasing hepcidin 1 
expression and decreasing the expression of HJV, BMP-2, BMP-4, and BMP-6 in 
the liver. HFE does not seem to have an effect on hepatic gene regulation during 
inflammation.  In  addition,  TNF-,  but  not  IL-6,  mediates  HJV  down-regulation 
during  inflammation,  whereas  IL-6  is  required  to  induce  hepcidin  expression  in 
HuH7 cells. Results also showed that TNF--induced HJV suppression is possibly 
mediated by a novel TNF- response element within the HJV promoter. 
In  this  study,  it  was  shown  that  in  wild-type  C57Bl/6  mice,  acute  inflammation 
significantly decreases serum iron and transferrin saturation levels and increases 
hepatic  iron  content,  though  not  significantly.  In  HFE  KO  mice,  LPS  decreases 
serum  iron,  while  it  has no effect on transferrin  saturation or  liver  iron  content. 
Moreover, as expected, the mRNA expression of acute-phase genes IL-6 and TNF-
 were strongly induced in the livers of LPS-treated wild-type and HFE KO mice as 
compared with saline-treated controls.   142 
The hypoferremia observed in LPS-injected mice in this study is due to cytokine 
production including IL-6 and TNF-. IL-6 is believed to cause indirect hypoferremia 
through  stimulation  of  hepcidin  expression  (Nemeth  et  al.  2004a),  a  finding 
confirmed in this study in IL-6-treated human hepatoma cells  in vitro. Increased 
hepcidin  in  turn  causes  sequestration  of  iron  in  RE  macrophages  and  reduces 
intestinal  iron  absorption  causing  hypoferremia  (Roy  and  Andrews  2005).  This 
effect  of  hepcidin  occurs  by  binding  to  IREG1  inducing  its  internalization  and 
degradation  (Nemeth  et  al.  2004b).  On  the  other  hand,  TNF--induced 
hypoferremia is hepcidin-independent (Laftah et al. 2004). TNF- sequesters iron in 
the liver and spleen because of its ability to down-regulate IREG1 expression in 
different  cells  including  macrophages,  hepatocytes,  and  endothelial  cells 
(Constante et al. 2006; Ludwiczek et al. 2003; Nanami et al. 2005). 
Hepatic hepcidin 1 expression in wild-type mice was induced by LPS in this study, 
in accordance with previous reports (Pigeon et al. 2001; Constante et al. 2006). 
Contradictory  reports  have  been  published  on  the  requirement  of  HFE  in  the 
hepcidin up-regulation during inflammation. In one report, the response to LPS is 
blunted  (Roy  et  al.  2004),  in  another  one  the  lack  of  response  is  because  of 
differences from animal to animal (Lee et al. 2004), and in a study by Constante et 
al. (2006) they showed that HFE KO mice responded to LPS similarly as wild-type 
animals. Here it was shown that LPS injection induces hepcidin 1 gene expression 
in HFE KO mice; the hepcidin induction in HFE KO was similar to that observed in 
wild-type  mice.  These  results  suggest  that  HFE  is  not  required  for  hepcidin 
induction  during  acute  inflammation  in  the  mouse  strain  tested  and  are  in 
agreement with other reports (Constante et al. 2006; Lee et al. 2004). 
Hepatic  HJV  expression in wild-type and  HFE KO mice was down-regulated by 
LPS. A similar finding was recently reported by Constante et al. (2007). These data   143 
imply  that  the  ability  to  down-regulate  HJV  expression  during  the  acute  phase 
response remains integral even in the absence of functional HFE.  
It  is  well  established  that  BMPs  induce  hepcidin  expression  through  Smad 
signalling via a common mediator, Smad-4 (Babitt et al. 2006; 2007). However, in 
mice with hepatic disruption of Smad-4, the response of hepcidin to inflammatory 
stimulation  is  blunted  (Wang  et  al. 2005).  Moreover,  a  recently  identified  BMP-
responsive element within the hepcidin gene promoter was found to be not only 
important  for  the  BMP  response  but  also  for  IL-6  responsiveness  (Verga 
Falzacappa  et  al.  2008).  These  data  suggest  that  there  is  possible  cross-talk 
between  the  IL-6  and  the  BMP-Smad  signalling  pathways.  Here  the  effect  of 
inflammation  on  hepatic  expression  of  BMPs  was  investigated.  Because  BMPs 
transmit signals through phosphorylation of Smad1, Smad5 and Smad8, the relative 
abundance of phosphorylated forms of these three Smads was also quantified in 
liver extracts of LPS- and saline- injected wild-type and HFE KO mice by Western 
blot analysis. Interestingly,  it was found that BMP-2, BMP-4, and BMP-6 mRNA 
expression levels were down-regulated in response to acute inflammation in wild-
type and HFE KO mice with no change in phosphorylated Smad1/5/8 expression in 
the liver. In addition, no change was observed in TGF- expression in response to 
inflammation.  These  findings  suggest  that  BMPs  are  not  required  for  hepcidin 
induction  during  inflammation,  and  the  link  between  inflammation  and  Smad 
signalling is downstream of BMP ligands, possibly at the level of Smad-4, and is 
HFE independent. This is the first demonstration that inflammation regulates BMPs’ 
expression in vivo; however, the exact mechanism needs further investigation. 
It seems that BMP-Smad signalling needs to be switched off during inflammation in 
order to induce hepcidin expression. This is evident by selective suppression of 
HJV, BMP-2, BMP-4, and BMP-6 in the liver of LPS-injected mice observed in this 
study.  However,  as  mentioned  previously  intact  Smad-4  is  required  for  proper 
hepcidin response to inflammatory stimuli.    144 
Although BMPs and HJV were suppressed in the liver of LPS-injected mice, no 
change in phosphorylated Smad 1/5/8 was observed in these mice. This might be 
due to other unidentified ligands or TGF- whose expression does not change in 
response  to  LPS;  therefore,  it  can  maintain  the  basal  expression  levels  of 
phosphorylated Smads.  
LPS is recognized by Toll-like receptor (TLR) 4 which, upon activation, produces 
pro-inflammatory cytokines such as TNF-, IL-1, and IL-6 (Hoshino et al. 1999). In 
this study it was shown that when HuH7 cells are exposed to IL-6, hepcidin mRNA 
expression  increased  3-fold  confirming  the  findings  by  other  groups  that  IL-6 
directly regulates hepcidin expression (Nemeth et al. 2004a; Nemeth et al. 2003). In 
contrast, no change in hepcidin expression was observed in cells treated with TNF-
. Similar findings were recently reported by Constante et al. (2007). This indicates 
that IL-6, but not TNF-mediates hepcidin induction during inflammation. 
To test whether IL-6 and TNF- are able to regulate HJV expression directly in 
hepatocytes, HuH7 cells were treated with the two different cytokines. Exogenous 
TNF-  suppressed  HJV  expression  in  a  time-dependent  fashion  reaching  its 
maximal suppression after 24 hours, whereas no response was observed in IL-6-
treated cells. HJV protein suppression was also demonstrated in this study for the 
first time in response to TNF- treatment in HuH7 cells. These findings indicate that 
TNF-, but not IL-6, mediates HJV suppression during inflammation.  
To  further  uncover  the  mechanism  of  HJV  suppression  by  TNF-  during 
inflammation,  the  HJV  promoter-reporter construct (HJVp1.2-luc) was used. This 
construct was transfected into HuH7 cells. In transfected cells, TNF- suppressed 
the luciferase activity suggesting that the promoter construct is responsive to TNF-
. Next, a single consensus TNF-  responsive element (TNFRE)  was identified 
within the cloned HJV promoter sequence. This sequence has been shown to be 
responsible for TNF--mediated down-regulation of different human genes such as   145 
osteocalcin, thrombomodulin, alkaline phosphatase, and c-myc (Li and Stashenko 
1993; Ohdama et al. 1991; Weiss et al. 1988; Watt et al. 1983).  
To  test  whether  this  TNFRE  mediates  the  TNF-  response,  site-directed 
mutagenesis was carried out to disrupt this sequence. Interestingly, the mutation of 
the identified TNFRE abolished TNF- responsiveness. It was concluded that the 
identified TNFRE is functional and may mediate TNF-  response; however, this 
needs further investigation. 
From the results shown here, it seems that the down-regulation of HJV and BMPs 
in  the  liver  during  inflammation  is  a  prerequisite  for  the  hepcidin  induction  by 
cytokines  during  inflammation  in  vivo.  This  concept  is  supported  by  the  recent 
findings that mice either lacking HJV or BMP-6 retain the ability to induce hepcidin 
in response to inflammatory stimuli (Meynard et al. 2009; Niederkofler et al. 2005); 
indicating  that  neither  HJV  nor  BMP-6  is  required  for  hepcidin  response  to 
inflammation. However, both HJV and BMP-6 have been shown to be required for 
hepcidin response to iron, in other words, they are important for iron sensing.  
The prospective mechanistic explanation is as follow. The iron sensing pathway 
through HJV-BMP-Smad signalling is switched off during LPS-induced inflammation 
by  the  selective  suppression  of  HJV  (by  TNF-)  and  BMP  (by  an  unknown 
mechanism)  expression  in  the  liver.  This  in  turn  stimulates  cytokine-induced 
hepcidin expression.   
The regulation of  HJV  and  hepcidin  by different cytokines may suggest a time-
dependent control of iron homeostasis during inflammation. It is well known that 
LPS signalling via TLR4 causes a release of pro-inflammatory cytokines which is 
time-dependent. TNF- is the first cytokine to be produced and can directly regulate 
HJV expression as shown in this study. TNF-, in turn, causes a production of other 
cytokines including IL1 and IL-6. IL-6 can directly modulate hepcidin expression in 
hepatocytes as shown here and by others.   146 
4.5 Conclusion 
 
The results from the present study demonstrate that the pro-inflammatory cytokines 
TNF- and IL-6 differently regulate hepcidin and HJV expression. TNF-seems to 
suppress HJV transcription possibly via a novel TNFRE within the HJV promoter, 
while IL-6 induces hepcidin expression via STAT3 signalling. The results from the 
acute inflammation study in mice has shown that although hepcidin expression is 
up-regulated as a result of inflammation, HJV and BMP expression is selectively 
repressed in the liver suggesting a crucial requirement for the down-regulation of 
these  genes  in  order  to  induce  hepcidin  during  inflammation.  However,  the 
response observed in gene expression seems to be HFE-independent. In addition, 
the results also suggest that the proposed link between inflammation and BMP-
SMAD signalling is downstream of HJV and BMP ligands, possibly at the level of 
common mediator Smad-4.  
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Chapter 5: Regulation of Hemojuvelin Expression by 
Upstream Stimulatory Factors 
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5.1 Introduction 
 
Hemojuvelin (HJV) is a membrane protein that is encoded by a gene originally 
cloned  by  Papanikolaou  et  al.  (2004).  HJV  mutations  are  associated  with  the 
majority of juvenile hemochromatosis. In both humans and mice,  HJV mutations 
cause low or undetectable levels of hepcidin, the key iron regulatory hormone; this 
suggests that HJV is a potent upstream regulator of hepcidin. It has recently been 
shown to act as a co-receptor for BMP-Smad signalling to regulate hepcidin gene 
expression (Babitt et al. 2007). 
HJV has been shown to be post-transcriptionally regulated. It has two isoforms: a 
secreted  soluble  form  (s-HJV)  which  is  generated  by  furin  cleavage,  and  a 
membrane-bound form (m-HJV) (Kuninger et al. 2006; Lin et al. 2008; Silvestri et 
al. 2008a). S-HJV has been shown to repress BMP signalling by competing with m-
HJV for BMP binding (Babitt et al. 2007; Lin et al. 2008). Therefore, any factor that 
increases s-HJV production could suppress hepcidin production. Further support 
for this hypothesis came from the finding that iron depletion and hypoxia, are both 
associated  with  low  hepcidin  expression,  and  associated  with  increased  s-HJV 
production (Lin et al. 2005; Silvestri et al. 2008a). 
Upstream  stimulatory  factors  (USFs)  were  initially  identified  by  Sawadogo  and 
Roeder  (1985)  as  a  binding  activity  that  actuate  the  adenovirus  major  late 
promoter. USF purification unveiled the existence of two proteins of 43kDa (USF1) 
and  44kDa  (USF2),  which  are  encoded by two  different genes that have been 
characterised in mice (Henrion et al. 1995; Henrion et al. 1996, Aperlo et al. 1996). 
Although  these  genes  are  ubiquitously  expressed  in  different  cell  types,  their 
relative expression levels are variable among different mammalian cells (Sirito et 
al. 1994; Viollet et al. 1996).  
USF1 and USF2 have been shown to bind to the consensus sequence CANNTG, 
called the E-box as homodimers or heterodimers; however, the heterodimer has  
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been shown to be the predominant binding species (Viollet et al., 1996). Since the 
demonstration of their involvement in transcriptional regulation of the adenovirus 
late  gene  promoter,  USFs  have  been  shown  to  regulate  different  genes 
responsible for a variety cellular processes. Among these are glucose-responsive 
genes,  genes  for  glycoprotein  B,  actin,  vasopressin,  and  genes  controlling  the 
circadian rhythm (Yamashita et al. 2001; Wang and Sul 1997; Casado et al. 1999; 
Vallone et al. 2004; Farina et al. 1996; McDonald et al. 2001; Camara-Clayette et 
al. 1999). More importantly, USFs have been shown to regulate the expression of 
TGF-  and  -2  microglobulin,  which  play  an  important  role  in  iron  metabolism 
(Scholtz et al. 1996; Gobin et al. 2003). In addition, our group recently showed that 
USFs are important for the regulation of hepcidin expression through binding to E-
boxes within the hepcidin  gene promoter (Bayele et al. 2006). The original link 
between USFs and iron metabolism was established by Nicolas et al. (2001) who 
found that mice with genetic ablation of Usf2 showed massive iron overload and 
lacked hepcidin expression. 
Unlike  hepcidin,  little  is  known  about  the  regulation  of  HJV  expression.  In  the 
previous  chapter,  it  was  demonstrated  that  HJV  was  transcriptionally  down-
regulated during inflammation in vivo, and this down-regulation was mediated via 
TNF-  in  vitro.  In  this  chapter,  the  aim  was  to  investigate  the  possible 
transcriptional regulation of HJV by USFs by using a HJV promoter construct. This 
was achieved by deletion mapping, transactivation, DNA-binding, and chromatin-
immunoprecipitation  (ChIP)  assays  in  human  hepatoma  cell  lines,  HepG2  and 
HuH7. 
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5.2 Methods 
 
5.2.1 Overexpression of USF1 and USF2 in a human hepatoma cell line 
 
To  investigate  the  effect  of  overexpression  of  USFs  on  the  endogenous  HJV 
mRNA expression levels, HepG2 cells were transfected with (1g) of USF1, USF2 
expression plasmids (kindly provided by Dr. Henry Bayele), and empty pcDNA3.1 
vector (Invitrogen) (control) using Lipofectamine 2000 (Invitrogen) as described in 
Section  2.5,  for  48  hours  in  6-well  plates  followed  by  RNA  extraction,  cDNA 
synthesis, and RT-PCR quantification of  HJV  mRNA as previously described in 
Chapter 2. 
 
5.2.2 Effect of USFs on the activity of HJV promoter construct 
 
To examine the effect of USFs on the luciferase activity of HJV promoter construct, 
HuH7 cells were either transfected with 200ng of HJVp1.2-luc alone or with USF1 
or USF2 expression plasmids (100ng) using Lipofectamine 2000, as described in 
Section 2.5, for 48 hours in 24-well plates followed by measurement of luciferase 
activity as described before. 
 
5.2.3 Generation of HJV promoter deletion constructs 
 
PCR was used to generate different deletions within HJV promoter using HJVp1.2-
luc (Section 2.3) as template. Primers used are listed in table 5.1. PCR products 
were then purified (Section 2.3.2), digested with NheI and Xho I (section 2.3.3), 
ligated  into  pGL3Basic  vector  (Section  2.3.4),  and  transformed  into  DH5- 
competent cells (Section 2.3.5). Purified plasmids were then digested with  NheI  
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and  XhoI  to  verify  that  they  contained  the  correct  inserts.  All  constructs  were 
sequenced to confirm their authenticity. To determine the basal activity of different 
promoter  deletions,  constructs  (200ng  each)  were  co-transfected  with  pSVgal 
(50ng)  into  HuH7  cells for  48  hours, and  reporter  activities  were  measured as 
described in Section 2.5. Luciferase levels were normalized with respect to gal 
activity. Two identical E-boxes (CAGCTG) were identified in the sequence of the 
HJV promoter deletion construct with the highest basal activity. 
 
 
Table 5.1 Primers used for generation of different HJV promoter deletions 
using PCR 
 
 
 
 
 
 
 
 
 
 
 
 
Oligo name 
 
 
Sense 
 
Anti-sense 
 
Construct 1 
 
 
CATGCTAGCGGACTTAGCT ATTTTTAAAA 
 
 
 
 
CATCTCGAGCTGCTGTCTCACTGAGGTCA 
 
        (XhoI restriction site is underlined) 
 
Construct 2 
 
 
CATGCTAGC GCAGTGACCA CAGAGTCACA 
 
Construct 3 
 
 
CATGCTAGC TGAAATACTC TGCAAAGATA 
 
Construct 4 
 
 
CATGCTAGC GATCTGAGCT GGATAGACTG 
 
Construct 5 
 
 
CATGCTAGC TATATTTTTG AATCTTTTTC 
      (NheI restriction site is underlined)  
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5.2.4 Electrophoretic mobility shift assay (EMSA) 
 
To  investigate  whether  USFs  bind  to  the  identified  E-boxes  within  the  HJV 
promoter, EMSA was performed using HepG2 nuclear extract or E.coli expressed 
USFs and radio-labelled E-box probes as described below. 
 
5.2.4.1 Preparation of nuclear extract 
 
A  HepG2 nuclear extract  was prepared  using Nuclear Extract  kit  (Active  Motif, 
USA).  Cells  were  grown  in  75cm
2  flasks  until  confluent,  then  all  medium  was 
aspirated and cells washed twice with PBS. After the second wash, 3mL of 1X 
Trypsin-EDTA (Invitrogen) was added to detach cells from the flask. Cells  were 
then transferred to 15mL conical tubes and centrifuged for 5 minutes at 1000 x g. 
Supernatant was discarded and the cell pellet was washed twice with PBS followed 
by centrifugation for 5 minutes at 1000 x g. Supernatant was discarded and the 
pellet was kept on ice. The pellet was gently resuspended in 500L 1X Hypotonic 
buffer by pipetting up and down several times, this was transferred to a pre-chilled 
microcentrifuge tube and  incubated for 15 minutes on ice. Then 25L of detergent 
was added and the tube was vortexed for 10 seconds. The suspension was then 
centrifuged for 30 seconds at 14,000 x g in a pre-chilled microcentrifuge at 4
oC. 
The  supernatant  (cytosolic  fraction)  was  transferred  into  a  pre-chilled 
microcentrifuge tube and stored at  -80
oC for future use. The nuclear pellet was 
then resuspended into 50L Complete Lysis Buffer by pipetting up and down and 
then vortexed for 10 seconds. Suspension was then incubated for 30 minutes on 
ice  on  a  rocking platform  set  at  150  rpm.  Tubes  were  then  centrifuged for  10 
minutes at 14,000 x g in a pre-cooled microcentrifuge. The supernatant (nuclear  
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fraction) was then transferred into a pre-chilled microcentrifuge tube, aliquoted and 
stored at -80
oC until ready to use.  
Protein concentration was determined (as described in Section 2.6.2) in 96-well 
microtiter plates (Nunc, UK). 
 
5.2.4.2 Expression and purification of recombinant USF1 and USF2  
 
5.2.4.2.1 Expression of recombinant USFs 
 
Recombinant USF1 and USF2 were expressed using pET25b-USF1 and pET25b-
USF2 constructs as previously described (Bayele and Srai 2009). These constructs 
were transformed into BL21(DE3) pLysS competent cells (Novagen). To induce 
protein  expression,  1mM  (final  concentration)  IPTG  was  added  to  logarithmic 
phase cultures (OD at 600 nm around 0.4-0.6) for 3 hours at 30
oC. Recombinant 
proteins were purified with the MagneHis system (Promega) as described below.  
 
5.2.4.2.2 Purification of recombinant USFs  
 
To each 1ml of bacterial culture, 110µl of FastBreak
TM  Cell Lysis Reagent was 
added with 1µl of DNase I, and incubated for 20 minutes at room temperature on a 
rotatory  wheel.  MagneHis
TM  Ni-Particles  were  vortexed  to  form  a  uniform  the 
suspension and 30µl was added to the cell lysate, mixed 10X  by pipetting and 
incubated  for  2  minutes  at  room  temperature.  The  tube  was  then  placed  in  a 
magnetic stand for 30 seconds to capture the MagneHis
TM Ni-Particles, and the 
supernatant  was  carefully  removed.  To  the  magnetic  particles,  150µl  of 
MagneHis
TM Binding/Wash Buffer was added and mixed with a pipette. The tube 
was then placed in a magnetic stand for 30  seconds, and the supernatant was 
carefully removed. The washing step was repeated two more times for a total of  
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three washes. After the third wash, 50µl of MagneHis
TM Elution Buffer was added, 
the  tube  was  incubated  for  2  minutes  at  room  temperature  and  placed  in  a 
magnetic stand to capture the particles. The supernatant, containing the purified 
protein,  was  then  carefully  removed  and analysed  by  running  on a  10%  SDS-
PAGE  to  check  the  purity.  The  proteins  were  visualised  by  Coomassie  Blue 
staining  (0.2%   Coomassie R-250, 20%  methanol, 5% glacial acetic acid, 75% 
water) followed by destaining (20% methanol, 5% glacial acetic acid, 75% water). 
 
5.2.4.3 Gel shift assay [Electrophoretic mobility shift assay (EMSA)] 
 
For mobility shifts, oligonucleotides containing the wild-type, mutant HJV E-boxes, 
or consensus E-box were synthesised (Sigma) as follows E-box1 oligonucleotides 
sense,  TCCCTCCCTGCTCAGCTGTCCAGTACTCTG  and  reverse 
complement  CAGAGTACTGGACAGCTGAGCAGGGAGGGA;  E-box2  sense, 
GAAAGGTATCCAATTGCCCACTGTAATTTT  and  reverse  complement 
GACGAAAAAAGCCAGCTGTCCAGAGAAGAA;  mutant  E-box  sense 
TCCCTCCCTGCTCAGCgaTCCAGTACTCTG  and  reverse  complement 
CAGAGTACTGGAtcGCTGAGCAGGGAGGGA (mutated nucleotides are in lower 
case); consensus E-box sense, CAC CCG GTC ACG TGG CCT ACA CC  and 
reverse complement GGTGTAGGCCACGTGACCGGGTG. Oligonucleotides were 
then annealed in quick ligase buffer (NEB) by heating the tubes containing oligos 
at 95
oC for 5 minutes and leaving them to cool down to room temperature. About 
100pmol of each duplex was end-labeled with γ
32P[ATP] (111 TBq/mmol; Perkin 
Elmer, Wellesley, MA) and T4 polynucleotide kinase (New England Biolabs) and 
diluted to 1pmol/L with Tris EDTA (pH 8.0). Approximately 1pmol of each probe 
was incubated with 10g nuclear extract or 5ng from recombinant USF1 or USF2 
in  binding  buffer  (4%  glycerol,  1mM  MgCl2,  0.5mM  EDTA,  0.5mM  DTT, 
10mMHEPES pH 7.9, 50mMNaCl, and 50g/mL poly [dI-dC] _ poly[dIdC]) in a total  
 
  155 
volume of 10L for 20 minutes at room temperature. For competitive inhibition, a 
100-fold  molar  excess  of  the  cold  oligonucleotides  was  added  to  the  binding 
reaction 10 minutes before adding the labeled probe. Following incubation, 1L 
from 10Xgel loading buffer (250mM Tris-HCl (pH 7.5), 0.2% (w/v) bromophenol 
blue and 40% (v/v) glycerol) was added to each sample. The samples were then 
resolved  on  a  4%  non-denaturing  polyacrylamide  gel  (4%  (v/v) 
acrylamide/bisacrylamide, 3%  (v/v) Glycerol, 0.05%  (v/v) TEMED, 0.075%  (w/v) 
APS) in 0.5 X TBE buffer (0.54% Tris base, 0.27% boric acid, 0.037% Disodium 
EDTA. 2H2O) pH (8.3). Gels were run at 120V until the bromophenol dye front had 
migrated to about 1cm from the bottom of the gel (approximately 1 hour). The gels 
were dried at 80°C for 6 hours using a gel dryer (Bio-Rad) and exposed to X-ray 
film (Fuji film) for 6 hours at - 80°C. The X-ray film was then developed in a dark 
room fitted with a red safety light using Compact X4 Xograph Imaging System 
(Xograph Healthcare Ltd, UK).  
 
5.2.5 ChIP assay 
To  confirm  the  binding  of  USF  to  HJV  E-boxes  in  vivo,  a  ChIP  assay  was 
performed using cross-linked HepG2 chromatin and USF-1 antibody as described 
in detail below. HepG2 cells were grown in 75cm
2 flasks to 90% confluence. DNA 
was cross-linked to histones by adding formaldehyde directly to the culture medium 
to a final concentration of 1% and incubating the cells for 10 minutes at 37
oC. Cells 
were washed twice with ice-cold PBS and scraped into conical tubes. Cells were 
then pelleted for 4 minutes at 2000 x g at 4
oC, resuspended into SDS lysis buffer 
(1%SDS, 10mM EDTA, 50mM Tris, pH 8.1), and incubated on ice for 10 minutes. 
The  lysate  was  then  sonicated  with  8  sets  of 30  second  bursts  followed  by  1 
minute cooling using Soniprep-15 sonicater (Sanyo MSE, UK) equipped with 2 mm 
tip and set to 5.5 amplitude. This procedure results in DNA fragment sizes of 200-
1000bp. Samples were then centrifuged for 15 minutes at 10000 x g at 4
oC; the  
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pellet was discarded and supernatant was diluted 10-fold in ChIP dilution buffer 
(0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl, pH 8.1, 167mM 
NaCl) and 1% of the diluted chromatin was kept as an input. To reduce nonspecific 
background,  salmon  sperm  DNA  and  protein  A-agarose  beads  (Sigma)  were 
added  to  the  sample  then  incubated  for  30  minutes  at  4
oC  on  rotatory  wheel 
followed  by  centrifugation  at  2000  x  g  for  5  minutes  at  4
oC  to  collect  the 
supernatant. Anti-USF1 antibody (10g; Santa Cruz Biotechnology) was added to 
the  sample  and  incubated  overnight  at  4
oC  on  rotatory  wheel.  As  a  negative 
control,  half of  the  pre-cleared  sample  was  incubated  with  10g of nonspecific 
immunoglobulin  G  (IgG)  of  the  same  isotype  (Sigma).  Chromatin 
immunoprecipitates  were  collected  with  fresh  protein  A  agarose/salmon  sperm 
DNA and washed sequentially for 3-5 minutes on a rotatory wheel in low-salt (0.1% 
SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 150mM NaCl), high-
salt (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 500mM 
NaCl), LiCl (0.25M LiCl, 1% NP-40, 1% sodium deoxycholate, 1mM EDTA, 10mM 
Tris, pH 8.1), and TE(10mM Tris-HCl, 1mM EDTA, pH 8) buffers. The immune 
complexes  were  then  eluted  with  1%  SDS  and  0.1  M  NaHCO3  at  room 
temperature for 15 minutes. To reverse cross-linking, the eluates were incubated at 
65°C overnight with NaCl (0.2 M final concentration) and then with 10 mM EDTA, 
40 mM Tris-HCl (pH 6.5), and 40 mg/mL proteinase K (Sigma) at 45°C for 1 hour. 
The  DNA
  was  extracted  with  a  QIAquick  PCR  purification  kit  (QIAGEN)
  and 
subjected  to  30  cycle-PCR  amplification  with  the  forward  primer  5'- 
TGGAGTAGGTAGGAGGATAGAC  -3'
  and  the  reverse  primer  5'- 
TAATGTTGAGCTCCTGGCCT -3'
 which were
 specifically designed from the HJV 
promoter . The 300-bp PCR
 product was resolved by 2% agarose-ethidium
 bromide 
gel electrophoresis and visualized under UV. The PCR product
 was cloned into the 
pGEM-T  Easy  vector  (Promega).  The  cloned  PCR  product  was  analyzed
  by 
sequencing  (Wolfson Institute for Biomedical Research, UCL) and compared with 
the human HJV promoter sequence to confirm its authenticity.  
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5.3 Results 
5.3.1 Effect of USF over-expression on HJV mRNA expression in HepG2 cells 
To investigate the effect of over-expression of USFs on HJV mRNA expression, 
HepG2 cells were either transfected with empty vector (control), USF1 or USF2 
expression plasmids followed by quantification of HJV mRNA expression by RT-
PCR. As shown in Figure 5.1, USF1 or 2 over-expression significantly increased 
HJV mRNA expression to a similar extent. 
 
 
 
 
 
 
 
Figure 5.1 Effect of USFs overexpression on HJV mRNA expression in HepG2 
cells.  
HepG2 cells were either transfected with  empty vector (control),  USF1or USF2 
expression plasmids followed by quantification of HJV mRNA by RT-PCR. Over-
expression of either of the USFs significantly increased  HJV mRNA expression. 
Data are mean±SEM, n=6 of three separate experiments. **p<0.01. 
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5.3.2 Effect of USFs on the activity of HJV transcription 
 
To  examine  the  effect  of  USFs  on  HJV  regulation,  HuH7  cells  were  either 
transfected with  HJVp1.2-luc alone or with USF1 or USF2 expression plasmids 
followed by measurement of luciferase activity. Co-transfection of HJVp1.2-luc with 
exogenous  USF1 and USF2 significantly increased the luciferase activity of the 
HJV promoter (Figure 5.2).   
 
 
 
 
 
 
 
 
 
Figure 5.2 Effect of USF1 and USF2 on luciferase activity of HJV promoter in 
transfected HuH7 cells.  
HuH7 cells were transfected with HJVp1.2-luc (200ng) alone or with USF1, USF2 
expression plasmids (100ng) followed by measurement of luciferase activity. Fold 
activation was calculated with respect to the activity of HJVp1.2-luc alone. Both 
USFs significantly increased luciferase activity of the HJV promoter. Data are mean 
± SEM (n=12) of 3 independent experiments. ***p<0.001. 
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5.3.3  Deletion  mapping  of  HJV  promoter  and  identification  of  enhancer 
elements 
Different deletion constructs were generated from HJVp1.2-luc using PCR (Figure 
5.4A). PCR products were then purified, ligated into pGL3Basic vector (Promega), 
and transformed into DH5- competent cells (Invitrogen). Purified plasmids were 
then digested with NheI and XhoI to verify that they contained the correct inserts 
(Figure 5.3). To determine the basal activity of different deletion constructs, 200ng 
of each construct was co-transfected with pSVgal (50ng) into HuH7 cells for 48 
hours, and reporter activities were measured. Luciferase levels were normalized 
with respect to gal activity. As shown in Figure 5.4B some of the constructs (1, 2, 
and  3)  showed  similar  activity  to  HJVp1.2-luc.  Constructs  4  and  5  showed 
significantly higher luciferase activity than HJVp1.2-luc. Further inspection of the 
sequence of the construct 4 revealed the existence of two identical E-boxes with 
the sequence CAGCTG as shown in Figure 5.5.  
 
 
 
 
 
 
Figure 5.3 2% Agarose/Ethidium bromide gel electrophoresis of different HJV 
promoter deletion constructs.  
Undigested plasmids (Lanes 2, 4, 6, 8, and 10) and NheI-XhoI-digested plasmids 
(Lanes 3, 5, 7, 9, and 11) were run on a 2%agarose/ethidium bromide gel. Inserts 
with correct sizes are shown in respect to a molecular weight marker (Lane1).  
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Figure 5.4 Deletion mapping of the human HJV gene promoter.  
(A)  HJVPp1.2-luc  was  subjected  to  deletions  by  PCR  to  generate  different 
fragments;  the  size  of  each  fragment  is  shown  in  brackets.  The  green  boxes 
represent  the  identified  E-boxes  (E1,  E2)  with  respect  to  the  position  of  the 
beginning  of  the  HJV  first  exon  (red  oval).  (B)  Basal  transcriptional  activity  of 
different promoter deletion constructs from panel A. Constructs (200ng each) were 
co-transfected  with  pSVgal  (50ng)  into  HuH7  cells  for  48  hours,  and  reporter 
activities were measured. Luciferase levels were normalized with respect to gal 
activity. Fold activation was based on the activity of HJVp1.2-luc, and assigned an 
arbitrary  activation  level  of  1.  Data  are  mean  ±SEM,  n=8  of  3  independent 
experiment. *p<0.05, **p<0.01.  
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gatctgagct ggatagactg aacaaaccct 
catcctaagc aactcacagc tcagatttct tctctggaca gctggctttt 
ttcgtccttc tgaaatactc tgcaaagata ggagaggggc tatgaactac 
ctctgctatg gatcttattc aaagtcagct acctcctaga tactatctgt 
agaacctaaa tgtaatattc agcatagcag ggatgaacat ggtaaatgaa 
aggtatccaa ttgcccactg taatttttaa aggccaggag ctcaacatta 
ttgaaaatgc tggagggctg cctggagtag gcagtgacca cagagtcaca 
caagctggaa ttggatatcc aacttgtctg tcatatttct ctcctccctc 
cctgacttgg cactcaatac tccatattct ttctaatcct ctaaccctcc 
ccactccccc aactcccaca ccctaccccc accaacgttc ctggaatttt 
ggacttagct atttttaaaa ccgtcaactc agtagccacc tccctccctg 
ctcagctgtc cagtactctg gccagccata tactccccct tccccccata 
ccaaaccttc tctggttccc tgacctcagt gagacagcag 
 
 
Figure 5.5 The sequence of the  HJV  promoter  deletion construct with  the 
highest basal activity showing two identical E-boxes.  
Spatial arrangement and nucleotide sequences of the E-boxes (blue) within the 
human HJV gene promoter and the start of first exon (yellow). 
 
 
 
 
 
5.3.4 Electrophoretic mobility shift assay 
 
To investigate whether USFs bind to HJV E-boxes in vitro, EMSA was performed 
using either HepG2 nuclear extract or recombinant purified USFs (Figure 5.6). The 
purified  proteins  or  HepG2  nuclear  extract  were  incubated  with  radio-labelled 
probes. As shown in Figure 5.7, E-box and consensus probes bound to nuclear 
protein  but  did  not  bind  to  mutant  E-box  probe.  Moreover,  similar  binding  was 
observed with either recombinant USf1 or USF2, which was not observed with 
mutant  probe  (Figure  5.8,  5.9).  This  binding  was  abolished  when  excess  cold 
competitor was added to the binding reaction.  
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Figure 5.6 SDS-PAGE of purified recombinant USF1 and USF2.  
Recombinant E-coli expressed USF1 (Lane 2) and USF2 (Lane 3) were purified 
from bacterial lysates using MagneHis system (Promega) and run on 10% SDS-
PAGE to check protein purity. Lane 1 is molecular weight marker (Biorad) that was 
used to verify the sizes of purified proteins, USF1 (43 KDa) and USF2 (44 KDa).  
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E-box 1  +  -  +   -  +  -  -  -  - 
E-box 2  -  -  -  -  -  -  +  -  + 
Cold competitor  -  -  -  -  +  -  -  -  + 
Mutant E-box   -  -  -  +  -  -  -  +  - 
Consensus E-box  -  +  -  -  -  +  -  -  - 
HepG2 NE  -  +  +  +  +  +  +  +  + 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Promoter occupancy USF1/USF2 in vitro using EMSA.  
HepG2 cell nuclear extracts (10 g) were incubated with radio-labeled E-
boxes  (lane  3,  7),  consensus  (lane  2,  6),  and  mutant  E-box  (lane  4,  8); 
where  indicated,  excess  unlabeled  or  cold  competitor  oligonucleotide 
(100pmol) was added to the binding reactions (lane 5, 9). Lane 1 is an E-
box oligo without nuclear extract as a negative control. Arrow indicates E-
box–nucleoprotein complex.  
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Figure 5.8 Binding of recombinant USF1 to HJV E-boxes in vitro.  
Recombinant USF1 (10ng) was incubated with radio-labelled E-boxes (lane 2, 4), 
consensus  (lane  6),  and  mutant  E-box  (lane  3,  5).  In  lanes  7  and  8,  excess 
unlabeled  or  cold  competitor oligonucleotide  (100pmol)  was  included  in  binding 
reactions. Lane 1  is  an E-box  oligo  without  recombinant protein as  a negative 
control.  
 
 
 
E-box 1  +  +  -  -  -  -  +  - 
E-box 2  -  -  -  +  -  -  -  + 
Mutant E-box 1  -  -  +  -  -  -  -  - 
Mutant E-box 2  -  -  -  -  +  -  -  - 
Consensus E-box  -  -  -  -  -  +  -  - 
E-box 1 cold comp.  -  -  -  -  -  -  +  - 
E-box 2 cold comp  -  -  -  -  -  -  -  + 
USF1  -  +  +  +  +  +  +  + 
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Figure 5.9 Binding of recombinant USF2 to HJV E-boxes in vitro.  
Recombinant USF2 (10ng) was incubated with radiolabeled E-boxes (lane 2, 3), 
consensus  (lane  4),  and  mutant  E-box  (lane  5,  7);  in  lanes  6  and  8,  excess 
unlabeled  or  cold  competitor oligonucleotide  (100pmol)  was  included  in  binding 
reactions. Lane 1  is  an E-box  oligo  without  recombinant protein as  a negative 
control. 
 
 
E-box 1  +  +  -  -  -  +  -  - 
E-box 2  -  -  +  -  -  -  -  + 
Mutant E-box 1  -  -  -  -  +  -  -  - 
Mutant E-box 2  -  -  -  -  -  -  +  - 
Consensus E-box  -  -  -  +  -  -  -  - 
E-box 1 cold comp.  -  -  -  -  -  +  -  - 
E-box 2 cold comp  -  -  -  -  -  -  -  + 
USF2  -  +  +  +  +  +  +  + 
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5.3.5 Chromatin immunoprecipitation assay (ChIP) 
 
 
To confirm the binding of USF to HJV E-boxes in vivo, ChIP assay was performed 
using sonicated cross-linked HepG2 chromatin (Figure 5.10) and USF1 or non-
specific  antibody.  The  immunoprecipitated  chromatin  was  then  reverse  cross-
linked, purified, and used for PCR to amplify a specific fragment within the HJV 
promoter  containing  the  E-box.    As  shown  in  Figure  5.11,  the  expected  PCR 
product was obtained from the chromatin immunoprecipitated with USF1 antibody 
but  not  with  non-specific  antibody.  Input  chromatin  (i.e.  without 
Immunoprecipitation), was used as a positive control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 Optimisation of chromatin sonication. Agarose/ethidium bromide 
gel image showing sonicated HepG2 cross-linked chromatin.  
Formaldehyde  cross-linked  HepG2  chromatin  was  sonicated  to  generate  DNA 
fragment sizes of 200-1000bp and an aliquot was run on a 1% agarose/ethidium 
bromide gel (lane 2) alongside molecular weight marker (Promega) (lane1).  
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Figure 5.11 Promoter occupancy by USF1 in ChIP assay.  
PCR  products  were  run  on  a  2%  agarose/ethidium  bromide  gel.  PCR  was 
performed on whole chromatin without immunoprecipitation (Input, lane 5) and on 
chromatin immunoprecipitated with either a non-specific antibody (lane 3), or with 
anti-USF1 antibody (lane 4). Lane 1 is a molecular weight  marker (sizes are in 
base pairs) and lane 2 is a water negative control for PCR reaction.  
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5.4 Discussion 
 
 
HJV  has  been  shown  to  be an  important  upstream  regulator  of  hepcidin  gene 
expression by acting as a BMP co-receptor (Babitt et al. 2006). Mutations in the 
gene  are  associated  with  severe  iron  overload  and  low  hepcidin  expression 
(juvenile  hemochromatosis).  However,  we  do  not  know  enough  about  the 
regulatory  mechanisms  that  underlie  its  expression.  In  this  study,  the  possible 
regulation of HJV expression by USFs was investigated. Over-expression of USF1 
and  USF2  in  HepG2  and  HuH7  cells  induced  HJV  mRNA  and  HJV  promoter 
activity. Moreover, gel mobility shift analysis demonstrated that protein complexes 
containing USF1 and USF2 transcription factors are able to bind the HJV E-boxes 
in  a  nuclear  extract  of  HepG2  cells.  Similar  binding  to  HJV  E-boxes  was  also 
shown using recombinant USFs. To further confirm USF binding in vivo using the 
ChIP assay, USF1 was shown to bind specifically to the HJV E-box.   
USFs  have  previously  been  shown  to  regulate  different  genes  and  more 
importantly 2-microglobulin, TGF-, and hepcidin (Scholtz et al. 1996; Gobin et al. 
2003; Bayele et al. 2006); these are all important for iron homeostasis. Moreover, 
USF2 has originally been linked to iron metabolism through gene ablation in mice 
(Nicolas  et  al.  2001).  USFs  bind  to  the  E-box,  an  enhancer  element  with  the 
consensus sequence CANNTG (Littlewood and Evan 1995). The E-box is a widely-
distributed  DNA  response  element.  Despite  of  its  conciseness  and  broad 
distribution, the E-box is a multifaceted sequence that regulates different genes 
responsible for different functions including cellular differentiation, proliferation, and 
tissue-specific responses. Recently, the circadian clock was shown to recruit the E-
box. In this regard, E-boxes possibly have a role in initiating the robust waves of 
gene expression characteristic of circadian transcription (Munoz et al. 2002). 
In  the  present  study,  the  effect  of  USF  over-expression  on  the  endogenous 
expression  of  HJV  mRNA  was  investigated  in  HepG2  cells.  These  cells  were  
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transfected  with  USF1  or  USF2.  Exogenous  USF1  and  USF2  significantly 
increased HJV mRNA expression demonstrating that USFs are important positive 
regulators of HJV expression in liver cells. In addition, co-transfection of the HJV 
promoter with exogenous USF1 and USF2 significantly enhanced reporter gene 
(luciferase) expression suggesting that USFs are potent positive regulators of HJV 
transcription. 
 
By deletion mapping of the HJV promoter, a comparison of luciferase activity of the 
different  constructs  demonstrated  that  the  full-length  HJV  promoter  construct 
produced similar or less luciferase than the deletion constructs. This may be due to 
suppressor  elements  within  the  promoter  sequence.  Further  inspection  of  the 
sequence of the construct with the highest luciferase activity revealed two identical 
E-boxes each with the sequence CAGCTG. These E-boxes have the same core 
sequence  that  is  recognised  by  members  of  the  basic  helix-loop-helix  leucine 
zipper  (bHLH-ZIP)  family  of  transcription  factors,  including  USF  (Bendall  and 
Molloy 1994; Atchley and Fitch 1997). Of note, deletion constructs that contain one 
E-box  showed  the  same  activity  as  the  full-length  construct.  In  addition,  the 
construct that encompassed both E-boxes showed higher luciferase than the full-
length construct. These findings suggest the importance of the E-box elements in 
HJV basal activity.  
The binding capacity of the identified E-boxes was investigated in vitro by EMSA. 
Transcription factor binding to the putative E-boxes  was tested using  a  nuclear 
extract from HepG2 cells; the probes containing  HJV  E-boxes bound a nuclear 
protein  complex.  To  further  confirm  whether  the  E-box  bound  to  USFs, 
recombinant USF1 and USF2 were used for EMSA. Both recombinant proteins 
bound to E-boxes but not to the mutant E-box probe. The binding was inhibited by 
a 100-fold molar excess of cold or unlabelled E-box oligonucleotide. This further 
confirmed that the promoter occupancy by USF was specifically at the E-boxes.   
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To investigate the HJV promoter occupancy by USF in vivo, the ChIP assay was 
performed  with  cross-linked  HepG2  chromatin.  Using  anti-USF1  antibody,  the 
target region of the HJV promoter containing E-box was immunoprecipitated. In 
contrast, no immunoprecipitation was obtained when using non-specific IgG. These 
findings strongly demonstrate the importance of USFs in the regulation of  HJV 
expression. 
 
USF1 has been shown to regulate the transcription of hepatic lipase (HL) (Botma 
et al. 2005), which is also induced by glucose in vitro (Tu and Albers 2001) and in 
type  two  diabetes  in  vivo  (Deeb et  al.  2003;  Rashid  et al. 2003).  HL plays  an 
important  role  in  the  remodelling  of  HDL  and  LDL  and  the  development  of 
dyslipidaemia (Jansen et al. 2002). The  USF1 gene on chromosome 1q21 has 
been  linked  to  type  two  diabetes  and  metabolic  syndrome  (Ng  et  al.  2005). 
Moreover,  hyperglycaemic  rats  showed  higher  expression  levels  of  USF1  and 
USF2 in hepatic nuclei (van Deursen et al. 2008). 
 
Glucose has also been shown to increase the expression of USF1 and USF2 in the 
nuclei of non-hepatic cells (Smih et al. 2002; Bidder et al. 2002; Weigert et al. 
2004), and hepatic cells (van Deursen et al. 2008). Moreover, USFs also play an 
important role in the gene regulation by glucose (Vallet et al. 1998; Smih et al. 
2002;  Bidder  et  al.  2002;  Weigert  et  al.  2004;  Wang  et  al.  2004)  and  insulin 
(Iynedjian 1998; Wang and Sul 1997; Nowak et al. 2005). These findings strongly 
suggest  a  link  between  these  transcription  factors  and  glucose  and  lipid 
metabolism.  
Taken together, the findings shown here and recently by our group (Bayele et al. 
2006) that USFs are involved in the regulation HJV and hepcidin expression further 
strengthen  the  link between  these  transcription factors  and  iron  metabolism.  In  
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addition,  the  findings  also  suggest  a  possible  link  between  glucose  and  iron 
metabolism. However, this needs further investigation.  
 
5.5 Conclusion 
 
 
The results presented in this chapter clearly demonstrate the involvement of USFs 
in  the  regulation of  HJV  expression  in  vitro  and  in vivo.  These findings further 
support the role of these transcription factors and iron homeostasis. Moreover, the 
role  of  these factors  in  glucose  and  lipid  metabolism  may provide  a  novel  link 
between glucose, lipid, iron metabolism, and circadian transcription. However, this 
hypothesis needs further investigation. 
   172 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6: General Discussion 
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There  is  no  doubt  that  the  discovery  of  HFE  and  hepcidin,  the  iron  regulatory 
hormone, has energised the study of iron metabolism. Outstanding progress in our 
understanding  of  hepcidin functions and  regulation has been  achieved  since  its 
discovery 10 years ago. It controls iron homeostasis by binding to IREG1 inducing 
its  degradation,  which  in  turn  controls  the  amount  of  iron  released  from 
macrophages, enterocytes, and hepatocytes. 
In recent years, studies of human diseases and genetically-modified mouse models 
have unveiled novel genes involved in hepcidin regulation and iron homeostasis, 
hemojuvelin being one of them. HJV has recently been identified to be an upstream 
regulator  of  hepcidin  expression  acting  as  a  BMP-co-receptor; however,  little  is 
known about the regulation of HJV expression. 
The  studies  described  in  this  thesis  were  aimed  to:  1)  Further  understand  the 
regulation of hepcidin and HJV expression by iron and inflammation, and the role of 
HFE, if any, in their regulation. 2) Study the possible regulation of HJV expression 
by  upstream  stimulatory  factors  (USFs)  that  have  previously  been  shown  to 
regulate hepcidin expression. 
 
6.1 Regulation of hepcidin expression by iron 
 
Hepcidin  is  regulated  by  iron.  However,  no  IREs  have  been  identified  in  the 
hepcidin gene suggesting an alternative signalling pathway rather than IRP-IRE to 
modulate its expression by iron. BMP-Smad signalling has been shown to be one of 
the most important pathways involved in hepcidin regulation. However, whether this 
pathway is involved in hepcidin modulation by iron is not clear. HFE expression has 
profound effects on cellular iron status through regulation of hepcidin expression. 
However, the precise mechanism by which HFE regulates hepcidin expression is 
not clearly understood. To explore the role of HFE in the regulation of hepcidin by   174 
iron, WT and HFE KO mice were either fed an iron-deficient diet or injected with 
iron (Chapter 3).  
The data show that iron regulates hepatic expression of hepcidin 1 and BMP-6, (i.e. 
increased by iron loading and repressed by iron deficiency), in WT and HFE KO 
mice. However, in iron-loaded HFE KO mice hepcidin 1 induction was significantly 
lower than that of iron loaded WT mice despite increased BMP-6 expression, which 
may be explained by the impaired phosphorylation of Smad-1/5/8 in these mice. 
Similar findings were recently reported by Corradini et al. (2009). No change in HJV 
expression was observed in response to iron deficiency or iron loading in WT or 
HFE KO mice. Similar findings were recently shown by others  (Constante et al. 
2007; Gleeson et al. 2007).  
Recent findings showed that hepcidin is not only induced by BMP-6, but it is also 
repressed  when  endogenous  BMP-6  is  reduced  in  vitro  (Babitt  et  al.  2007).  In 
addition,  s-HJV  selectively  inhibited  BMP-6  signalling  in  vivo  and  in  vitro 
(Andriopoulos et al. 2009). Taken together, these findings and data shown here 
suggest that BMP-6 is important for hepcidin regulation by iron in vivo. Moreover, 
the lack of Smad phosphorylation in iron loaded HFE KO mice, despite increased 
BMP-6 expression, suggests that HFE is involved in the regulation of downstream 
signals of BMP-6 that induce hepcidin expression in response to iron loading in 
vivo. 
The  data  shown  here,  together  with  the  recent  reports  (Corradini  et  al.  2009; 
Schmidt et al. 2008; Kautz et al. 2008), suggest that the iron-sensing process may 
occur at two levels (Figure 6.1). Hepatic BMP-6 expression increases in response 
to iron loading,  via an as yet unknown HFE-independent mechanism(s). BMP-6 
then signals via Smad-1/5/8 to induce hepcidin expression via Smad-4. From the 
presented data it was proposed that HFE is involved in the BMP-6 signalling and 
hence there is less hepcidin induction in response to iron-loading in HFE KO mice. 
During iron deficiency, hepatic BMP-6 decreases which in turn decreases Smad-  175 
1/5/8  phosphorylation  and  hepcidin  expression.  However,  this  process  is  not 
dependent on HFE. Other mechanisms may also contribute to hepcidin suppression 
during  iron  deficiency  such  as  TMPRSS6,  which  is  believed  to  sense  iron 
deficiency, although the mechanism by which this occurs has not been identified 
(Du et al. 2008); generation of s-HJV (Silvestri et al. 2008a; Lin et al. 2005); and 
increased hepatic HIF-1 expression (Peyssonnaux et al. 2007). However, more 
recent studies failed to demonstrate transcriptional suppression of hepcidin by HIF-
1(Volke et al. 2009). These conflicting findings underscore the need to study the 
role of HIF-1 in hepcidin regulation during iron deficiency.  
The second mechanism of iron sensing is thought to involve HFE and TFR2. It was 
recently proposed that HFE is displaced from TFR1 by holotransferrin, and then 
forms a complex with TFR2 to induce hepcidin expression (Schmidt et al. 2008; 
Gao et al. 2009). Moreover, recent studies suggest a possible cross-talk between 
TFR2 and BMP-Smad signalling. In isolated mouse hepatocytes, holotransferrin not 
only induced ERK1/2 phosphorylation, but also increased phosphorylation of Smad-
1/ 5/8 (Ramey et al. 2009). In addition, in mice with genetic disruption of HFE and 
TFR2,  Smad-1/5/8  phosphorylation  was  reduced  (Wallace  et  al.  2009). 
Interestingly, Noggin, a soluble protein that prevents BMP-Smad signalling, blocked 
holotransferrin-induced hepcidin expression in vitro (Ramey et al. 2009) suggesting 
the involvement of BMP-Smad signalling in hepcidin induction by holotransferrin. 
However,  how  BMP-Smad  and  TFR2  signalling  interact  remains  to  be  fully 
elucidated. 
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Figure 6.1 Mechanism of hepcidin induction during iron loading.  
During iron overload, hepatic BMP-6 expression is induced, which then binds to 
BMPR to initiate the Smad signalling cascade that activates hepcidin expression. 
However, HFE seems to be important for Smad-1/5/8 phosphorylation in response 
to iron loading.  Hepcidin expression is also induced by binding of diferric-TF to the 
TFR2/HFE complex, which is believed to signal via ERK1/2. However, the exact 
signalling mechanism is unclear. Recent evidence suggests a possible cross-talk 
between TFR2/HFE and Smad signalling; though, how they interact remains to be 
determined.   
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6.2  Regulation  of  hepcidin  and  HJV  expression  by  LPS-induced  acute 
inflammation in vivo and pro-inflammatory cytokines in vitro 
 
LPS  is  recognised  by  the  Toll-like  receptor  (TLR)  4,  which  produces  pro-
inflammatory cytokines such as TNF-, IL-1, and IL-6 (Hoshino et al. 1999). In this 
study  (Chapter  4),  WT  and  HFE  KO  mice  respond  to  LPS-induced  acute 
inflammation  by  inducing  hepcidin  1  expression  and  suppressing  HJV,  BMP-2, 
BMP-4, and BMP-6 expression in the liver. These findings suggest that HFE does 
not have a role in the regulation of these genes during inflammation. This is the first 
demonstration  that  LPS-induced  acute  inflammation  regulates  hepatic  BMP 
expression in vivo. However, the exact mechanism of this downregulation needs 
further investigation. 
Studies  in  human  hepatoma  (HuH7)  cells  showed  that  TNF-,  but  not  IL-6, 
mediates HJV downregulation during inflammation, whereas IL-6 mediates hepcidin 
upregulation. A similar finding was recently reported by Constante et al. (2007). 
Interestingly, in vitro studies demonstrate for the first time that TNF- induced HJV 
suppression is possibly mediated by a TNF-  response element within the  HJV 
promoter. 
Taken together, these findings suggest that the suppression of hepatic HJV and 
BMP  expression  during  acute  inflammation  is  a  prerequisite  for  the  hepcidin 
induction in vivo. This hypothesis is supported by the finding that mice either lacking 
HJV  or  BMP-6  retain the ability to induce hepcidin in response to inflammatory 
stimuli  (Meynard  et  al.  2009;  Niederkofler  et  al.  2005).  The  hypothesised 
mechanism is as follows (Figure 6.2): iron sensing through HJV-BMP is switched off 
during acute inflammation by selective suppression of HJV and BMP expression in 
the liver. This in turn stimulates cytokine-induced hepcidin expression. 
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Recently, mice lacking either BMP-6 (Meynard et al. 2009) or Smad-4 (Wang et al. 
2000)  showed  impaired  hepcidin  induction  in  response  to  LPS  and  IL-6, 
respectively.  In  addition,  a  recently  identified  BMP  response element  within  the 
hepcidin gene promoter was shown to be important not only for BMP response, but 
also for IL-6 responsiveness (Verga Falzacappa et al. 2008). Taken together, these 
findings  suggest  a  possible  cross-talk  between  IL-6  and  BMP-Smad  signalling. 
However,  the  results  presented  here  suggest  that  the  proposed  link  between 
inflammation and BMP-Smad signalling is downstream of HJV and BMP ligands, 
possibly at the level of Smad-4. 
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Figure 6.2 Proposed mechanism of LPS-induced cytokines in the regulation 
of hepcidin and HJV expression in the liver.  
LPS is taken up by the Kupffer cells via TLR-4 and induces TNF-, IL-1, and IL-6. 
TNF- suppresses HJV expression via a TNFRE within the HJV promoter, while IL-
6 induces hepcidin expression via the STAT3- pathway.  LPS also represses the 
expression of BMPs (2, 4, and 6), via an as yet unknown mechanism. On the other 
hand, the expression of TGF- is not affected by LPS, which could maintain basal 
expression  levels  of  phosphorylated  Smads.  Based  on  these  results,  it  was 
hypothesised  that  iron  sensing  through  HJV-BMP-Smad  pathway  needs  to  be 
switched off during inflammation in order to induce hepcidin expression. Moreover, 
the proposed link between IL-6 and the Smad pathway is downstream of HJV and 
BMPs, probably at the level of Smad-4. 
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6.3 Regulation of HJV expression by upstream stimulatory factors 
 
Upstream stimulatory factors have been shown to regulate the expression of plenty 
of genes responsible for various cellular processes. Among these are TGF-, -2 
microglobulin, and hepcidin that play important roles in iron homeostasis (Scholtz et 
al. 1996; Gobin et al. 2003; Bayele et al. 2006). Nicolas and co workers (Nicolas et 
al. 2001) who showed that mice with genetic disruption of USF2 presented massive 
iron overload and lacked hepcidin expression, provided the original link between 
USFs and iron metabolism. 
In this study (Chapter 5), it was shown that the exogenous USFs increased the 
expression  of  HJV  mRNA  as  well  as  the  reporter  gene  (luciferase)  in  vitro 
suggesting that USFs are potent positive regulators of HJV transcription. Moreover, 
the identified E-boxes within the HJV promoter bound a nuclear protein complex, 
and recombinant USF1 and 2 in vitro by EMSA. In addition, the binding of USF1 to 
HJV E-box was demonstrated in vivo by the ChIP assay. Taken together, these 
findings suggest that USFs are involved in the regulation of HJV expression via E-
boxes and further strengthen the link between these transcription factors and iron 
metabolism.  
The role of USFs in glucose and lipid metabolism (Vallet et al. 1998; Smih et al. 
2002; Bidder et al. 2002; Weigert et al .2004; Wang et al. 2004; Tu and Albers 
2001) suggest a possible novel link between glucose, lipid, and iron metabolism 
which is mediated by USFs. However, this hypothesis needs further investigation. 
 
 
 
 
 
   181 
6.4 Conclusions  
 
From the studies described in the thesis, it was concluded that: 
 
  Hepcidin  regulation  by  iron  status  is  modulated  by  the  BMP-6-Smad 
signalling pathway in vivo.  
  HFE seems to be involved in the regulation of the downstream signalling of 
BMP-6 that induces hepcidin expression during iron loading. 
  TNF- seems to suppress HJV expression via a novel TNFRE within the 
HJV promoter.  
  There is a crucial requirement for an HFE-independent downregulation of 
HJV  and  BMP  expression  during  acute  inflammation  in  order  to  induce 
hepcidin expression. 
  The  proposed  link  between  inflammation  and  BMP-Smad  signalling  is 
downstream of HJV and BMPs, possibly at the level of Smad-4. 
  USFs are involved in the regulation of HJV expression in vivo and in vitro 
further  supporting  the  importance  of  these  transcription  factors  in  iron 
homeostasis.  
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6.5 Future Work 
 
In the present study, it was shown that iron regulates BMP-6 mRNA expression in 
the  liver  in  vivo,  via  an  as  yet  unknown  mechanism.  Therefore,  further  studies 
investigating the mechanism of BMP-6 regulation by iron need to be performed at 
the promoter level to determine the presence of iron regulatory elements that could 
mediate  iron  responsiveness.  This  will  be  performed  by  using  bioinformatics  to 
detect  the  presence  of  iron  response  elements  within  the  BMP-6  promoter 
sequence.  Once  identified,  the  functionality  of  these  response  elements  will  be 
tested by reporter and gel shift assays. 
 
The  results  also  showed  that  LPS  downregulates  BMP  2,  4,  and  6  mRNA 
expression in the liver in vivo; however, the mechanism of this suppression needs 
further investigation. The effect of different pro-inflammatory cytokines, such as IL-6 
and TNF- on BMP 2, 4, and 6 mRNA expression will be examined in vivo and in 
vitro to determine the mechanism of BMP suppression during acute inflammation.  
 
The regulation of HJV and hepcidin expression by USFs and the involvement of 
these transcription factors in glucose metabolism may provide a novel link between 
glucose and iron metabolism. Therefore, further studies investigating the effect of 
glucose  on  HJV  and  hepcidin  expression  and  the  involvement  of  USF  in  this 
regulation need to be performed at both mRNA and promoter levels of hepcidin and 
HJV.    
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